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SUMMARY 
 
Double-strand breaks (DSBs), which are among the most dangerous DNA 
lesions, are estimated to occur at a rate of ten per cell per day in primary 
human or mouse fibroblasts (Lieber, 2010). These naturally occurring DSBs 
are generated upon collapse of stalled DNA replication forks, replication 
across nicks, reactive oxygen species of endogenous origin or the untimely 
action of DNA endonucleases (topoisomerases or RAG and AID) (Lieber, 
2010). 
Failure to repair damaged DNA has a well-established role in the onset of 
cancer. Despite the intense effort currently put to the identification of proteins 
and pathways involved in the recognition of the various forms of DNA 
damage, we still lack a clear understanding at the molecular level of DNA 
repair mechanisms and their regulation. In particular, the hierarchy and 
mutual influence of post-translational modifications (PTMs) on recruitment, 
function and stability of DNA repair proteins at sites of damage represent new 
challenges in the field. Appreciating the importance of PTMs will not only 
allow understanding how dysfunctions of these machineries contribute to the 
development of cancer and to acquired resistance to therapy, but will also 
provide the necessary knowledge to target key components of DNA repair 
pathways and their regulators in the treatment of cancer. 
This study is aimed to answer important unresolved biological questions 
regarding the molecular mechanism that controls the function of Exonuclease-
1 (EXO1), a common component of machineries processing stalled replication 
forks, DSBs and DNA base mismatches.  
Previous work from our laboratory demonstrated that the function of human 
and yeast EXO1 at DSBs and stalled forks, respectively, is rigorously 
controlled by specific protein-protein interactions (Eid et al., 2010; Engels et 
al., 2011). Additional studies from our laboratory showed that, in response to 
stalled DNA replication, the cellular level of human EXO1 is regulated by 
phosphorylation-dependent ubiquitylation that channels EXO1 to proteasome-
mediated degradation (El-Shemerly et al., 2008; El-Shemerly et al., 2005).  
In this study we extend these findings and, taking advantage of a combination 
of molecular biology and biochemical techniques as well as cell biology 
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assays, we provide new mechanistic insights on the regulation of EXO1. 
Indeed, by taking advantage of an immunofluorescence-based high-
throughput screen followed by image and computational analysis of the 
acquired data, we identified UBC9-dependent pathways as major effectors of 
EXO1 stability, indicating that the proteasome-mediated degradation of EXO1 
occurring in response to stalled DNA replication is sumoylation-dependent. 
Moreover we found that the UBC9-PIAS1/PIAS4 pathway controls EXO1 
protein stability in vivo both in basal and DNA damaged conditions and we 
were able to reconstituted EXO1 sumoylation in vitro with purified 
recombinant human or yeast EXO1 as substrates and components of the 
sumoylation machinery. The de-sumoylating enzyme SENP6 was found to 
constitutively interact with EXO1 both in vivo and in vitro and depletion of 
SENP6 promotes EXO1 degradation. We also showed that sumoylation and 
ubiquitylation occur sequentially on EXO1 since interfering with the former, by 
UBC9 depletion or chemical inhibition of the E1-SUMO activating enzyme, 
compromises the latter. In a second moment, we demonstrated that 
sumoylation is required for EXO1 recruitment to DNA in response to damage 
since UBC9 depletion decreases the ratio of chromatin-bound to free EXO1 
and the localization of EXO1 at sites of damage, thus resulting in decreased 
EXO1-mediated resection of DNA ends. In vitro studies combined with mass 
spectrometric analysis allowed identification of lysine residues K655 and 
K801/802 as major sumoylation sites in EXO1; Chromosomes spreads analysis 
from cells expressing high levels of wild-type EXO1 showed a high rate of 
chromosomes breaks upon camptothecin treatment. This was not the case for 
cells expressing a SUMO-deficient EXO1 mutant, pointing to an important 
mechanism that cancer cells with up-regulated EXO1 gene expression may 
put in place to survive. 
 
 
 
 
 
 
 
	   7	  
ZUSAMMENFASSUNG 
 
Doppelstrangbrüche (DSB), die zu den gefährlichsten DNS Läsionen 
gehören, treten Schätzungen zufolge mit einer Rate von etwa zehn pro Zelle 
pro Tag in primären humanen oder murinen Fibroblasten auf (Lieber, 2010). 
Diese natürlich vorkommenden DSB entstehen durch den Kollaps von ins 
Stocken geratenen DNS Replikationsgabeln, Replikation über eine 
Diskontinuität (DNA nick) hinweg, reaktive Sauerstoffspezies endogenen 
Ursprungs oder durch die vorzeitige Aktion von DNS Endonukleasen 
(Topoisomerasen oder RAG und AID) (Lieber, 2010). 
Versäumnisse in der Reparatur beschädigter DNS kommen eine gut etablierte 
Rolle in der Entstehung von Krebs zu.  
Trotz der grossen Bemühungen hinsichtlich der Identifikation von Proteinen 
und Signalwegen, welche zur Erkennung unterschiedlicher Formen von DNS 
Schädigungen beitragen, fehlt uns bis anhin ein klares Verständnis auf der 
molekularen Ebene der DNS-Reparaturmechanismen und deren Regulation. 
Im Speziellen gelten die Hierarchie und die gegenseitige Beeinflussung von 
post-translationalen Modifikationen (PTM) in der Rekrutierung, Funktion und 
Stabilität von DNS-Reparaturproteinen an Stellen von Beschädigungen als 
neue Herausforderungen auf diesem Gebiet. 
Das Erkennen der Wichtigkeit von PTM wird uns nicht nur erlauben zu 
verstehen, wie Fehlfunktionen dieser Maschinerien zu der Entwicklung von 
Krebs und dem Aufkommen von Therapieresistenzen beitragen sondern es 
wird uns auch das nötige Wissen vermitteln um gezielt 
Schlüsselkomponenten der DNS-Reparaturwege und deren Regulatoren in 
der Krebstherapie zu nutzen. 
Diese Studie zielt darauf ab, wichtige biologische Fragen zu beantworten, die 
den molekularen Mechanismus betreffen, welcher die Funktion der 
Exonuklease-1 (EXO1), einer gemeinsamen Komponente der Maschinerien, 
die ins Stocken geratene Replikationsgabeln, DSB und Basenfehlpaarungen 
bearbeiten, kontrolliert.  
In früheren Arbeiten unseres Labors demonstrierten wir, dass die Funktion 
von humaner und Hefe-EXO1 bei DSB respektive bei blockierten Gabeln 
rigoros von spezifischen Protein-Protein-Interaktionen kontrolliert wird (Eid et 
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al., 2010; Engels et al., 2011). Weitere Studien unseres Labors zeigten, dass 
in Antwort auf eine stockende DNS-Replikation das zelluläre Niveau von 
humaner EXO1 von phosphorylationsabhängiger Ubiquitinierung reguliert 
wird, welche EXO1 dem Proteasom-vermittelten Abbau zuführt (El-Shemerly 
et al., 2008; El-Shemerly et al., 2005).  
In dieser Studie haben wir diese Beobachtungen ausgeweitet und liefern 
unter Zuhilfenahme von einer Kombination aus molekularbiologischen und 
biochemischen Techniken sowie zellbiologischen Analysen neue 
Erkenntnisse über die Regulation von EXO1. 
Tatsächlich konnten wir durch ein auf Immunofluoreszenz basierendes High-
Throughput-Screening, gefolgt von bild- und computergestützten Analysen 
der Daten, UBC-9-abhängige Signalwege als bedeutende Effektoren von 
EXO1 Stabilität identifizieren, was darauf hinweist, dass der Proteasom-
vermittelte Abbau von EXO1 als Antwort auf stockende DNS-Replikation 
sumoylierungsabhängig ist. 
Des Weiteren fanden wir, dass der UBC9-PIAS1/PIAS4 Signalweg EXO1 
Proteinstabilität in vivo sowohl in basalem wie auch in DNS beschädigtem 
Zustand kontrolliert und wir waren in der Lage, EXO1 Sumoylierung in vitro 
mit purifiziertem, rekombinantem humanem oder Hefe-EXO1 als Substrate 
und Komponenten der Sumoylierungsmaschinerie wiederherzustellen. 
Es zeigte sich, dass das de-sumoylierende Enzym SENP6 in vivo wie auch in 
vitro konstitutiv mit EXO1 interagiert und dass Abreicherung (depletion) von 
SENP6 den EXO1-Abbau fördert. 
Wir demonstrierten auch, dass Sumoylierung und Ubiquitinierung sequenziell 
an EXO1 stattfinden, da durch störendes Eingreifen in das erstere durch 
UBC9 Abreicherung oder chemischer Inhibition des E1-SUMO aktivierenden 
Enzyms der zweite Mechanismus beeinträchtigt wird. 
Später waren wir in der Lage zu zeigen, dass Sumoylierung nötig ist für die 
Rektrutierung von EXO1 an die DNS in Antwort auf Beschädigung, da UBC9 
Abreicherung das Verhältnis von Chromatin-gebundenem zu freier EXO1 und 
die Lokalisierung von EXO1 an beschädigten Stellen senkt, was schliesslich 
in einer Senkung von EXO1-vermittelter Resektion von DNS-Enden resultiert. 
In vitro Studien in Kombination mit massenspektrometrischen Analysen 
erlaubten die Identifikation der Lysin K655 und K801/802 als wichtige 
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Sumoylierungsstellen in EXO1; Chromosome Spread Analysen von Zellen, 
die hohe Level Wildtyp EXO1 exprimieren, zeigten eine hohe Rate von 
Chromosomenbrüchen nach Camptothecin-Behandlungen. Dies war nicht der 
Fall bei Zellen, die ein SUMO-defizientes, mutante EXO1 exprimierten, was 
auf den wichtigen Mechanismus hindeutet, mit Hilfe dessen Krebszellen mit 
hochregulierter EXO1 Genexpression überleben können. 
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PART I 
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1. INTRODUCTION 
1.1 DNA damage: causing and curing cancer 
 
Cells are constantly subjected to DNA damaging events caused by 
exogenous and endogenous factors creating up to 105 DNA lesions per day. 
Exogenous factors include physical genotoxic agents, such as ionizing 
radiation (IR) occurring during treatments exposing the body to X-rays or 
ultraviolet (UV) light from sunlight. Also chemical agents such as methyl 
methanesulfonate (MMS) which attaches alkyl groups to DNA bases, 
mitomycicn C (MMC),  cisplatin and nitrogen mustard which introduce 
covalent links between bases of the same DNA strand (intrastrand crosslinks) 
or of opposite DNA strands (interstrand crosslinks or ICLs), etoposide and 
camptothecin (CPT) which inhibit topoisomerase II and topoisomerase I, 
respectively, inducing the formation of single-strand breaks (SSBs) or double-
strand breaks (DSBs) by trapping topoisomerase-DNA covalent complexes , 
represent external sources of damage [1]. Endogenous factors include, for 
example, reactive oxygen species (ROS) generated by the cells during 
metabolic processes; these, results in DNA breaks and spontaneous DNA 
alterations, such as dNTP misincorporation during DNA replication, DNA 
deamination, depurination and alkylation (Figure 1) [2, 3].  
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Figure 1. DNA damage: causes and effects. Endogenous and environmental sources of DNA 
damaging agent inflict damage to the DNA that range from modified bases, intra- and inter-
strand crosslinks, cyclobutane pyrimidine dimers, 6-4 photoproducts, single- and double-
stranded DNA breaks. Upon sensing DNA damage the cells activate the DDR network which 
activates cellular processes such as cell-cycle checkpoint control, transcription, DNA repair 
machinery, senescence and/or cell death. DNA repair pathways act independently or 
coordinate to repair DNA lesions. Modified after (Ghosal, G. and J. Chen, DNA damage 
tolerance: a double-edged sword guarding the genome. Transl Cancer Res, 2013. 2(3): p. 
107-129.) 
 
To counteract DNA damage and maintain genome integrity, cells need to 
adequately respond to such genotoxic stresses. This is achieved by activation 
of evolutionary conserved DNA-damage response (DDR) pathways that 
results in a two-pronged effect: a block in the cell cycle progression and the 
concomitant induction of DNA repair. Depending on the extent of damage 
suffered by DNA, cells may repair all lesions and re-enter the cell cycle, a 
condition known as checkpoint recovery or, in the case of excessive damage, 
be eliminated by programmed cell death (apoptosis). Alternatively, cells 
undergo an apparently permanent arrest after DNA damage. This state is 
known as "replicative senescence" and consists of an irreversible growth-
arrest program that prevents unlimited cell proliferation. Although senescent 
cells in vitro may remain indefinitely viable, this may not be the case in vivo 
[4]. Genes coding for proteins that are involved in genome surveillance, such 
as DNA repair genes, are referred to as “caretakers”. Mutations or defects in 
such genes predispose an individual to cancer and may enhance 
tumorigenesis, a common condition in numerous hereditary cancer 
syndromes. Affected individuals inherit a defective allele of a caretaker gene 
and eventually acquire a mutation of the second allele in a somatic cell, an 
event that facilitates tumour survival and disease progression. Examples of 
inherited mutations in caretaker genes are those of the WRN DNA-helicase 
that are linked to the development of lymphomas or mutations in the BLM 
DNA-helicase that result in a leukemia-prone phenotype and mutations in the 
BRCA1 or BRCA2 genes that lead to increased incidences of breast and 
ovarian cancers, respectively [5]. 
Proper DNA replication is necessary to assure inheritance of the correct 
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genetic information to daughter cells and maintain genome stability. Genomic 
instability arising from the above-mentioned events is at the base of 
tumorigenesis but it is also used in cancer therapy to induce DNA lesions and 
apoptotic pathways in cancer cells. Indeed, there is evidence supporting the 
idea that DNA alterations during replication occur at early stages of 
tumorigenesis in many types of cancers promoting the activation of 
oncogenes, genes inducing over-proliferation [6]. In precancerous cells, such 
lesions are counteracted by a powerful DNA damage response (DDR) which 
induces senescence and apoptosis [7, 8] Upon further genetic and epigenetic 
rearrangements down-regulating the DDR, tumorigenesis progression takes 
place [9] as confirmed by the cancer-prone phenotype of many DDR 
syndromes (Table 1). 
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Table 1. (Modified after (Negrini, S., V.G. Gorgoulis, and T.D. Halazonetis, Genomic 
	   15	  
instability--an evolving hallmark of cancer. Nat Rev Mol Cell Biol, 2010. 11(3): p. 220-8.) 
 
In such cases, senescence and apoptosis bypass is facilitated despite 
accumulation of DNA damage [10]. In general we can say that cancer is 
fueled by genomic instability since most of cancers are characterized by 
chromosomal instability (CIN), accumulation of DNA base mutation and 
microsatellite instability (MIN) [9].  
On the other hand, cancer cells are usually more susceptible to genotoxic 
agents compared to normal cells, likely due to the fact that first, they divide 
more rapidly and second, cancer cells usually carry alterations in some 
components of DNA repair pathways that arise during tumour development. 
Another important consideration in this respect is that the high proliferation 
rate of cancer cells and the associated metabolic stress, like hypoxia and 
mitotic stress, renders them more reliant on anti-stress mechanisms, such as 
DDR pathways [11]. Thus, combinatorial treatments with conventional DNA-
damaging chemotherapeutic drugs and inhibitors of specific DNA repair 
pathways, might be the best choice in the treatment of cancer. Moreover, few 
years ago, it was observed that many non-oncogenic (NOA, non-oncogenic 
addiction) pathways are of vital importance for cancer cells, despite such 
pathways are not essential for normal cells survival. Thus, targeting NOAs 
represents a further step towards the selective growth repression of cancer 
cells [10]. 
To conclude, exposing to light the events that cause DNA lesions and the 
peculiar and precise mechanisms evolved by cells to repair them, will facilitate 
the understanding of tumorigenesis. 
 
1.1.1 Replication stress 
 
Replication fork stalling represents the initial event which, if not properly 
solved, may lead to failure in proper duplication of the genetic information and 
thus to chromosomal aberrations or mitotic catastrophe, resulting in 
tumorigenesis or apoptosis, respectively. Particular regions of the genome, 
known as common fragile sites (CFSs), are more prone to breakage than 
others upon exposure of cells to replicative stress; such regions are the first 
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being damaged [6]. Other regions of the genome, called early-replicating 
fragile sites (ERFSs) seem to be replication stress sensitive; these segments 
are located in highly transcribed, repetitive and CpG-rich regions where 
replication-transcription collisions create lesions [12]. When DNA replication 
slows down because of the presence of the lesion, multiple mechanisms act 
to sense the damage, stabilize and restart the stalled forks [13].  
 
 
1.1.2 Double-strand breaks (DSBs) 
 
Double-strand breaks represent the most toxic DNA lesions since they can 
trigger profound genomic rearrangements or generate genetic modifications of 
essential biological processes. Harmful cases are those in which the DSB is 
the result of exposure of DNA to exogenous or endogenous stresses leading 
to replication forks stalling and collapse. In other cases, DSBs are 
physiologically induced by cellular enzymes in processes like meiotic 
differentiation, mating-type switching in Saccharomyces cerevisiae [14] or in 
V(D)J and class switch recombination to promote the diversity of the immune 
response system [15]. 
 
1.1.2.1 Hydroxyurea-induced DNA damage 
 
Hydroxyurea (HU) is a powerful inhibitor of the ribonucleotide reductase 
(RNR) enzyme that catalyzes the formation of deoxyribonucleotides, used in 
the synthesis of DNA, from ribonucleotides [16]. HU treatment of cells leads to 
starvation of DNA polymerase at replication forks for dNTPs, reducing, and 
only rarely completely depleting, the purine bases dGTP and dATP pool [17]. 
Changes in individual dNTP pools were observed in HU-treated mammalian 
cells, likely due to the compensatory activity of deoxyribonucleotide saving 
pathway typical of higher eukaryotes. Budding yeast represent an easier 
system to study HU-dependent effects on replication since they do not 
possess any deoxyribonucleoside kinase activities and they completely rely 
on ribonucleotide reductase to synthesize deoxyribonucleotides [18]. Previous 
studies suggested that HU-treatment does not exhaust the dNTP pools most 
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likely because cells evolved mechanisms in order to arrest DNA replication as 
soon as the pool of deoxyribonucleotides reaches a minimum threshold, likely 
to conserve basal dNTPs for processes such as DNA repair. Indeed, it was 
shown that nucleotide excision repair pathway is sensitive to dNTP pool 
depletion in cultured human fibroblasts [19]and moreover, HU-treated yeast 
cells complemented with artificial dNTP pools showed increased cell survival 
upon DNA damage [20].  
 
1.1.2.2 Camptothecin-induced DNA damage 
Camptothecin (CPT) is a cytotoxic antitumor drug; it interferes with DNA 
replication by inhibiting the activity of Topoisomerase I, an enzyme required to 
remove the super helical tension accumulating in front of advancing 
replication forks [21]. CPT stabilizes the so-called 'cleavable complexes' 
between Topoisomerase 1 and the 3' broken DNA end [22]. Indeed, 
Topoisomerase I releases topological stress by breaking the DNA double 
helix on one strand and passing the other strand through the break until re-
ligation of the 5' rotating end to the 3' end [23]. CPT-treated mammalian cells 
were shown to generate replication forks-associated DNA double-strand 
breaks resulting in extended and perhaps permanent cell cycle arrest in S/G2 
phase upon removal of the drug, likely due to the presence of unrepaired DNA 
breaks [24]. CPT activity is specifically toxic during S-phase, although the 
levels of Topoisomerase 1 and cleavable complexes are relatively constant 
throughout the cell cycle. It was suggested that there is some interaction 
between the cleavable complexes and the moving replication machinery in S-
phase resulting in irreversible fork arrest and the conversion of the cleavable 
complexes to an irreversible enzyme-linked DNA strand-break. These breaks 
will collapse into double-strand breaks, highly toxic lesions. 
 
1.1.3 DSBs signaling 
 
When a DSB occurs on DNA, a number of different proteins are recruited to 
the site of damage in a time- and space-highly coordinated way. MRE11, 
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RAD50 and NBS1 proteins, members of the MRN complex in mammalian 
cells, are among those proteins first sensing the lesion and being recruited on 
chromatin. MRN is a highly conserved protein complex and it is essential for 
cell survival, since null mutations in any of the components result in 
embryonic lethality in mice [25]. Indeed, MRN-defective syndromes are 
characterized by mutation, for example, in MRE11 gene (ataxia-
telangiectasia-like disorder or ATLD) [26], in NBS1 gene (Nijmegen breakage 
syndrome) or in RAD50, leading to a variant form of Nijmegen breakage 
syndrome (NBS-variant) [27]. The MRN complex first binds and processes 
broken DNA ends leading to recruitment and activation of the ATM (ataxia-
telangiectasia mutated) kinase [28]. In response to DSBs, ATR (ataxia-
telangiectasia and Rad3-related) kinase activity is triggered in an ATM-
dependent manner in the S and G2 phase of the cell cycle [29]. Activated 
ATM phosphorylates H2AX at the conserved C-terminal S139 residue in 
response to DSBs [30]. H2AX phosphorylation occurs on megabase regions 
flanking the DSBs within seconds after the DNA damage occurs, suggesting 
that H2AX phosphorylation may be a critical event in early DNA damage 
signaling [31]. One key function of phosphorylated H2AX (γ-H2AX) is to 
provide a high-affinity binding site for MDC1 (mediator of DNA damage 
checkpoint 1), which binds γ-H2AX via its C-terminal tandem BRCT repeats. 
MDC1 functions as a molecular bridge between γ-H2AX and the NBS1 
component of the MRN complex, and helps providing a platform for various 
dynamic interactions for these and additional checkpoint and DNA repair 
proteins within the vicinity of the damage sites. Moreover, this interaction 
protects γ-H2AX from de-phosphorylation [32]. The key function of activating 
ATM/ATR signaling is the initiation of cell cycle arrest at G1/S, intra-S-phase 
and G2/M checkpoints. ATM phosphorylates the checkpoint kinase-2 (CHK2) 
at Thr-68, while ATR phosphorylates the checkpoint kinase-1 (CHK1) at Ser-
317 and Ser-345 [33]. Specifically, ATM/ATR-dependent phosphorylation of 
CHK2 and CHK1 facilitates intra-molecular auto-phosphorylation leading to 
full checkpoint kinase activation and further transmission of the signal to key 
cell-cycle regulators, including the CDC25 family of phosphatases, the kinase 
WEE1 and p53, which itself can undergo phosphorylation by ATM at Ser-15. 
Temporal cell-cycle arrest induced in response to DNA damage is established 
	   19	  
through activation of the kinase WEE1 and inhibition of CDC25 activity, which 
results in inactivation of cyclin-dependent kinases (CDKs) at different stages 
of the cell cycle. A more sustained arrest is instead provided by p53-induced 
transcription of the CDK inhibitor p21 [34]. Cell cycle arrest presumably 
provides time to allow DNA repair to occur before the lesions are encountered 
by a replicative polymerase during DNA replication as well as to prevent the 
mis-segregation of chromosomal fragments during anaphase. 
 
 
1.1.4 DSBs repair 
 
Classically, two conceptually different mechanisms can in principle repair 
DSBs occurring in the genome of higher eukaryotes: Non-homologous end 
joining (NHEJ) and homologous recombination repair (HR) [35]. As their 
names imply, NHEJ simply restores integrity in the DNA by joining the two 
ends without necessarily preserving the original sequence. As a result, it is 
error-prone. Because a second DNA molecule is not required for the function 
of this repair pathway, it is active throughout the cell cycle. HR, on the other 
hand is equipped to maintain fidelity in the sequence of the DNA molecule. To 
achieve this, HR requires an undamaged homologous sequence that serves 
as template for repair of the broken strands. There are two sources of 
homology in mammalian cells. The homologous chromosome that is present 
throughout the life cycle of the cell and the sister chromatid that is generated 
after DNA replication and which, therefore, exists only during the S and G2 
phases of the cell cycle. Accumulating evidence supports the view that HR 
uses the sister chromatid as template rather than homologous chromosomes, 
a requirement that restricts the function of this pathway to the S and G2 
phases of the cell cycle. This requirement probably derives from the fact that 
in a eukaryotic cell nucleus the homologous chromosomes are 
accommodated in distinct and frequently distantly located domains that 
renders difficult the search for homology (a key step of HR). In addition, using 
sequences on the homologous chromosome as template carries the implicit 
risk of generating gross chromosomal rearrangements (GCRs) such as 
deletions, inversions or loss of heterozygosis [36]. 
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The fact that at least two genetically and conceptually distinct repair pathways 
are involved in the repair of DSBs raises questions regarding their 
coordination. If these pathways operate independently of each other it is 
possible that they compete against each other. On the other hand, if they 
collaborate, then the question is how their functions are coordinated. As 
stated above, the choice between either pathway depends on the phase of 
the cell cycle. Studies of either NHEJ- or HR-deficient cells suggest that these 
two pathways compete for the repair of DSBs [37]. HR-deficient cells have a 
significant DSB repair defect only during the S/G2/M phases, whereas NHEJ-
deficient cells showed reduced repair efficiency at all cell cycle stages [38]. 
The mechanisms by which cells decide between these two repair pathways 
have been studied for the past few years. According to the evidence obtained 
so far, DNA-end resection is a critical step that favors the choice of HR over 
NHEJ and it is regulated by cyclin-dependent kinases (CDKs), the master 
regulators of the cell cycle [30]. Analysis of end resection in yeast revealed 
that inhibition of CDK1/cdc28 in the G2-phase prevented end resection and 
checkpoint activation as well persistence of Mre11 at the DSB site, consistent 
with the idea that processing of the break had stalled. This suggests that 
CDK1 controls Mre11-associated nuclease function at the DSB, but does not 
influence its recruitment to DNA ends [39]. In addition, Sae2, a DNA 
endonuclease that controls the initiation of DNA end resection in yeast [34] is 
regulated by CDK-dependent phosphorylation. Mutation of Sae2 Ser-267 to 
the non-phosphorylatable residue alanine (S267A) caused an end-processing 
phenotype comparable with deletion of Sae2. In contrast, mutating the same 
residue into a residue that mimics constitutive phosphorylation (S267E) 
complemented these phenotypes and bypassed the need for CDK activity in 
DSB end resection [40]. The Sae2-null and S267A mutants showed delayed 
HR and enhanced NHEJ, whereas the S267E mutant showed slightly 
enhanced recombination and a decrease in NHEJ. This indicates that 
CDK1/cdc28-mediated phosphorylation of Sae2 in yeast regulates the 
balance between HR and NHEJ during the cell cycle. The motif of Sae2 that 
contains the residue Ser-267 is highly conserved amongst orthologs in higher 
eukaryotes, and mutation of the analogous residue in human CtIP also 
resulted in hypersensitivity to camptothecin [40]. These results suggest that 
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similar CDK control of DNA end resection exists in other organisms.  
Moreover, it was shown that phosphorylation of a putative CDK site in human 
CtIP [CTBP (C-terminus-binding protein of adenovirus E1A)-interacting 
protein] enables it to interact with the BRCA1 C-terminal tandem BRCT 
domain, an interaction that is required for efficient end resection [41]. This, in 
turn, suggests that the BRCA1-CtIP interaction influences the balance 
between HR and NHEJ. Collectively, these results support a model in which 
the commitment to DSB end resection and repair is regulated in order to 
ensure that the cell activates the most appropriate DSB repair pathway to 
optimize genome stability (Figure 2). 
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Figure 2. DNA repair pathways involved in the repair of double-strand break. (A) Rapid 
association of Ku to DSBs promotes NHEJ by recruiting DNA-PKcs. Sequential 
phosphorylation events on multiple DNA-PKcs amino acid clusters favors the initial 
processing of DNA ends by ARTEMIS, followed by DNA-PKcs-dependent protection of DNA 
ends required for DNA ligation. (B) Alternatively to NHEJ, MRN, which is initially recruited to 
DSBs by PARP in competition with Ku, mediates the initial stages of DSB resection together 
with CtIP and BRCA1 to promote homologous recombination in S and g2. 53BP1 has an 
inhibitory role on DSB resection and is negatively regulated by BRCA1 by unknown 
mechanisms. The MRN/CtIP/BRCA1 complex can also promote DSB resection following de-
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protection of DNA ends when NHEJ fails. Extensive DSB resection and formation of RPA-
coated 3' ssDNA ends is induced by EXO1 and BLM. ATM plays a central role in the 
regulation of DSB resection. Displacement of RPA from the 3' ssDNA ends and assembly of 
RAD51 filaments mediated by BRCA2 leads to strands invasion into homologous DNA 
sequences. Recruitment of RAD51 to ssDNA ends is regulated by the ATR pathway, which is 
activated following DSB resection. D loop structures formed after strand invasion can be 
cleaved by MUS81/EME1 or displaced by RTEL1 during SDSA to generate crossover events, 
respectively. Noncrossovers are generated also by dissolution of Holliday junctions (HJs) by 
the BLM/TOPOIII complex, whereas HJ resolution by the nucleases GEN1 and SLX1/SLX4, 
which associates with MUS81/EME1, can generate both crossover and noncrossover events. 
(C) Limited DSB resection carried out by CtIP and MRN in G1 results in alternative NHEJ. (D) 
Following DSB resection, 3' ssDNA ends with homologous sequences can be directly 
annealed by RAD52. Modified after (Ciccia, A. and S.J. Elledge, The DNA damage response: 
making it safe to play with knives. Mol Cell, 2010. 40(2): p. 179-204.) 
 
1.1.4.1 Homologous recombination (HR) 
 
The goal of HR is to facilitate recovery of information lost as result of damage 
to both DNA strands by retrieving it from an undamaged homologous 
sequence. To this end, damaged and undamaged DNA molecules need to 
directly interact. In particular, the damaged DNA molecule will need to first 
undergo processing in order to generate DNA structures that can “read-off” 
sequence information. Furthermore, the chromatin structure on both DNA 
molecules will need to be modified in order to facilitate the search for the 
homologous sequences in the sister DNA molecule. Once homology has been 
found, sequence information will need to be copied and finally the interacting 
DNA molecules will need to be separated. 
HR starts with the resection of DNA ends around the DSB, forming 3’-single 
stranded DNA (ssDNA) stretches [42]. This form of DNA can invade and pair 
to homologous sequences present in an intact DNA molecule and is also 
suitable to be extended by DNA polymerases to copy the missing sequence 
information. In cells of higher eukaryotic organisms the initial resection of DNA 
ends is orchestrated by the MRN complex [43], assisted by the function of the 
resection-promoting factor CtIP  [44-46]. These proteins collaborate to trim the 
DNA ends to an intermediate form in a process so-called “short-range” 
resection. The trimmed DSB is then resected more extensively in a step of 
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“long-range” resection [30, 44]. Possible candidates are the exonuclease-1 
(EXO1) and the Bloom’s syndrome protein (BLM) together with the nuclease 
DNA2 [46]. The generated single-stranded 3’-overhangs are coated by the 
replication protein A (RPA) heterotrimer, the major mammalian ssDNA binding 
protein. This rapid binding by RPA is believed to protect the ssDNA and to 
prevent the formation of secondary DNA structures [47]. In addition, RPA also 
mediates the recruitment of the ATR/ATRIP complex to the single stranded 
regions and initiates the DDR signaling cascades, which among others inhibit 
cell cycle progression through activation of the corresponding checkpoints 
[48].  
The subsequent DNA strand invasion and homology search requires the 
formation of a nucleoprotein filament composed of Rad51 bound to ssDNA. 
Since RPA binds more avidly to ssDNA than Rad51, additional activities are 
required to load Rad51 onto RPA-coated ssDNA and to displace RPA. In 
mammalian cells, an important mediator complex is BRCA1/BARD1 and 
BRCA2 (FANCD1)/DSS1, bridged by the PALB2 (partner and localizer of 
BRCA2) (FANCN) [49]. The direct loading of Rad51 is believed to be through 
its direct interaction with BRCA2 [50]. This interaction is thought to be limited 
to S and G2 phases of the cell cycle by CDK-dependent phosphorylation of 
BRCA2 [51]. The Rad51 nucleoprotein filament then invades a duplex DNA of 
the sister chromatid and searches for homology. Once found, the invading 
strand sets up a structure, which involves pairing with the complementary 
strand and displacement of the other, resulting in a so-called D-loop 
(displacement loop) structure. At this point, HR can be completed via several 
pathways and different outcomes. Synthesis-dependent strand annealing 
(SDSA) or double strand break repair (DSBR) have been described to occur 
in case of two-ended DSBs. In SDSA the elongated invading strand pairs with 
the second DSB end. This process only produce non-crossovers, hence 
SDSA is the preferred recombination-mediated pathway for DSB repair in 
somatic cells to prevent loss of heterozygosity. Alternatively, during DSBR, 
the D-loop gets extended and captures the second DSB end, creating a 
double Holliday junction (HJ) between the four strands that can undergo 
branch migration, a process catalyzed by members of the RecQ helicase 
family [52]. HJ intermediates can be resolved in different ways resulting in 
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either non-crossovers or crossovers, the later being predominant during 
meiotic recombination. The BLM/Topo IIIα can dissolve HJ to form non-
crossover products [53]. Alternatively, the MUS81-EME1 complex may cleave 
HJs to yeild crossovers [54]. Two more HJ resolvases that has been recently 
identified in humans cells, GEN1 and SLX1/SLX4 promotes the resoultion of 
HJs by a mechanism that is believed to generate crossovers and non-
crossovers [55-57]. 
In the abscence of a homology, single-strand annealing (SSA) can be the 
pathway of choice. SSA involves the exposing of repetitive sequences by 
resection of both 5’-strands until sequences are uncovered and annealed. 
DNA flaps are then removed by nucleases followed by DNA synthesis and 
ligation of the nicks. Since SSA involves the deletion of the intervening 
sequences, it is considered as a mutagenic repair pathway. One-ended DSBs 
generated through uncapping telomeres or collapsed replication forks after 
encountring a single strand break (SSB) or nick, are repaired by break-
induced repair (BIR). In BIR, the invading 3’-strand forms a replication fork 
that copy long tracts from the donor DNA molecule. This process could 
potentially lead to loss of heterozygosity. 
 
1.1.4.2 Non-homologous End joining (NHEJ) 
 
NHEJ is the major pathway for DSBs repair in mammalian cells. It involves 
joining the two ends of a DSB through a process largely independent of 
homology. NHEJ provides a relatively simple mechanism for the repair of 
DSBs throughout the cell cycle, but of particular importance during G0-, G1-, 
and early S-phase [58]. NHEJ only works efficiently and with high fidelity in 
the repair of DSBs displaying complimentary overhangs, 5’ phosphates and 3’ 
hydroxyl groups, so called ‘clean’ DSBs, such as those produced by 
nucleases. In yeast and mammalian cells, approximately 25-50% of nuclease 
DSBs is repaired by precise NHEJ [59]. If the ends are not compatible, then 
processing is required and this can result in mutagenic deletions or insertions 
at the break site [60]. The molecular mechanism by which NHEJ operates 
could be simplified in three main steps: first both ends of the broken DNA are 
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captured, second a molecular bridge is formed which brings the two DNA 
ends back together, finally the broken DNA ends are re-ligated.  
Central to NHEJ in organisms from yeast to man is the Ku protein, a 
heterodimer of two subunits called Ku70 and Ku80 [61]. Biochemical studies 
of mammalian Ku have showed that it can bind DNA in a non-sequence-
dependent manner and that binding is dependent on DNA DSBs [62]. The 
NHEJ process is initiated by the binding of the Ku70/80 heterodimer to both 
ends of the broken DNA molecule, forming a ring-shaped structure, in which 
the opening of the ring accommodates a DNA helix. This feature allows the 
Ku heterodimer to slide over the ends of a broken DNA molecule [63]. It is 
believed that the association of a DNA end with the Ku heterodimer creates a 
platform for the assembly of other NHEJ key enzymes and proteins. In 
vertebrates, Ku serves as the DNA targeting subunit for the DNA-dependent 
protein kinase catalytic subunit (DNA-PKcs), which together with the Ku forms 
the DNA-PK holoenzyme. The association of the DNA-PKcs with DNA 
activates its serine/threonine kinase activity. Among the different 
phosphorylation targets of DNA-PKcs are XRCC4, the nuclease Artemis and 
DNA-PKcs itself, which can undergo autophosphorylation. This 
autophosphorylation is believed to influence its conformation and dynamics, 
serving to relieve blockage of the ends by DNA-PKcs, hence facilitating 
access of other repair factors [64]. Occasionally, the generated DSBs might 
require further processing to generate ligatable 5’-phosphorylated ends in 
order for repair to be completed. The nuclease Artemis, a single-stranded 5’-
3’ exonuclease, which upon phosphorylation by DNA-PKcs acquires an 
additional endonuclease activity specific for hairpins and ssDNA overhangs, 
as well as the polynucleotide kinase (PNK), together with DNA-PKcs have 
been shown to stimulate DNA-processing for efficient NHEJ [65]. The 
processed DNA-ends might lead to the generations of DNA gaps that are 
filled in by DNA polymerases. Members of the DNA polymerase X family of 
polymerases, including polymerase µ, polymerase λ and terminal 
deoxyribonucleotidyltransferase (TdT), have been shown to fill the gaps 
generated during NHEJ. Finally, NHEJ is completed by ligation of the DNA 
ends, a step carried out by the NHEJ ligase complex (also known as X4-L4), 
which is composed by XRCC4, DNA ligase IV and XLF [59]. 
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Alternative NHEJ acts in the absence of classical NHEJ factors such as Ku, 
XRCC4 or DNA ligase IV. There, repair events involve small deletions and 
require short stretches of homology between the ligatable DNA ends. 
Microhomology-mediated end-joining (MMEJ) is the dominant pathway during 
alternative end-joining. In this repair mechanism DNA is slightly resected (less 
than 100 nucleotides) to expose regions of homology, which lead to 
reattachment of the two DNA ends of the break. The DNA is further processed 
by nucleases that remove flaps and overhangs and eventually by DNA 
polymerases that fill in the gaps [66]. 
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1.2 The DNA damage response (DDR) 
 
DNA lesions and replication stress are sensed by the DNA Damage 
Response (DDR) signal transduction cascade, which leads to the repair of 
damage and allows cells to proceed through the cell cycle [61].  In eukaryotic 
cells, the DDR uses signal sensors, transducers and effectors (Figure 3). 
 
 
 
Figure 3. DNA damage and DNA damage response (DDR). Both external insults and internal 
hazards can cause DNA damage. DNA damage response is coordinated by various proteins 
whose function can be categorized as DNA damage sensors, transducers, mediators and 
effectors. Double strand DNA damage (DSB) can be detected by MRN complex (sensor) to 
recruit and activate transducer ATM (Ataxia Telangectasia Mutated) to activate CHK2 
(effector), with the help of DDR mediators MDC1 (mediator of DNA damage checkpoint), 
53BP1 (p53-binding protein 1), and BRCA1 (breast cancer 1). In contrast, single strand DNA 
damage (SSB) could be detected by sensor protein (replicative protein A), to recruit and 
activate transducer ATR (Ataxia Telangectasia- and Rad3-related), to activate CHK1 
(effector), with the help of mediators TopBP1 (topoisomerase-binding proteins 1) and Claspin. 
p53 and CDKs are the major downstream substrates in response to DSB and SSB 
respectively. Modified after (Li, X., et al., The yin-yang of DNA damage response: roles in 
tumorigenesis and cellular senescence. Int J Mol Sci, 2013. 14(2): p. 2431-48.)  
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The sensors include those proteins directly recognizing the aberration on DNA 
and activating the most upstream DDR kinases ATM and ATR. Such kinases 
represent the transducers promoting the series of phosphorylation events 
within the DDR network. The substrates of ATM and ATR represent the 
effectors, proteins involved in essential processes for genomic stability 
maintenance such as DNA replication, DNA repair and cell cycle control. In 
general we can define the DDR response mechanism as a phosphorylation-
based transduction pathway, since the most upstream transducers are large 
serine/threonine kinases phosphorylating hundreds of proteins at Ser/Thr-Glu 
motifs [63]. 
DNA-damaging agents mediate the activation of the two main players starting 
the DDR cascade: ATM and DNA-PK. Together with ATR, they represent 
members of the phosphatidylinositol 3-kinase-like protein kinase (PIKKs) 
family and they act in conjunction with members of the poly(ADP-ribose) 
polymerase (PARP) family [61]. Unlike ATM, which regulates many different 
substrates, DNA-PK acts on a small group of proteins involved in DSB ends 
re-joining. ATR is activated only in a second step of the repair process, in 
complex with its partner protein ATRIP [52]. The PARP family has 16 
members but only two of them are involved in the DDR, PARP1 and PARP2; 
they are activated upon SSBs and DSBs and their activity consists in the 
attachment of poly (ADP-ribose) chains on proteins as a signal for other DDR 
factors to be recruited on chromatin at the sites of damage (Figure 4).  
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Figure 4. Cell-cycle-specific DNA structures and lesions and the checkpoint kinases that 
respond to them. During G1 phase, double-strand creaks (DSBs) lead to activation of the 
phosphoinositide 3-kinase related kinases DNA-PK and ATM, whereas other types of 
damage, such as ultraviolet-induced pyrimidine dimers, are processes by nucleotide-excision 
repair enzymes and lead to ATR activation. DSBs or nicks that are not repaired during G1 
result in collapse of replication forks, which activates ATM (following DSBs resection, ATR is 
also activated). S-phase DNA damage, such as stalled forks or gaps that are generated 
during replication, activate ATR. In pathological conditions, for example, when cells contains 
mutations in genes of the ATM-ATR pathway, accumulation of reversed forks is processed by 
nucleases that lead to extensive gaps or DSBs. Topological problems during replication can 
form catenanes, which can result in nicks or, if unresolved, can lead to DSBs during 
chromosome segregation. Modified after (Branzei, D. and M. Foiani, Regulation of DNA repair 
throughout the cell cycle. Nat Rev Mol Cell Biol, 2008. 9(4): p. 297-308.) 
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1.2.1 ATM and ATR Kinases specificity 
 
The study of the two apical kinases ATM and ATR represent most of the 
knowledge collected until now about the DDR. Upon identification of the DNA 
lesion by sensor proteins, ATM and ATR phosphorylate DDR amplifying 
proteins which recruit the substrates of the two kinases [69]; such substrates 
can be phosphorylated directly by ATM/ATR or indirectly by CHK1 and CHK2 
kinases which are themselves ATM/ATR targets [61]. The Triple T complex 
(TEL2-TTI 1-TTI 2) is responsible for ATM and ATR stability since it 
associates with the heat shock protein HSP90 and promotes the synthesis of 
new PIKKs. In-vivo and in-vitro studies suggested that different types of DNA 
lesions are sensed by ATM and ATR; ATM is primarily activated by double-
strand DNA breaks (DSBs) while ATR activation arises upon a broader range 
of lesions interfering with DNA replication, also including DSBs.  
In response to DSBs, ATM is activated by being recruited to the damaged 
sites where it phosphorylates its direct substrates BRCA1, CHK2 and p53 and 
mediates the consequent DNA repair cascade activation, cell-cycle arrest, 
apoptosis and other downstream pathways [67]. As previously reported, ATM 
is a mediator in the DDR process and therefore it needs to be regulated by 
upstream sensor proteins, which, in the case of DSBs, are represented by 
Mre11-Rad50-Nbs1, members of the MRN complex. 
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Figure 5. Activation of ATM by DSBs: 
Recognition of DNA ends and 
chromatin by ATM. The MRN complex 
functions as a sensor of DNA ends and 
activates ATM. The ATM activated by 
DNA ends (red) phosphorylates 
substrates such as CHK2 and p53, and 
the H2AX in flanking nucleosomes. 
Phosphorylated H2AX (γ-H2AX) is 
recognized by MDC1, which triggers a 
feed-forward loop that spreads 
activated ATM and γ-H2AX over large 
chromatin domains. Modified after 
(Marechal, A. and L. Zou, DNA damage 
sensing by the ATM and ATR kinases. 
Cold Spring Harb Perspect Biol, 2013. 
5(9).) 
 
 
 
The exact mechanism by which 
MRN activates ATM is not yet 
completely understood, although 
in-vitro studies suggested that  
the presence of purified MRN 
proteins stimulates ATM kinase activity only in the presence of free dsDNA 
ends, blunt ends or also dsDNA ends with short single-strand DNA (ssDNA) 
overhangs, as binding substrate [28]. Specifically, it was also shown that the 
carboxyl terminus of Nbs1 directly interacts with ATM [68]. Following this 
initial activation step, ATM mediates the phosphorylation of the histone variant 
H2AX (γ-H2AX refers to the phospho-form of H2AX) which occurs within 
minutes after the DNA damage, spreading over >500 Kb chromatin domains 
flanking the lesion. This event is important for the recruitment of many DNA-
repair proteins and chromatin-remodeling factors around the damaged site but 
not for phosphorylation of other ATM substrates [69]. In order to be able to 
phosphorylate H2AX contained in the nucleosomes flanking the lesion and 
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thus to be able to propagate the phosphorylation to other histones along the 
chromatin, ATM interacts with the FHA domain on MDC1, another mediator 
protein, which at the same time binds the previously phosphorylated γ-H2AX, 
so that ATM can keep phosphorylating the immediately adjacent histone. 
Auto-phosphorylation of ATM has been reported to be essential for the 
binding with MDC1 (Figure 5). ATR, the second kinase involved in the DDR 
pathway, is activated upon direct interaction between ATRIP, its partner 
protein, and RPA-coated ssDNA, a key structure generated upon DNA ends 
resection in response to DSBs occurring during S-phase of cell cycle [70]. 
Thus, we can say that ATR activation is resection-dependent and that 
lengthening of RPA-coated ssDNA switches the signal cascade from an ATM- 
to an ATR-activating mode. ATR-ATRIP recruitment to DNA promotes its own 
trans-autophosphorylation at T1989 residue and the additional recruitment of 
the RAD17-RFC2-5 clamp loads to junctions between ssDNA and dsDNA. 
The 911-checkpoint clamps, including RAD9-RAD1-HUS1 proteins, is then 
loaded on dsDNA. TOPBP1 interacts with RAD9 and Rhino, a protein 
interacting with the 9-1-1 complex, and it stimulates the ATR-ATRIP complex 
kinase activity (Figure 6). ATR substrates, CHK1 effector kinase, RPA and 
other targets are then phosphorylated. Moreover, CHK1 was shown to be 
phosphorylated consecutively in respect to CHK2 (ATM substrate), supporting 
the fact that ATR is involved in a second wave of activation [71, 72]. Activated 
CHK1, in turn, is essential for the intra-S and G2/M checkpoint responses and 
for RAD51 recombinase phosphorylation, important for the repair of DSBs in 
S-phase.  
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Figure 6. A fail-safe, multistep mechanism for ATR activation. Increased amounts of ssDNA 
are generated by resection of DNA ends or by uncoordinated DNA unwinding and synthesis 
at replication forks. Extensively resected DNA ends are no longer recognized by ATM 
efficiently. Once coated by RPA, ssDNA recruits the ATR-ATRIP complex (1), and promotes 
ATR trans-autophosphorylation (2). RPA-ssDNA also promotes the recruitment of the Rad17-
Rfc2-5 clamp loader to junctions between ssDNA and dsDNA, and the loading of Rad9-Rad1-
Hus1 (9-1-1) checkpoint clamps onto dsDNA (3). TopBP1 interacts with the phosphorylated 
Rad9 and with Rhino, which associates with 9-1-1 (4). the TopBP1 recruited to dsDNA by 9-
1-1 and rhino engages the ATR-ATRIP complex on RPA-ssDNA through the ATR 
autophosphorylation site T1989. This process enables TopBP1 to stimulate ATR-ATRIP to its 
full capacity (pink) on ssDNA (5). TopBP1 may also function as a scaffold to facilitate ATR 
substrate recognition. This multistep process for ATR activation ensures that ATR is only 
activated when both ssDNA and ssDNA/dsDNA junctions are present at sites of DNA damage 
and are recognized by DNA damage sensors, providing a fail-safe but reversible mechanism 
to signal DNA damage. The dashed green lines represent phosphorylation events, and the 
solid black line represents the loading of 9-1-1 by Rad17-RFC2-5 complex. Modified after 
(Marechal, A. and L. Zou, DNA damage sensing by the ATM and ATR kinases. Cold Spring 
Harb Perspect Biol, 2013. 5(9).) 
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 1.2.2 Cell cycle checkpoints activation 
 
The term ‘cell-cycle checkpoint’ refers to mechanisms put in place to enforce 
dependency in the cell cycle by ensuring timely execution of process such as 
DNA replication or mitosis [73]. Thus, checkpoint pathways have the ability to 
control phase transitions. Given the critical significance of error-free DNA 
replication and chromosome segregation for the maintenance of genomic 
integrity and the prevention of cancer, cells have evolved the ability to trigger 
different cell cycle checkpoints upon DNA damage. These can transiently 
delay cell-cycle progression in G1, S or G2 phases or even impose prolonged 
cell-cycle arrests in either G1 or G2 before entry into the subsequent S phase 
or mitosis (Figure 7). At the molecular level, common denominator of all 
checkpoint pathways is the inhibition of cell cycle "controllers", namely the 
cyclin-dependent kinases. These are protein complexes responsible of 
ensuring the timely triggering and the execution of key events at phase 
transitions. 
 
 
Figure 7. Cell cycle checkpoints. Modified after (Gabrielli, B., K. Brooks, and S. Pavey, 
Defective cell cycle checkpoints as targets for anti-cancer therapies. Front Pharmacol, 2012. 
3: p. 9.) 
 
 
	   36	  
1.2.2.1 The G1/S checkpoint 
 
To prevent replicating damaged DNA, cells exposed to genotoxic stress in G1 
phase activate ATM/ATR. The latter, in a cascade of phosphorylation events, 
activate the downstream kinases CHK2/CHK1 that, in turn, directly 
phosphorylate the protein kinase WEE1. WEE1 phosphorylates CDK2 at two 
residues (Thr14/Tyr15) located in Gly-rich P-loop of the kinase, which is the 
ATP binding site. Such phosphorylation does not affect nucleotide binding but 
hampers catalysis [79]. In addition, checkpoint kinases phosphorylate 
members of the CDC25 family of double-specificity phosphatases on several 
serine or threonine residues. CDC25 phosphatases specifically remove 
phosphate from the two inhibitory sites in CDKs ATP-binding site, thus 
causing full activation of the CDK/Cyclin complexes [74]. Whereas Cdc25B 
and -C are not required for mouse development or checkpoint function [75], 
and inhibition of these phosphatases by DNA damage essentially occurs by 
sequestration mechanisms (see below), CDC25A degradation via ubiquitin-
proteasome pathways is a primary control mechanism both in dividing cells 
and in response to DNA damage [76]. Phosphorylation of CDC25A at Ser-124 
by CHK2 was reported to be the primary event responsible for ubiquitylation-
dependent degradation of the phosphatase. Later work showed, however, the 
inconsistency of these observations [77]. Specifically, phosphorylation of 
CDC25A on Ser-76 by CHK1 was shown to serve as priming event that 
facilitates phosphorylation on Ser-79 and Ser-82 by protein kinase CK1 or 
glycogen synthase kinase-3β (GSK-3β) [78]. This, in turn, allows recruitment 
of the SCFβ-TRCP E3 ligase that promotes CDC25A ubiquitylation [79]. The 
CHK1/CHK2-CDC25A checkpoint is rapid, since it is dependent on post-
translational modifications, but it is also transient and can delay the G1/S 
transition only for a few hours. If the cell needs to impose a prolonged G1 
arrest, a second pathway involving the tumour suppressor p53 is activated. 
Briefly, upon DNA damage p53 is directly phosphorylated by both ATM/ATR 
at Ser-15 and Ser-37 and the transducer kinases CHK2/CHK1 at Ser-20. In 
addition, the E3 ubiquitin ligase MDM2 that normally binds p53 and ensures 
rapid p53 turnover, is targeted by ATM/ATR, as well as by CHK2/CHK1 [80]. 
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These simultaneous modifications of p53 and MDM2 lead to disruption of the 
dimeric complex, p19ARF-mediated sequestration of MDM2 in the nucleolus 
with consecutive stabilization and accumulation of the p53 protein. Acetylation 
of p53 at the C-terminal Lysines that were target of MDM2 as well as at 
additional sites in the DNA binding domain facilitate p53 tetramerization, 
binding to its responsive elements in gene promoters and induction of 
transcription [81]. p53 most prominent targets at the G1/S transition is 
p21CIP1/WAF1 (inhibitor of cyclin-dependent kinases). Specifically, p21CIP1/WAF1 
inhibits kinase activity by physical engaging the complex with an inhibitory 
domain that stretches over both CDK2 and Cyclin E to obstruct substrate 
binding [82]. Inhibition of CDK2/Cyclin E activity, in turn, results in incomplete 
phosphorylation of the tumor suppressor pRb, with consequent failure in 
releasing E2F1-3, the activating members of the E2F family of transcription 
factors, that are responsible for the transcription of Cyclin A and other S-
phase genes [83] . 
 
1.2.2.2 The S-phase checkpoint 
 
During the S phase of cell cycle, human cells replicate the entire genome, 
which is composed of some three billion base pairs, to obtain two identical 
copies. In order to preserve the genetic information the duplication has to be 
carried out with highly fidelity. Cells encountering altered DNA structures 
during replication activate the so-called intra-S-phase checkpoint, which slows 
down ongoing DNA synthesis and prevents firing of new origins. This 
checkpoint operates via two parallel pathways, both of which are regulated by 
the ATM/ATR signaling cascade.  
One branch of these effector mechanisms is through the CDC25A-
degradation cascade described above. In addition to regulating 
CDK2/CyclinE, CDC25A is able to remove inhibitory phosphates from 
CDK2/CyclinA complexes to promote loading of the initiation factor CDC45 
onto chromatin. CDC45 is a protein required for the recruitment of DNA 
polymerase α into assembled pre-replication complexes, hence the inhibition 
of CDK2 activity result in the inhibition of new origin firing [34]. 
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The other branch of the intra-S-phase checkpoint operates through the ATM-
mediated phosphorylation of NBS1 [75] and SMC1 (Structural maintenance of 
chromosomes 1) on several sites. However, how phosphorylated SMC1 
contribute in slowing down DNA replication is unknown. 
Both branches of the intra-S-phase checkpoint lead to a transient slow down 
of DNA replication to allow repairing the lesions before completion of 
replication. In case of failure to repair damage during this transient delay, cells 
complete replication and exit S phase. However, cells subsequently arrest in 
the G2 phase to tackle the persistent DNA damage. 
 
1.2.2.3 The G2 checkpoint 
 
The G2 checkpoint prevents cells from entering mitosis when they suffer DNA 
damage during transition through the G2 phase, or alternatively if they have 
progressed into G2 with unrepaired DNA lesions that occurred during the 
previous S or G1 phases. As sketched for the G1/S checkpoint, the final 
target of the G2 checkpoint is a CDK. Signals from unfinished DNA replication 
(through ATR/CHK1) or damaged DNA (through ATM/CHK2) activate the 
kinases WEE1/MYT1 that, in turn, phosphorylate active CDK1/CyclinB 
complexes causing inhibition of enzymatic activity. In parallel, checkpoint 
kinases phosphorylate CDC25 phosphatases [76]. Particularly, CHK1-
dependent phosphorylation of CDC25A at Ser-124 and Thr-507 and of 
CDC25C at Ser-216 mediate recruitment of 14-3-3 proteins that displace the 
phosphatases from the nucleus, a mechanism that appears to be the primary 
way employed to inhibit CDC25A function during G2 and mitosis [84] as well 
as CDC25C. The mechanism of inhibition of CDC25B, which mediates the 
activation of CDK1/Cyclin B at the centrosome during prophase, has been 
extensively studied in relation to its mitotic role [85] but is less characterized in 
response to DNA damage. 
Moreover, additional factors upstream of CDC25 or cyclin B/CDK1, such as 
the Polo-like kinases PLK3 and PLK1 [86], the PLK1 activator AurA [87] and 
protein phosphatase PP2A [88] are also part of the G2/M checkpoint. Similar 
to G1 checkpoint, maintenance of the G2/M checkpoint partly relies on 
transcriptional regulation by p53 that, upon stabilization, induces transcription 
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of the cell-cycle inhibitor p21CIP1/WAF1. In addition, the expressions of 14-3-3σ 
(scaffold and signaling protein), PUMA (BCL2 binding component 3), BAX 
(BCL2 partner and apoptotic activator), GADD45 (growth arrest and DNA-
damage-inducible gene) are also regulated and are required for efficient 
arrest [86].  
 
 
1.3 DNA nucleases 
 
1.3.1 General features of DNA nucleases in DNA damage response 
 
DNA, the carrier of genetic information of the majority of living organism, is 
composed of a sugar-phosphate backbone and four organic bases. DNA 
suffers from various environmental stresses, including attacks by UV light, 
radiation and carcinogens, which constantly modify its structure. Moreover, 
DNA accumulates errors that are intrinsic to the process of replication and 
displays unusual structures during recombination. In order to avoid alterations 
of the base sequence or entanglement of the DNA, these modifications must 
be corrected by the various repair protein machineries. Such DNA repair 
proteins usually form complexes with other proteins, likely to facilitate 
targeting and gain efficiency. A core component of these complexes are 
nucleases, which play crucial roles in recognizing and processing replication 
or recombination intermediates. In addition, through their participation to 
various DNA repair processes such as mismatch repair (MMR), base excision 
repair (BER), nucleotide excision repair (NER) and double strand break 
repair, they also play a role in resolving DNA mismatches that occur during 
replication or eliminating damaged nucleotides. 
As previously elucidated, double-strand breaks can be repaired by two main 
mechanisms depending on the phase of the cell cycle in which the lesion 
occurs, namely Non-Homologous End Joining (NHEJ) and Homologous 
Recombination (HR) [89]. The latter is based on the presence of the sister 
chromatid which is used as a template for the invading single-stranded DNA 
filament to elongate.  
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Such single-stranded DNA filaments are 3' overhangs generated during the 
process of resection, the initial step in the HR pathway to repair DSBs. 
Resection is performed by nucleolytic enzymes (Table 2) which can be 
regarded as molecular scissors that catalyzes the cleavage of phosphodiester 
bonds between the phosphate and the sugar moieties in the backbone of the 
DNA. Nucleases can be generally divided into exonucleases and 
endonucleases. Exonucleases can be further classified as 5’-end processing 
or 3’-end processing enzymes, according to the polarity of consecutive 
cleavage. On the other hand, endonucleases hydrolyze internal 
phosphodiester bonds within a polynucleotide chain, without the requirement 
of a free DNA end. 
 
 
Table 2. Modified after (Nucleases in homologous recombination as targets for cancer 
therapy)  
 
Single-stranded 3'-overhanging DNA filaments represent an important 
substrate for many downstream events occurring during the repair of the 
lesion, such as Rad51 binding to initiate homologous pairing and strand 
exchange and Rad52-mediated annealing [90], activation of the DNA damage 
response and arrest of the cell cycle upon DNA damage [70]. Moreover, 
checkpoint proteins recognize ssDNA and also affect the rate at which ssDNA 
arises, suggesting that the DDR regulates accumulation of ssDNA by 
regulating the activity of nucleases [91]. Mutations in some of the nucleases 
involved in the DDR are directly associated with diseases or they show 
defects in DNA repair, accumulation of damage and greater risk of genome 
instability leading to predisposition to cancer (Table 3). Furthermore, DNA 
repair enzymes, thus including nucleases, are also commonly upregulated in 
some cancer types to ensure efficient repair of DNA damage caused by 
chemo- or radiotherapy, and this can lead to drug resistance. Interfering with 
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nucleases activity by chemical inhibition or downregulation may potentiate the 
effects of anti-cancer drugs and it may represent a new approach in the 
synthetic lethality therapy [92].  
 
  Synthetic lethality or 
sickness (SLS) is the 
most promising 
approach for cancer 
therapy; it requires 
two mutations which, 
by themselves, are 
not effective on cell 
survival, but when 
combined they lead to 
cell death. If any of 
the two genes is  
Table 3. Modified after (Nucleases in homologous recombination as targets for cancer 
therapy) 
 
cancer-specific, upon inhibition of the second gene it results in higher 
selective killing of cancer cells without side toxic effects on normal cells. Since 
cancer cells are often defective for DDR factors and DNA repair proteins, the 
use of specific repair inhibitors will take advantage of this concept. Indeed, 
breast cancer patients defective for the recombination mediator BRCA2 and 
treated with chemical inhibitor against the base excision repair factor Poly 
(ADP-ribose) polymerase (PARP), show increases sensitization of cancer 
cells due to the interference with the ssDNA breaks repair pathway by the 
PARP inhibitor [93, 94].       
In this case, replication forks are stalled and ssDNA nicks are converted into 
dsDNA breaks that cannot be repaired in these recombination-deficient cells. 
HR-deficient cancer cells are also induced to higher sensitivity upon PARP 
inhibition due to the same concept. [95, 96]. Regarding nuclease involved in 
HR, some examples are provided: ERCC1-defective cells resulted to be 
synthetically lethal with ATR inhibition. ERCC1 represent the non-catalytic 
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subunit of XPF protein which is an endonuclease involved in many DNA repair 
pathways such as nucleotide excision repair (NER), interstrand crosslink 
repair (ICLR), HR and NHEJ [97]. CDC4- and MRE11-defective cancer cells 
[98] and RAD54B-defective colorectal cancer cells [99] have shown synthetic 
lethality upon FEN1 inhibition; FEN1 is a member of the Rad2/XPG family of 
exonucleases and it has also gap endonuclease and RNaseH activities. It has 
a very important role in DNA replication and repair [100]. Finally BLM 
helicase-deficient cells depleted for MUS81 complexes are synthetic lethal. 
MUS81 is another endonuclease of the XFP family which acts in complex with 
the non-catalytic subunits EME1 and EME2; it has increased expression 
during S/G2 transition of the cell cycle which confirm its role in processing 
replication and recombination intermediates. Indeed MUS81 is responsible for 
the cleavage of collapsed replication forks induced by DNA damaging events 
[101, 102]. 
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1.3.1.1 Exonuclease 1 (EXO1) 
 
EXO1 is a member of the Rad2/XPG family of nucleases. It was originally 
identified in the fission yeast Schizosaccharomyces pombe upon induction to 
undergo meiosis. S. pombe Exo1 was shown to catalyze the removal of 
mononucleotides from the 5’ end of a DNA duplex or DNA nicks by degrading 
in 5’-3’ polarity, acting preferentially on double-stranded DNA ends (dsDNA) 
producing 3’ single stranded overhangs. The human EXO1 gene encodes a 
protein that bears only 27% identity to its yeast ortholog [103]. However, it has 
been demonstrated that human EXO1 can complement the DNA damage 
sensitivity and the mutator phenotype that result from deletion of Exo1 in 
Saccharomyces cerevisiae [104], indicating that at least certain aspects of 
EXO1 function appear to be conserved. In vitro, human EXO1 was show to be 
a structure specific nuclease, possessing 5’-3’ exonuclease and 5’-flap 
endonuclease activities [105]. 
EXO1 has also been reported to possess RNase H activity.  EXO1 molecular 
mechanism of action was recently clarified and shown to be similar to that of 
other FEN nucleases [106].  
EXO1 is involved in several DNA repair pathways including MMR, double 
strand break repair, post-replication repair as well as meiotic and mitotic 
recombination [107] and telomere maintenance. The first established role for 
yeast EXO1 was deduced from its ability to physically interact with yeast and 
human MSH2, followed by the demonstration of its participation in MMR [108]. 
It was later demonstrated that EXO1 plays both catalytic and structural roles 
during MMR-mediated repair [109]. Briefly, upon detection of a mismatched 
base, the MMR machinery is recruited (Figure 8), EXO1 carries out a 
controlled 5' to 3' directed excision step that removes nucleotides in the newly 
made strand past the mismatch, creating a ssDNA gap that serves as a 
platform for DNA polymerase. The polymerase fills in the excised stretch, 
finally a DNA ligase seals the nick completing the MMR [110].  
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Figure 8. Schematic representation of 
mismatches and MMR pathway involving 
EXO1 activity. The MMR system recognizes 
base-base mismatches (a) or an insertion-
deletion loop (b). MutS homologs bind to the 
affected site of DNA, which triggers ATP-
dependent conformational changes and the 
binding of MutL homologs. These in turn 
recruit other proteins, including PCNA and 
EXO1 with the subsequent excision of the 
damaged strand. The interactions of the bound 
proteins trigger DNA looping, which brings the 
two sites together. The resultant gap in the 
strand is then filled by DNA polymerases and 
the break is removed by DNA ligase Modified 
after (Hewish, M., et al., Mismatch repair 
deficient colorectal cancer in the era of 
personalized treatment. Nat Rev Clin Oncol, 
2010. 7(4): p. 197-208). 
 
The involvement of EXO1 in DNA 
repair pathways suggests it could be 
also be a target for mutation in 
tumourigenesis. Consistent with this, a 
cancer-prone phenotype has been observed in Exo1-defiecient mice, where a 
clearly increased susceptibility to lymphoma development was observed 
[111]. Mounting evidence has shown that EXO1 plays an important role in 
DSB repair by executing a long-range resection step to generate extended 
stretches of ssDNA. This ssDNA serves to induce cell cycle checkpoints and 
is required for RAD51 mediated strand invasion of the sister chromatid for an 
efficient HR cascade. Cells depleted of EXO1 show chromosomal instability, 
hypersensitivity to IR and defects in HR-dependent DSB repair [112]. In a two-
step mechanism of DSB repair, the MRN complex detects a DSB and, 
collaborating with CtIP, promotes DNA end resection generating short ssDNA 
overhangs [44]. This initial resection step is followed by a more extensive step 
of resection carried out by redundant enzymes with EXO1 being an important 
exonuclease among them [113]. 
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Accumulating evidence suggests that EXO1 plays also an important role at 
the replication fork. Data from Saccharomyces cerevisiae demonstrated that 
Exo1 acts in a redundant manner with Rad27 (FEN1 in human) in processing 
Okazaki fragments during the process of DNA replication [111]. Moreover, 
Exo1 was shown to be recruited to stalled replication forks where it plays a 
role in preventing fork reversal by resecting newly synthesized strands and 
helping to resolve sister chromatid junctions [83]. During NER, EXO1 
promotes enlargement of DNA gaps, which is a signal for ATR-mediated DNA 
damage response [114-116].  
EXO1 nucleolytic activity is tightly regulated under DNA replication stress and 
other cellular responses to DNA damage. It was demonstrated in our and 
other laboratories that such control is exerted either by post-translational 
modifications or by direct interaction with other proteins. Results from our 
laboratory show that in mammalian cells, upon replication fork stalling, EXO1 
is phosphorylated in an ATR-dependent manner, with this phosphorylation 
targeting it to ubiquitin-mediated degradation through the proteasome 
pathway. We also showed that EXO1 interacts with CtIP in vivo and in vitro 
and that its exonucleolytic activity is restrained in vitro  by this interaction 
[117]. Others have shown that also ATM-mediated signals can control EXO1, 
namely by providing evidence that phosphorylation of EXO1 by ATM occurs in 
response to ionizing radiation and result in a decrease of enzymatic activity, in 
a manner that allows loading RAD51 and the completion of HR. At telomeres, 
EXO1 exerts extensive G-rich strands resection promoting telomeric 
recombination, which leads to increase genomic instability in telomerase-
deficient cells [118].  
Missense mutations in EXO1 have been identified in patients with atypical 
HNPCC (non-polyposis colorectal cancer) [119] and EXO1-deficient mice 
show reduced survival, higher mutation rates and increased susceptibility to 
develop lymphomas [111]. A multi-mutations hypothesis was suggested by in-
vitro studies on yeasts, in which a weaker mutation phenotype of EXO1 might 
be combined with other mutator alleles acquiring pathogenic features [120]. 
On the other hand, HNPCC patients over-expressing EXO1 show increased 
genetic instability and promoted cancer progression probably due to the loss 
of the mutant allele [133].   
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Abstract 
The complexity of living cells is primarily determined by the genetic 
information encoded in DNA and gets fully disclosed upon translation. A major 
determinant of complexity is the reversible post-translational modification 
(PTM) of proteins, which generates variants displaying distinct biological 
properties such as subcellular localization, enzymatic activity and the ability to 
assemble in complexes.   Decades of work on phosphorylation have 
unambiguously proven this concept. In recent years, the covalent attachment 
of Ubiquitin or Small Ubiquitin-like modifiers (SUMO) to amino acid residues 
of target proteins has been recognized as another crucial PTM, re-directing 
protein fate and protein-protein interactions.  
This review focuses on the role of ubiquitylation and sumoylation in the control 
of DNA damage response  (DDR) proteins. To lay the ground, we begin with a 
description of ubiquitylation and sumoylation, providing established examples 
of DNA damage response elements that are controlled through these PTMs. 
We then examine in detail the role of PTMs in the cellular response to DNA 
double-strand breaks illustrating hierarchy, cross-talk, synergism or 
antagonism between phosphorylation, ubiquitylation and sumoylation. We 
conclude offering a perspective on ubiquitin and SUMO pathways as targets 
in cancer therapy. 
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Introduction 
The components of signal transduction pathways are organized in a 
hierarchical manner and communicate with one another. In its simplest 
formulation, a signaling pathway can be represented with a linear cascade 
where unidirectional arrows connect a stimulus to the final response through a 
defined number of intermediates. The recent sequencing of animal and plant 
genomes and the advent of systems biology have changed this perspective. 
Proteome scale interaction studies have unveiled the existence of interfaces 
between pathways and shown that the multiplicity of interactions among their 
components likely accounts for the arrays of biological outputs observed. 
While this novel perspective represented per sè a step forward, it still had the 
intrinsic limitation of merely providing a static snapshot of biological networks. 
The need for a more realistic picture of signal transduction prompted the 
development of predictive modeling that, by representing the dynamic flow of 
information, accounts for the fluctuation of variables as it actually occurs in 
defined biological systems (Barabasi and Oltvai, 2004). Despite their intrinsic 
limitation though, “snapshots” provided by reductionist approaches currently 
represent our best option to study and explain the functioning of signal 
transduction networks at the molecular level. 
Considering that proteins are the constitutive elements of cellular networks 
and they hierarchically relate to each other, modification of structural or 
enzymatic traits of one or more elements in a network will necessary affect 
the network properties and result in outputs that are directly observable (i.e., 
cell proliferation in response to growth factors, cell cycle arrest or terminal 
differentiation in response to antimitogens or differentiation factors, 
respectively). Alteration of the properties of network components is achieved 
through post-translational modifications (PTM), consisting in the covalent 
addition of chemical groups to one or more amino acids of a protein target in a 
manner that is, in most cases, reversible. The hierarchical, synergistic or 
antagonistic combination of PTMs defines a code that translates in distinct 
outputs. 
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Historical perspective 
Ubiquitin entered the arena of scientific discoveries in 1978 as result of 
pioneering work initiated in the midst of more trendy studies addressing how 
the information contained in DNA is decoded to generate the variety of 
proteins that make up a cell (Ciechanover, 2009). The concept prompting this 
pioneering investigation was that synthesis and destruction of cellular proteins 
are homeostatic, with a perfect equilibrium being a necessary condition for 
life. Ciechanover and colleagues observed that reticulocytes get rid of 
lysosomes during terminal differentiation but retain the ability of degrading 
hemoglobin. Starting from this observation, they set out to identify this non-
lysosomal mechanism of protein degradation. Using classic biochemical 
protocols consisting of chromatographic fractionation of crude cell extracts 
followed by reconstitution of the enzymatic activity of interest through 
complementation of fractions, they discovered that proteolysis occurs through 
a cascade of events culminating in the covalent addition of a heat-stable 
component to proteins targets. Such component was named ATP-dependent 
proteolysis factor 1 (APF-1) and is now known as ubiquitin (Ciehanover et al., 
1978). Protein modification by APF-1, in turn, was shown to facilitate selective 
target recognition by the proteolytic machinery (Hershko et al., 1980). The 
subsequent discovery of several ubiquitin-like proteins (UBLs) helped 
shedding light on the complexity of this post-translational modification. UBLs 
were essentially demonstrated to have functions other than the control of 
protein degradation. This is the case of NEDD8, which can be covalently 
linked to cullins (Hori et al., 1999), the scaffold components of multisubunit 
ubiquitin E3-ligases, affecting their activity; ISG15, which is attached to 
components of signal transduction pathways triggered by IFN-γ or 
lipopolysaccharide and plays a role in inflammatory and immune responses 
(Malakhov et al., 2003); Urm1, which has low sequence homology to ubiquitin 
(Goehring et al., 2003), though it displays a similar fold and is involved 
oxidative stress responses in yeast; finally, the Atg cascade controlling 
autophagy in yeast and man, which is the main mechanism responsible for 
the degradation of cellular components in response to nutrients starvation. 
This consists of the E1-like enzyme Atg7, the E2-like components Atg3 and 
	   60	  
Atg7, and the E3-like Atg12-Atg5 conjugate that facilitates transfer of the 
ubiquitin-like modifier Atg8 to phospholipids (Hanada et al., 2007). 
Ubiquitylation 
Ubiquitin is a highly conserved regulatory protein of 76 amino acids (8.5 kDa), 
which is constitutively expressed in all tissues of eukaryotic organisms. In 
mammalian cells, ubiquitin is encoded by 4 genes: RSP27A, UBA52, UBB 
and UBC (Kimura and Tanaka, 2010). The ATP-dependent conjugation of 
ubiquitin C-terminal glycine (G76) to lysine residues in the substrate leads to 
the formation of an isopeptide bond. Ubiquitin itself contains 7 lysines 
behaving as acceptors for additional ubiquitin molecules to generate poly-
chains. Ubiquitylation is carried out in a cascade of reactions: first, a thiolester 
bond is formed in an ATP-dependent manner between a cysteine in the active 
site of the E1-activating enzyme and ubiquitin G76. Second, ubiquitin is 
transferred to the active cysteine of an E2-conjugating enzyme. Finally, an 
E3-ligase enzyme binds the E2-Ub complex and transfers ubiquitin to lysine 
residues of the acceptor substrate (Hershko and Ciechanover, 1998) (Fig. 1). 
Mammalian cells express only 2 E1s, approximately 38 E2s and more than 
600 E3s.  
 
E2-conjugating enzymes - E2-conjugting enzymes can be classified in 17 
subfamilies (Michelle et al., 2009) characterized by an active core called UBC 
(ubiquitin-conjugating) domain that contains the cysteine residue required for 
catalysis. Five of the 38 known E2 enzymes lack the catalytic cysteine and 
are called UEV (ubiquitin E2 variant) proteins. UEV can either bind an active 
E2, thus regulating its activity, or bind an activating cofactor once they are 
ubiquitylated (Polo et al., 2002). Ubiquitin E2 enzymes are structurally similar 
to UBL modifiers E2s, though the former can specifically interact with the two 
E1s involved in ubiquitylation (Ye and Rape, 2009). Each E2 enzyme can 
interact with multiple E3s, as demonstrated for Cdc34 (E2) and SCF 
complexes (E3) (Skowyra et al., 1997) or the UBE2C / UBE2S (E2s) and the 
APC/C (anaphase promoting complex / cyclosome; E3) (Williamson et al., 
2009) or as shown in network interaction studies (Markson et al., 2009). 
Specificity is provided by the N-terminal region of the E2 where the amino 
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acidic sequence determines the secondary structure of loops (L1 and L2) 
specifically contacting two loops and an α-helix of the E3 (Zheng et al., 2000). 
For E2s interacting with more than one E3, the residue involved in recognition 
usually differs from one E3 to the other (Zhang et al., 2005a). The binding 
affinity between ubiquitin-charged E2s and their cognate E3s is generally 
high, rendering very fast the kinetic of interaction (Das et al., 2009). Moreover, 
binding sites for E1 and the specific E3 often overlap in the E2, such that the 
E2 must dissociate from the E3 to be charged with ubiquitin by the E1 and 
vice-versa (Eletr et al., 2005). E2 enzymes catalyze ubiquitin chains initiation 
and elongation. Whereas some of them, such as UBE2W and UBE2E in 
humans, are specifically used by their E3, BRCA1, for chain initiation, the 
heterodimeric complex UBE2N-UBE2V1 and UBE2K are mainly involved in 
chain elongation (Christensen et al., 2007;Rodrigo-Brenni and Morgan, 
2007;Jin et al., 2008b). Few E2s can mediate both processes, as illustrated 
by yeast Cdc34 that, together with SCF, is responsible for initiating ubiquitin 
chains formation on Sic1 (cell cycle inhibitor subunit of cyclin-dependent 
kinase 1) in a non-interacting manner, but also for the chains elongation by 
direct interaction with the substrate (Petroski and Deshaies, 2005). 
 
E3-ligases - E3s are often part of multimeric complexes and can be divided in 
two main classes: HECT (Homologous to E6AP COOH-terminus) and RING 
(Really Interesting New Gene). HECT E3s bind ubiquitin on a cysteine in their 
catalytic domain and transfer it to the substrate in an E2-independent manner 
(Kulathu and Komander, 2012). The C-terminal domain of HECT E3s is highly 
conserved and retains both catalytic activity and the determinants for chain 
type specificity (You and Pickart, 2001), while the N-terminal region 
determines substrate specificity (Huang et al., 1999). Established members of 
the HECT family are E6AP, a partner of the oncogenic E6 protein of human 
papillomavirus, responsible for p53 downregulation (Huang et al., 1999), 
Itch/AIP4, with roles in the inflammatory signaling pathways (Chastagner et 
al., 2006) and Nedd4 and Nedd4L that participate in the development of 
mouse central nervous system (Kumar et al., 1992). 
The vast majority of E3-ligases known to date belongs to the RING family and 
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is characterized by the presence of the Cys/His-rich RING finger domain. The 
RING finger brings in close proximity substrate and activated E2 enzyme, with 
the latter directly transferring ubiquitin to the former. A domain structurally 
related to the RING finger, the U-box, is found in many E3 ligases of this class 
(Deshaies and Joazeiro, 2009). Rad18 was the first identified RING domain-
containing protein and, together with the E2-conjugating enzyme Rad6, was 
shown to be essential for post-replicative bypass of UV-induced DNA damage 
in yeast (Bailly et al., 1997). The RING domain, along with a B-box (zinc-
binding fold similar to the RING) and a coiled-coil region (CC), collectively 
called RBCC supradomain, characterizes the 80 members of the TRIM 
(Tripartite Interaction Motif) family of E3-ligases (Marin, 2012). A small 
subfamily of E3 ligases is characterized by the presence of three RING 
domains: an N-terminal (N-RING), a in-between (IBR) and a C-terminal 
(RING2 or C-RING) (Eisenhaber et al., 2007). Parkin, a protein involved in 
Parkinson’s disease, is the best characterized member of this subfamily 
(Chaugule et al., 2011). The Cullin/RING ubiquitin ligase (CRL) subfamily 
represents the largest subgroup of the RING-finger E3 ligases (Deshaies and 
Joazeiro, 2009). CRLs are multisubunit E3s composed of a RING finger 
domain protein (Rbx1 or Rbx2) responsible for recruiting the ubiquitylated E2 
enzyme, a scaffold protein member of the Cullin family and a receptor for 
substrate recognition (F-box protein). Some CRLs additionally feature a linker 
protein, such as Skp1 in the SCF complex or CRL1 and DDB1 in the CRL4 
complex (Deshaies and Joazeiro, 2009). CRLs are activated by a post-
translational modification consisting in conjugation of NEDD8 to the Cullin 
component (Pan et al., 2004).  
 
Atypical ubiquitin chains - Ubiquitylation indicates the process of single 
ubiquitin moiety addition to a substrate as well as its extension to form 
ubiquitin polymers. Chain extension can occur at all seven lysine residues 
present on ubiquitin (K6, K11, K27, K29, K33, K48, K63) (Ikeda and Dikic, 2008). 
E2s such as UBE2N (UBC13) or UBE2RI (CDC34) show specificity for 
linkage to K63 or K48, respectively (VanDemark et al., 2001;Petroski and 
Deshaies, 2005). Others, like UBE2D and UBE2E, can promote different 
types of ubiquitin chains formation (Kim et al., 2007). K48 and K63 linked 
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chains represent the two mostly studied modifications by ubiquitin, with the 
first essentially involved in degradation by the 26S proteasome (Komander 
and Rape, 2012) and the second mainly affecting the function of signaling 
components (Sun and Chen, 2004) and DNA repair proteins (Chen and Sun, 
2009). Proteins undergoing degradation are recognized by the substrate 
receptor component of the 26S proteasome only if they contain chains longer 
than 4 ubiquitin moieties (Thrower et al., 2000). The processivity of such 
chains, which is the number of ubiquitin moieties attached to a protein or to a 
growing ubiquitin chain while it is associated to the E3 ligase, determines the 
rate of substrate degradation (Rape et al., 2006). K6-linked chains do not 
likely have a proteolytic role (Kim et al., 2011). K11-linkage, on the contrary, 
plays a key role in the degradation of cell cycle regulators as well as in 
endoplasmic reticulum associated degradation (ERAD) and membrane 
trafficking (Behrends and Harper, 2011). Little is know about the relatively low 
abundant K27-, K29- and K33-linkages (Komander and Rape, 2012). An 
additional type of ubiquitin chain assembly was recently discovered, the so-
called LUBAC (linear ubiquitin chains assembly complex), which is formed by 
a complex of two E3 RING-finger ligases, HOIL-1L and HOIP. This type of 
linkage is characterized by head-to-tail assembly, in which the C-terminal 
glycine of the previous ubiquitin is linked to the methionine residue of the next 
ubiquitin. Linearly-linked ubiquitin chains are mainly involved in targeting 
proteins with a role in innate and adaptive immune signaling pathways 
(Walczak et al., 2012).  
 
Deubiquitylating enzymes – Ubiquitylation is a reversible process, with 
deubiquitinases (DUBs) being responsible for the disassembly of ubiquitin 
chains (Nijman et al., 2005). Deubiquitylation controls cell cycle transitions, 
proteasome- and lysosome-dependent degradation pathways, DNA repair, 
endocytosis and signal transduction pathways among others. Importantly, 
DUBs participate in controlling the dynamic state of histone ubiquitylation. An 
essential function played by DUBs is the co-translational activation of 
ubiquitin, which is expressed as fusion to ribosomal proteins or in linear poly-
ubiquitin chains (Reyes-Turcu et al., 2009). A second important function is the 
recycling of free ubiquitin from unattached chains (Komander et al., 2009). 
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The human genome encodes approximately 100 DUBs, distinguished in five 
families: ubiquitin C-terminal hydrolases (UCH), ubiquitin specific proteases 
(USP/UBP), ovarian tumor (OUT), Josephines and JAB1/MPN/Mov34 
metalloenzymes  (JAMM) (Reyes-Turcu et al., 2009). Whereas the first four 
families behave as cysteine proteases, JAMM function as zinc-dependent 
metalloproteases. To prevent inappropriate or unscheduled cleavage of 
substrates, DUBs activity is controlled by a variety of PTMs, including 
phosphorylation, ubiquitylation and sumoylation (Reyes-Turcu et al., 2009). 
Besides the catalytic domain, DUBs feature protein-protein interaction 
domains and ubiquitin-binding domains that facilitate formation of multimeric 
complexes and interaction with substrates, respectively. In most cases, 
binding to ubiquitin causes DUBs to undergo conformational changes that 
expose the catalytic site, which is often hidden by a loop or a larger domain 
(Reyes-Turcu et al., 2009). DUBs such as USP14, UCH37 and POH1 are 
often found associated with the 19S subunit of the proteasome, a feature that 
allows hydrolyzing the poly-ubiquitin chain from the substrate and recycling 
ubiquitin prior to channeling the target protein into the proteasome (Finley, 
2009). Reactive oxygen species (ROS) reversibly inactivate Cys-based DUBs, 
as exemplified by the key regulator of genomic stability USP1, the oxidation of 
which facilitates PCNA mono-ubiquitylation and the consecutive recruitment of 
Polη for the repair of oxidation-induced lesions (Cotto-Rios et al., 2012). 
 
Shuttling to the proteasome - The destiny of proteins modified by K48 poly-
ubiquitin chains is degradation by the 26S proteasome. In the DNA damage 
response (DDR), this task is facilitated by shuttling that is orchestrated by 
dedicated receptor proteins such as yeast Rad23, Dsk2, Ddi1 and the 
Shp1/Cdc48/p97 complex. Receptor proteins recognize poly-ubiquitin chains 
in their targets by virtue of Ubiquitin-Associated (UBA) domains and interact 
with subunits of the proteasome via Ubiquitin-Like (UBL) folds, thus effectively 
shuttling cargoes to the proteasome (Grabbe and Dikic, 2009). The yeast 
Rad23, which was originally identified for its role in nucleotide excision repair 
(NER), and its human homologues hHR23A and hHR23B are paradigmatic to 
this pathway. Rad23 contains two UBA and an N-terminal UBL domain that 
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dynamically interacts with either one of the two UBA domains (Goh et al., 
2008). Binding of an UBA domain to poly-ubiquitin chains of the cargo protein 
displaces the UBL domain that becomes available for interacting with the 
proteosomal subunit 5a (Mueller and Feigon, 2003), facilitating the delivery of 
cargos to the proteasome. Paradigmatic is human p97 and its ubiquitin-
binding partner, the heterodimer UFD1-NPL4, that are recruited to DNA 
lesions and selectively remove K48-ubiquitin conjugates allowing the 
subsequent deposition of 53BP1, BRCA1 and Rad51 to regions undergoing 
repair (Meerang et al., 2011). 
Sumoylation 
SUMO proteins and ubiquitin have only limited sequence identity but they fold 
in a similar manner (Bayer et al., 1998). SUMO-2 and SUMO-3 are 95% 
identical but display only 43% identity to SUMO-1. SUMO proteins are 
generated as inactive precursors and processed by Sentrin/SUMO-specific 
proteases (SENPs) that catalyze the removal of a C-terminal oligopeptide, 
exposing the glycine that is conjugated to lysine residues in the target (Xu and 
Au, 2005).  
As for ubiquitin, SUMO-1, SUMO-2 and SUMO-3 are conjugated to substrates 
through a dedicated E1-E2-E3 cascade. SUMO proteins bind the activating 
enzyme E1 (SAE1 and SAE2 in mammals, (Gong et al., 1999)) in an ATP-
dependent manner and are transferred to the conjugating enzyme UBC9, 
which is the only E2 dedicated to SUMO conjugation (Johnson and Blobel, 
1997). UBC9 is able to recognize and transfer SUMO to targets in the 
absence of a co-adjuvating E3, though E3-like proteins containing an SP-
RING domain facilitate the process by enhancing the affinity of UBC9 for its 
substrates (Bernier-Villamor et al., 2002). In the absence of an E3, acetylation 
apparently provides a means for UBC9 to discern between substrates 
carrying extended vs. regular recognition motifs (see below) (Hsieh et al., 
2013).  
The distinct mechanism of SUMO recognition and conjugation likely depends 
on the different distribution of charged residues on the surface of SUMO 
proteins as compared to ubiquitin (Melchior, 2000). Of the SUMO E3-ligases 
identified to date, some display exquisite specificity, such as RanBP2 that 
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selectively targets RanGAP1 and Sp100 (Pichler et al., 2002). Others, like the 
PIAS family of proteins that are the mammalian homologues of yeast Siz 
proteins, act as repressors of STAT3 (Chung et al., 1997) and a number of 
transcription factors (Schmidt and Muller, 2003). Similarly to RING ubiquitin 
ligases, the Siz/PIAS SUMO E3-ligases do not physically bind SUMO but 
rather interact non-covalently with it. Furthermore, through their zinc-binding 
SP-RING domain they associate with UBC9. In this manner Siz/PIAS bring 
SUMO-loaded UBC9 in close proximity with the protein target and facilitate 
transfer of the SUMO mojety (Hochstrasser, 2001). Among other SP-RING 
type SUMO E3s, TOPORS was the first reported example of an E3 ligase 
supporting the transfer of both ubiquitin and SUMO (Rajendra et al., 
2004;Weger et al., 2005). 
SUMO-2 and SUMO-3 can polymerize to form chains on protein substrates 
whereas SUMO-1 is only added as monomer (Tatham et al., 2001). It is 
established that some substrates are modified either by SUMO1, namely 
RanGAP1 (Saitoh and Hinchey, 2000), or SUMO2/3, namely PML, whereas 
others are modified indifferently by both SUMO1 and SUMO2/3 (Vertegaal et 
al., 2006). The reason for such heterogeneity in the SUMO conjugation 
process is currently unknown, though it may be in part explained by the 
different pools of SUMO proteins available in the cell, with SUMO1 being 
mostly conjugated and SUMO2/3 forming a free pool that is mobilized in 
response to environmental stress (Saitoh and Hinchey, 2000). 
The minimal core consensus sequence for recognition and sumoylation of 
target proteins is defined as Φ-K-X-D/E (with Φ being a hydrophobic residue). 
An extended sumoylation motif consisting in the sequence Φ-K-X-D/E-X2-
(E/D)4-5 may comprise sites of phosphorylation in the acidic stretch that 
follows the sumoylated lysine (Yang et al., 2006). 
As for other PTMs, sumoylation is a reversible process. The enzymes 
reversing sumoylation belong to the class of SENP proteins that control 
SUMO maturation from precursor polypeptides. Of the six SENP enzymes 
present in the mammalian genome, SENP1 and SENP2 display the ability of 
their yeast counterpart Ulp1 to control both the maturation of SUMO proteins 
and desumoylation reactions. SENP1 and SENP2 display a slight preference 
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for pre-SUMO1 or pre-SUMO2/3, respectively, in the process of maturation 
but act equally well on both during deconjugation (Xu and Au, 2005). SENP3 
and SENP5 preferentially remove monomeric SUMO2/3 moieties, whereas 
SENP6 and SENP7 selectively act on SUMO2/3 chains and do not participate 
in the maturation of SUMO proteins (Mikolajczyk et al., 2007). SENP enzymes 
are themselves controlled by sumoylation, ubiquitylation and subcellular 
localization (Hickey et al., 2012). 
The role of sumoylation at the organism level became apparent thanks to 
studies that were first conducted in budding yeast. These showed that 
depletion of Ubc9 causes cell cycle arrest at G2/M, with cells displaying large 
buds and containing a single nucleus and a short spindle (Seufert et al., 
1995). Likewise, studies conducted in fission yeast showed that deletion of 
the Ubc9 homologue hus5 is not lethal but results in chromosome segregation 
defects (al-Khodairy et al., 1995). Subsequent data from chicken DT-40 cells 
showed that Ubc9 is essential for the viability of higher eukaryotic cells and 
knockout results in the formation of multiple nuclei, likely due to cytokinesis 
defects, with a significant proportion of cells entering apoptosis (Hayashi et 
al., 2002). Studies conducted in mice confirmed the severe phenotype of 
Ubc9 knockout, with embryonic lethality observed at early post-implantation 
stage. Furthermore, blastocysts failed to expand after 2 days in culture and 
displayed defects in chromosome condensation and segregation as well as 
dismorphic nuclear envelopes and disruption of nucleoli and PML bodies 
(Nacerddine et al., 2005). Sumoylation has also been linked to human 
pathologies, in that human SUMO1 haploinsufficiency was found to be 
responsible for cleft lip and palate, a finding corroborated by a mouse model 
(Alkuraya et al., 2006). Others, however, reported no obvious developmental 
defects in SUMO1 knockout mice (Evdokimov et al., 2008;Zhang et al., 2008), 
suggesting possible redundancy among SUMO proteins.   
A peculiarity distinguishing SUMO from other PTMs is the ability of triggering 
fully-fledged responses despite minor amounts of the proteins involved in the 
response are actually modified by SUMO, a phenomenon denoted as “the 
SUMO enigma” (Hay, 2005). This was demonstrated to be the case for 
transcriptional repression, where modification by SUMO is apparently required 
for the recruitment of transcription factors into repressive protein complexes, 
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with their sequestration remaining permanent even upon SUMO removal 
(Wilkinson and Henley, 2010).  SUMO modification of only a small population 
of a substrate at any given time point was also suggested to occur for DNA 
repair proteins such as TDG. Thymidine-DNA glycosylase is part of the base 
excision repair system (BER) and displays the ability of specifically 
addressing uracil/thymidine base mismatches (Sancar et al., 2004). The rate-
limiting step in the enzymatic reaction carried out by TDG is its dissociation 
from the abasic site (AP site) generated as first step in the BER process. The 
high affinity of TDG for the structure generated upon removal of the base is an 
important self-protection mechanism put in place by the cell since AP sites 
can turn into DNA strand breaks, thus threatening genome stability 
(Hardeland et al., 2002). Sumoylation is the appropriate solution to this issue, 
in that SUMO-modified TDG looses affinity for the abasic site allowing 
recruitment of the (AP)-endonuclease that acts in the next step of BER 
(Sancar et al., 2004). To re-initiate the circle, de-sumoylation by SENPs/ULPs 
renders TDG promptly available for the next round of lesion recognition and 
processing (Hardeland et al., 2002). Thus, SUMO modification of minimal 
amounts of TDG is sufficient to address the repair of uracil/thymidine base 
mismatches in a highly controlled manner. 
The assembly of proteins complexes in response to sumoylation was 
addressed by means of two-hybrid screens that led to the discovery of 
proteins bearing SUMO-interacting motifs (SIMs) (Hannich et al., 2005). SIM-
containing proteins display the ability to recognize a structure formed by the 
opposing β2-strand and α1-helix of SUMO1-3 that contain hydrophobic and 
positively charged residues and form a groove in which the SIM peptide can 
be bound in parallel or anti-parallel orientation with respect to the β2-strand of 
SUMO (Kerscher, 2007). Negative charges in the SIM-peptide, represented 
by acidic amino acids or phosphorylation sites, facilitate electrostatic 
interaction with lysines or arginines of SUMO β2-strand and α1-helix 
(Kerscher, 2007). 
 
PTMs in DNA damage response: the old and the new 
The cascade of events resulting from detection of DNA damage and 
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orchestrating its repair has been best described for DNA double-strand breaks 
(DSBs). A detailed account of ubiquitylation and sumoylation events occurring 
at DSBs will be followed by a brief mention to the signaling triggered by other 
types of DNA lesions. 
 
DSB recognition - Initial players consist of proteins or proteins complexes 
such as Ku70 and Ku80 or MRE11/RAD50/NBS1 (MRN) that, through 
recognition and binding to DNA ends, facilitate recruitment and activation of 
the protein kinases DNA-PKcs or ATM, respectively. The latter function as 
transducers of the DNA damage signal and help coordinating repair with 
checkpoint activation and cell cycle arrest (Sancar et al., 2004). When the 
sister chromatid is available as template, repair is addressed through the 
error-free pathway of homologous recombination (HR) rather than the 
predominant but error-prone pathway of non-homologous end-joining (NHEJ) 
(Sancar et al., 2004). HR initiates upon recognition of DNA ends by the MRN 
complex, an event that facilitates recruitment of ATM through direct interaction 
with the C-terminus of the NBS1 component (Falck et al., 2005) (Fig. 2A). 
Recruitment of ATM to chromatin was also reported to occur in response to 
hypotonic stress-induced chromatin modifications. In this case, however, no 
physical breaking of the double helix occurs and ATM is recruited by a non-
canonical mechanism involving the protein ATMIN (Zhang et al., 2012).  
ATM is an homodimer and exists in a complex containing the protein 
phosphatase PP2A, which maintains ATM inactive by catalyzing its 
constitutive dephosphorylation (Goodarzi et al., 2004), and the histone 
acetyltransferase Tip60, which is maintained at low level by CUL3-dependent 
ubiquitylation and plays a role in the modification of chromatin at sites of 
damage (Murr et al., 2006;Sun et al., 2009). NBS1-dependent ATM 
recruitment at sites of damage is followed by ATM autophosphorylation at 
S1981 with ensuing activation of the kinase.  
The mechanism of DSB repair operating in the absence of a homologous 
template for recombination-mediated repair is non-homologous end joining. In 
this case, DNA ends are bound by the Ku70/Ku80 heterodimer that recruits 
DNA-PK catalytic subunit, causing inward translocation of the heterodimer 
and positioning the catalytic subunit at DNA ends. Next, depending on the 
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complexity of the lesion, different processing factors are recruited, such as the 
endonuclease Artemis and the polynucleotide kinase/phosphatase PNKP. 
Autophosphorylation-induced DNA-PKcs release leads to the final step of the 
process, with XRCC4, DNA ligase IV and XLF performing ligation of the DNA 
ends (Dobbs et al., 2010).  
 
Site marking - ATM-mediated phosphorylation of H2AX at the C-terminal S139 
(Rogakou et al., 1998), possibly paralleled by dephosphorylation of Y142 (Cook 
et al., 2009), marks the site of damage and contributes to destabilize 
nucleosome structure (Fig. 2A). In turn, phosphorylated H2AX acts as docking 
site for MDC1 that, by virtue of the high affinity of its C-terminal BRCT tandem 
repeats for the phospho-S139 epitope in γH2AX, is the first proteins localizing 
at sites of damage (Bekker-Jensen and Mailand, 2010). MDC1 orchestrates 
the consecutive assembly of factors that will, in turn, mediate the recruitment 
of DNA repair proteins. Such factors comprise 53BP1, BRCA1 and the E3-
ubiquitin ligase RNF8.  The latter binds phosphorylated MDC1 via its N-
terminal FHA domain. SUMO1 modification of HERC2 and RNF168 by the 
E3-ligase PIAS4 promotes recruitment of RNF8 to the complex and stabilizes 
the interaction between RNF8 and the E2-conjugating enzyme Ubc13 
(Danielsen et al., 2012). In turn, RNF8 contributes to remodel chromatin 
around sites of damage through a transient K48 and a persistent K63 
ubiquitylation of both H2A and H2AX, facilitating the subsequent recruitment 
of the DNA repair factors BRCA1 and 53BP1 (Huen et al., 2007;Mailand et al., 
2007). Once bound to DNA, MDC1 is sumoylated at K1840 by PIAS4 in a 
manner that facilitates its recognition and ubiquitylation by the E3-ligase 
RNF4, with consequent degradation (Luo et al., 2012). Additional factors 
recruited to phosphorylated H2AX consist of chromatin remodeling complexes 
such as INO80 and SWR1 in yeast (Morrison et al., 2004;van Attikum et al., 
2007) and p400 in humans (Xu et al., 2010). K63 histone di-ubiquitylation by 
RNF8, in turn, allows binding of the adaptor protein RAP80 through its UIM 
motifs (Sato et al., 2009) and the recruitment of Abraxas (ABRA1), which acts 
as anchor for BRCA1 at sites of DNA damage (Bekker-Jensen and Mailand, 
2010). The BRCA1 complex, in turn, contains the DUB BRCC36, which is 
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able to depolymerize K63 ubiquitin chains, thus contributing to maintain 
steady-state levels of ubiquitin at sites of damage (Shao et al., 2009). The 
initial histone ubiquitylation by RNF8 represents a docking signal for another 
E3-ubiquitin ligase, RNF168, which recognizes di-ubiquitylated K63 on histone 
H2A via its MIU domain and amplifies the signal by further ubiquitylating 
histones around the site of damage (Doil et al., 2009;Pinato et al., 
2009;Stewart et al., 2009). The importance of RNF8-/RNF168-dependent 
ubiquitylation is well exemplified by the RIDDLE syndrome, where recessive 
mutations in the RNF168 gene lead to the expression of aberrant RNF168 
protein isoforms, resulting in failure of 53BP1 and BRCA1 accumulation at IR-
induced foci and of the subsequent activation of DNA damage responses 
(Stewart et al., 2009). Sumoylation of RNF8, RNF168 and BRCA1 mediated 
by PIAS1 and PIAS4 enhances their E3-ligase activity, contributing to render 
more efficient histone ubiquitylation at DSBs (Galanty et al., 2009). Through 
interaction with the ubiquitin-conjugating UBE2L6/UBCH8, RNF8 controls the 
degradation of the demethylase JMJD2A/KDM4A resulting in the uncovering 
of H4K20me2 mark and promoting the recruitment of 53BP1 at DNA damage 
sites (Mallette et al., 2012). RAD18 is another ubiquitin E3-ligase recruited at 
DNA lesions through recognition of K63 ubiquitylated histones and acting 
downstream of RNF8/ RNF168 (Huang et al., 2009). In concomitance with the 
events described above, the constitutive phosphorylation of MDC1 by casein 
kinase 2 (CK2), allows the former to capture additional molecules of ATM that 
phosphorylate both H2AX in the neighbouring nucleosomes and MDC1 itself 
(Polo and Jackson, 2011).  
Phosphorylation does not only serve the function of facilitating the assembly 
of modules that become visible in DNA damage-induced foci, but also 
contributes to break up interactions during repair processes. This is the case 
of the transcriptional repressor and ring finger protein KAP1/TIF1β/TRIM28, 
which is released from chromatin upon ATM-mediated phosphorylation of 
S824, an event that results in the dissociation of heterochromatin protein 1 
(HP1) from chromatin and contributes to remodel regions undergoing repair 
(Goodarzi et al., 2008). 
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DNA end resection - Marking DNA double-strand break sites is followed by 
the recruitment of repair proteins in charge of processing DNA ends to create 
structures that are suitable to recombination. This task is initially 
accomplished by the MRN complex that in conjunction with CtIP/RBBP8 
carries out initial trimming at the break, a step that is followed by extensive 
processing of DNA ends by the redundant function of EXO1 and the 
DNA2/BLM complex (Mimitou and Symington, 2009;Eid et al., 2010). Proteins 
participating in DNA processing are also controlled by PTMs.  
CtIP is phosphorylated in a CDK-dependent manner in S and G2 phases of 
the cell cycle at T847 and S327. Whereas phosphorylation of the former affects 
resection activity, modification of the latter influences BRCA1 binding (Yu and 
Chen, 2004;Huertas and Jackson, 2009). In response to DSBs CtIP is 
additionally phosphorylated by ATM (Matsuoka et al., 2007). Binding of 
BRCA1/BARD1 to CtIP is mediated by the BRCT domain of BRCA1 and 
causes ubiquitylation of CtIP in a manner that does not target it to degradation 
but facilitates binding to DNA and enrichment at sites of damage (Yu et al., 
2006). This is an example of ubiquitylation as means to selectively target 
protein to a defined region in the cell or to a structure. 
EXO1 protein level is controlled by ATR-dependent phosphorylation and poly-
ubiquitylation by an as yet unknown E3 ligase in response to stalled 
replication (El-Shemerly et al., 2005;El-Shemerly et al., 2008), whereas its 
exonuclease activity is controlled in a PIKK-dependent manner upon induction 
of DSBs both in yeast and man (Morin et al., 2008;Bolderson et al., 2010). 
Sumoylation of EXO1 has also been reported (Tatham et al., 2011), though its 
functional significance awaits clarification. 
The Bloom syndrome helicase (BLM) plays an important role in homologous 
recombination and in the repair of damaged replication forks (Jones and 
Petermann, 2012). Modification of BLM by SUMO is necessary for a balanced 
γH2AX response in HU treated cells, with cells that express SUMO-deficient 
forms of BLM displaying excessive γH2AX phosphorylation, accumulation of 
DNA breaks and hypersensitivity to DNA damage (Ouyang et al., 2009). In 
HU-treated cells expressing SUMO-deficient forms of BLM, the ability to 
localize RAD51 at damaged replication forks is compromised and sister-
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chromatid exchanges does not occur. This led to the suggestion that 
sumoylation represents a switch between pro- and anti-recombinogenic roles 
for BLM in HR (Ouyang et al., 2009). 
Resection of DNA ends by EXO1 or the BLM/DNA2 complex leads to the 
formation of long 3’-overhangs that are the structures participating in 
homologous recombination. Replication Protein A (RPA) is the major ssDNA 
binding protein complex present in eukaryotes and consists of three subunits: 
RPA1 (70 kDa), RPA2 (32 kDa) and RPA3 (14 kDa). RPA1 has high affinity 
for DNA and is the docking subunit for a number of proteins involved in DNA 
synthesis and repair (Fanning et al., 2006). RPA2 has lower affinity for DNA 
and, thanks to its C-terminal winged helix domain, binds weakly but 
specifically to AID, to BER proteins such as UDG or to NER proteins such as 
XPA (Fanning et al., 2006). RPA2 is the major target of phosphorylation 
events that occur during DNA replication and the DNA damage response. 
RPA3 is the only component with no affinity for DNA but playing an important 
role in the stabilization of the trimeric protein complex (Fanning et al., 2006). 
The association between the SUMO protease SENP6 and RPA1 during 
transition through S-phase maintains RPA1 in a hypo-sumoylated state. 
Camptothecin-induced DSBs weaken the interaction between RPA1 and 
SENP6, facilitating RPA1 sumoylation at K449 and K577, an event that results in 
increased interaction with Rad51 and displacement of RPA from the ssDNA 
filament (Dou et al., 2010). 
Sumoylation of MRE11 and RAD54 has also been reported (Tatham et al., 
2011), though the functional significance of this PTM is as yet unknown. 
 
Proximal and distal signaling - Three members of the PIKK family of protein 
kinases, namely ATM, ATR and DNA-PK, orchestrate the response to 
genotoxic damage, consisting in accrual of DNA processing and repair 
proteins at sites of damage and in cell cycle arrest. Unlike ATM or DNA-PK 
that are activated by DNA ends (Uematsu et al., 2007;You et al., 2007), ATR 
activation specifically depends on the presence of ssDNA generated by 
processing different types of damage (Zou and Elledge, 2003) or naturally 
occurring at replication forks (MacDougall et al., 2007). The triggering of ATR 
typically occurs after ATM activation (Jazayeri et al., 2006). The checkpoint 
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kinases CHK1 and CHK2 are phosphorylated by ATR at S317 and S345 (Zhao 
and Piwnica-Worms, 2001) and by ATM or ATR at seven residues in the N-
terminal domain (Matsuoka et al., 2000), respectively. This triggers homo-
dimerization of the checkpoint kinases and full activation through auto-
phosphorylation (Lee and Chung, 2001) (Fig. 2B).  
The ATR-CHK1 pathway controls the timing of replication origin firing in S-
phase in the absence of DNA damage (Shechter et al., 2004) and triggers 
G2/M arrest in response to γ-irradiation (Liu et al., 2000). ATR-mediated 
phosphorylation of CHK1 at S345 exposes a degron-like region at the C-
terminus of the kinase allowing recognition by the cytoplasmic Cul1/FBX6 or 
the nuclear Cul4A/CDT2 SCF E3-ligase complexes that promote poly-
ubiquitylation and degradation of CHK1 (Zhang et al., 2009;Huh and Piwnica-
Worms, 2013). It has been proposed that proteolysis of activated CHK1 
results in checkpoint termination (Zhang et al., 2005b). 
The ATM/CHK2 axis controls both the transient and the sustained cell cycle 
arrest that follows detection of DNA damage (Fig. 2B) (Shiloh and Ziv, 2013). 
Namely, by phosphorylating CDC25 phosphatases and the WEE1 kinase, 
CHK2 blocks cell cycle transitions mediated by Cyclin-CDKs, whereas by 
phosphorylating p53, MDM2 and PML it promotes apoptosis (Antoni et al., 
2007).  
Both CHK1 and CHK2 impinge on the machinery driving cell cycle transitions 
by directly phosphorylating controllers of cyclin-dependent kinases such as 
the WEE1 kinase and the CDC25A and CDC25C phosphatases (Bartek et al., 
2004) (Fig. 2B). WEE1 catalyzes phosphorylation of two residues in the Gly-
rich P-loop of CDK1, namely T14 and Y15, in a manner that does not affect 
nucleotide binding but hampers catalysis (Ferrari, 2006). CDC25 
phosphatases specifically remove the phosphate from the two residues in the 
ATP-binding site of CDKs, causing full activation of Cyclin/CDK complexes 
(Ferrari, 2006). Inhibition of CDC25C by DNA damage essentially occurs by a 
14-3-3-mediated sequestration mechanism, whereas CDC25A degradation 
via ubiquitin-proteasome pathways is a primary control mechanism both in 
dividing cells and in response to DNA damage (Donzelli and Draetta, 2003). 
Phosphorylation of CDC25A on S76 by CHK1 (Jin et al., 2008a) serves as 
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priming event to facilitate phosphorylation on S79 and S82 by protein kinase 
CK1 or glycogen synthase kinase-3β (GSK-3β) (Kang et al., 2008;Honaker 
and Piwnica-Worms, 2010). This, in turn, allows recruitment of the SCFβ-TRCP 
E3 ligase that promotes CDC25A poly-ubiquitylation (Busino et al., 2003). 
 
DNA damage recovery – Following completion of DNA repair, cell cycle 
restart is contributed by degradation of molecules that were involved both in 
signaling DNA damage and in blocking cell cycle progression. This is the case 
of the adaptor protein Claspin, which is targeted by SCF-βTrcP upon PLK1-
dependent phosphorylation (Mamely et al., 2006;Peschiaroli et al., 2006) and 
whose level is maintained low throughout G1 by the APC/CDH1 E3-ligase 
(Bassermann et al., 2008), and of the kinase WEE1 (Bartek and Lukas, 2007). 
 
Other DNA lesions - Additional examples of regulation of DNA damage 
responses by ubiquitylation are provided by Fanconi Anemia (FA), 
Translesion DNA Synthesis (TLS) and Nucleotide Excision Repair (NER). FA 
is an X-linked disease characterized by mutations in genes coding for factors 
of this DNA repair pathway. Upon exposure to DNA interstrand cross-linking 
(ICL) agents, FANC proteins form a nuclear “core-complex” in which FANCL 
is the E3 ubiquitin ligase responsible, together with its cognate E2 UBE2T, for 
the mono-ubiquitylation of FANCI and FANCD2 proteins (the ID-complex) on 
residues K561 and K523, respectively, an event required for the formation of 
damage-induced foci (Wang, 2007). Mutation of the ubiquitin-binding domain 
on FANCI-FANCD2 results in hypersensitivity to mitomycin C or cisplatin 
(Smogorzewska et al., 2007). In TLS, which represents one of the main 
mechanisms allowing DNA lesion bypass in S-phase (Waters et al., 2009), 
ubiquitylation of PCNA plays a key role (see below). BER addresses the 
repair of modified bases or abasic sites resulting from 
depurination/depyrimidinatuon events (Almeida and Sobol, 2007). In addition 
to TDG (see above), which participates in lesion recognition and processing, 
the BER scaffold component XRCC1 is controlled by phosphorylation (Loizou 
et al., 2004) and sumoylation (Gocke et al., 2005). The E3-ligase 
CHIP/STUB1 adds another layer of control to BER by mediating ubiquitylation 
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of the pool of XRCC1 and Polβ that are not directly participating in the 
process of lesion recognition and repair (Parsons et al., 2008). 
 
 
Interdependence of PTMs 
 
Hierarchical priming - An interesting feature of PTMs is their reciprocal 
influence, as clearly established for histones, where the antagonism or the 
synergism of certain modifications defines a “code” that guides protein-DNA 
interactions (Sims and Reinberg, 2008). These, in turn, influence the 
compaction of chromatin and ultimately affect biological responses such as 
transcription, DNA replication and DNA repair (Kouzarides, 2007). Such 
effects can be cumulative or exclusive, with a clearly defined hierarchy of 
PTMs affecting a given target protein. In the DDR, a notable example of 
consecutive PTMs occurring in a hierarchical manner is represented by FEN1, 
the flap endonuclease responsible for cleavage of single stranded 5’ 
overhangs in Okazaki fragments during DNA replication and also involved in 
DNA repair. Phosphorylation at S187 in FEN1 catalytic domain by cyclin 
A/CDK2 results in its release from PCNA, the DNA polymerase processivity 
factor that stimulates FEN1 nuclease activity (Henneke et al., 2003). 
Subsequent modification of K168 in FEN1 by SUMO3 facilitates K354 
ubiquitylation by the E3 ligase PRP19, resulting in FEN1 degradation at the 
end of S-phase, an event that contributes to ensure a timely transition to G2 
(Guo et al., 2012).  
 
Competition for the substrate - In addition to the ability of sumoylation to 
directly alter the properties of the protein undergoing this modification, it may 
also serve as a competitor to other PTMs. Indeed, since sumoylation targets 
lysine residues in the substrate, similarly to ubiquitylation, methylation or 
acetylation, the modification of one or more lysine in the substrate could block 
access to other PTM machineries, thus indirectly affecting protein function 
(Walsh et al., 2005). Established examples of competition among PTMs are 
RanGAP1, which upon sumoylation preferentially binds the nuclear pore 
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complex (Melchior, 2000), the NF-κB signaling pathway (Huang et al., 2003) 
and PCNA (Hoege et al., 2002). Specifically to the latter, early studies showed 
that mono-ubiquitylation mediated by RAD6 (E2) and RAD18 (E3), K63 poly-
ubiquitylation by MMS2, UBC13 and RAD5 and sumoylation by UBC9 all 
affect the same lysine residue (K164) (Hoege et al., 2002). Subsequent work 
clearly established that PCNA mono-ubiquitylation supports translesion 
synthesis, a pathway allowing stalled DNA replication to proceed beyond 
damage through the replacement of processive polymerases with specialized 
polymerases (Bienko et al., 2005;Garg and Burgers, 2005). K63 poly-
ubiquitylation, on the other hand, facilitates synthesis by a template-switch 
mechanism, a complex but essentially error-free pathway that utilizes the 
undamaged, newly synthesized daughter strand of the sister chromosome as 
template (Branzei and Foiani, 2010). Finally, PCNA SUMOylation prevents 
the formation of DSBs and the occurrence of inappropriate recombination 
events at stalled DNA replication forks by a mechanism involving the anti-
ricombinogenic activity of the helicase Srs2 in yeast (Papouli et al., 
2005;Pfander et al., 2005) and possibly by a similar mechanism in humans 
(Gali et al., 2012). 
 
Cross-talking - A number of ubiquitin E3-ligases display the ability to bind 
SUMO chains on proteins that, in turn, become their substrates. A reported 
case is PML, which undergoes modification by SUMO-1 as well as by SUMO-
2/3. Whereas attachment of SUMO-1 determines confinement of the protein in 
PML nuclear bodies (Muller et al., 1998) formation of SUMO2/3 chains 
facilitates the recruitment of the E3-ligase RNF4, which ubiquitylates the 
SUMO chains ultimately targeting PML to degradation (Lallemand-
Breitenbach et al., 2008;Tatham et al., 2008;Weisshaar et al., 2008). RNF4 
displays the ability to interact with other sumoylated substrates, such as 
MDC1 and RPA, via its N-terminal SUMO interaction motif (SIM) and to 
subsequently regulate their stability (Galanty et al., 2012). Another interesting 
case is BRCA1, which co-localizes with and is sumoylated by PIAS1 and 
PIAS4 at sites of damage. This, in turn, was reported to enhance BRCA1 E3-
ligase activity possibly through a SUMO-dependent increase of the E3-E2 
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interface (Morris et al., 2009) 
 
Synergy - The advent of proteome-wide studies allowed appreciating the fact 
that, like phosphorylation, sumoylation triggered by a defined stimulus or 
stress does not target a single components but a vast majority of the protein 
machinery involved in the response. Work conducted in yeast established that 
lack of overall sumoylation in a hypomorphic mutant of the SUMO E2 Ubc9 
impaired survival in response to DNA damage (Cremona et al., 2012). This 
resulted from incomplete replication of damaged DNA as well as defective 
resection at DSBs. The authors found that DNA damage-induced sumoylation 
occurred independently of phosphorylation events that were triggered by the 
checkpoint and was proposed to act in parallel with them to support cell 
survival (Cremona et al., 2012). A study conducted using SILAC-based mass 
spectrometry identified 844 different SUMO conjugates, the abundance of 
which did not seem to change in response to DNA damage (Psakhye and 
Jentsch, 2012). Interestingly though, the set of sumoylated proteins enriched 
in response to DNA damage was specifically that of the HR machinery. The 
authors found that DNA end resection and the consecutive generation of long 
ssDNA tracts acted as trigger to the wave of sumoylation that characterized 
the response. Sumoylation of HR proteins was found to occur independently 
and in parallel, with no influence of one sumoylation event on the other, and to 
entirely depend on the SUMO E3-ligase Siz2. Sumoylation promoted physical 
interaction among HR proteins, thus facilitating DNA repair (Psakhye and 
Jentsch, 2012). 
 
Ubiquitin and SUMO as targets in cancer therapy 
Ubiquitylation and/or sumoylation defects have been implicated in the 
pathogenesis of a number of human diseases among which is cancer (Sun, 
2006;Bettermann et al., 2012).  
 
Ubiquitin and cancer - Examples of over-expression of ubiquitinylation 
pathway components in cancer cells are the p53-specific ARF-BP1/Mule 
HECT E3-ligase, the F-box proteins SKP2 and β-TrcP1, the SCF component 
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Cul-4A and the RING-finger proteins RNF11, ZNF164 (Chen et al., 2006) and 
RNF5 (Bromberg et al., 2007). Mutation or deletion of E3-ligases that normally 
function as tumor suppressors has also been reported. This is the case of the 
RING-finger E3-ligases BRCA1/BARD1 and SIAH1 (Chen et al., 2006). 
Finally, epigenetic inactivation of genes coding for the E3-ligase HACE1 (Hibi 
et al., 2008) or the RING-finger protein CHFR (Chen et al., 2006) has been 
observed in several types of carcinomas. 
Based on the reasoning that E3 enzymes are druggable targets, 
pharmaceutical companies embarked on high-throughput screenings in 
search for compounds that would target the active site of E3-ligases or block 
interaction with their substrates (Sun, 2006;Hoeller and Dikic, 2009). A 
notable example of the latter is Nutlin, which impairs the p53-HDM2 
interaction by filling a groove in HDM2 where p53 is accommodated (Vassilev, 
2007). Despite the initial enthusiasm raised by Nutlin and its derivatives, the 
limitation of its efficacy in cells expressing wild-type p53 excluded their use in 
a number of other cancers. More discouraging, the cytostatic effect of Nutlins 
in p53-deficient cells indicated that they did not solely inhibit the p53/HDM2 
interaction (VanderBorght et al., 2006). The p53-targeting molecule RITA 
(NSC652287), identified in a screening conducted on a pair of isogenic cell 
lines differing only in their p53 status, was shown to bind p53 N-terminus 
(Issaeva et al., 2004). However, RITA did not specifically target the p53-
HDM2 dimer but also other p53 protein complexes (Hjerpe and Rodriguez, 
2008). Similar issues were encountered with other inhibitors of E3-ligases 
(Guedat and Colland, 2007).  
The E1-activating enzyme and the proteasome have also been considered as 
possible targets, with the caveat that inhibiting the ubiquitylation cascade at its 
apex may impair pathways of vital importance to the survival of normal cells. 
This is particularly true if one considers the widespread use of ubiquitylation in 
the control of cellular functions. Nonetheless, inhibitors of the chymotryptic 
activity of the proteasome have been identified and characterized. 
Compounds such as bortezomib have received approval from FDA and are 
currently used for the treatment of multiple myeloma and mantle cell 
lymphoma (Guedat and Colland, 2007;Rastogi and Mishra, 2012). Similarly, 
ATP-competitive inhibitors blocking the transfer of ubiquitin from the E1-
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activating enzyme to E2-conjugating components of the cascade have been 
identified (Guedat and Colland, 2007). Inhibition of deubiquitylating enzymes 
has also been explored as possible alternative to the development of 
inhibitors of the ubiquitylation cascade. A compound specifically targeting 
USP7 was shown to stabilize p53, activate p53-dependent transcription, block 
cell growth and induce apopotosis (Guedat and Colland, 2007). Recently, a 
novel strategy based on the use of combinatorial libraries of ubiquitin variants 
has led to the identification of mechanisms of DUBs inhibition and provided 
the demonstration that this approach could be applied to the discovery of 
specific E2 or E3 inhibitors (Ernst et al., 2013). 
 
SUMO and cancer - With regard to the role of SUMO in cancer, Ubc9/UBE2I 
was found overexpressed in ovarian carcinoma specimens (Mo et al., 2005). 
Xenografts studies conducted in mice revealed that tumors expressing 
wildtype Ubc9 grew better than controls, while tumors expressing dominant 
negative Ubc9 exhibited reduced growth (Mo et al., 2005). A comprehensive 
study reported an increase in UBC9 expression in primary colon and prostate 
cancer compared with their normal tissue counterparts, whereas UBC9 levels 
were found lower in metastatic breast, prostate, and lung cancer in 
comparison with their corresponding normal and primary adenocarcinoma 
tissues (Moschos et al., 2010). Increased UBC9 expression was also 
observed in melanoma-infiltrated lymph nodes, with depletion of UBC9 
resulting in sensitization of melanomas to the cytotoxic effects of topotecan 
and cisplatin (Moschos et al., 2007). A comprehensive collection of studies on 
UBC9 mRNA expression pattern in different cancer types can be found at 
www.nextbio.com. Based on these findings, targeting UBC9 in cancer therapy 
was initially proposed (Mo et al., 2005). However, given the widespread use of 
sumoylation as PTM controlling numerous metabolic pathways, altering the 
overall pattern of sumoylation in the cell was countered by others as a non-
specific and ineffective method to combat cancer (Bawa-Khalfe and Yeh, 
2010). In support of arguments to UBC9 as valid target in cancer therapy is 
the differential expression issue, with higher levels of UBC9 in cancerous vs. 
normal tissues offering a possible therapeutic window (Mo and Moschos, 
2005). In this respect, crystallographic studies mapping the surfaces in UBC9 
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involved in the interaction with specific E3s and their substrates represent a 
promising avenue to the design of small compounds disrupting selective 
sumoylation reactions (Mo and Moschos, 2005).  
Increased levels of the desumoylating enzyme SENP1 were reported in 
thyroid oncocytic adenocarcinoma (Jacques et al., 2005) and prostate cancer 
(Cheng et al., 2006). A transgenic mice model showed that overexpression of 
Senp1 in the prostate led to the development of prostatic intraepithelial 
neoplasia at an early age (Cheng et al., 2006). Promising results have been 
obtained in studies aiming at the identification of SUMO-specific protease 
(SENP) inhibitors (Hemelaar et al., 2004;Borodovsky et al., 2005) or based on 
the screening of cysteine-protease inhibitor libraries (Albrow et al., 2011). The 
latter, in particular, led to the identification of two classes of compounds: the 
first, containing a reactive aza-epoxide electrophile linked to an extended 
peptide backbone and the second, containing an acyloxymethyl ketone 
reactive group. Structure-activity relationship studies led to the design of 
covalent inhibitors of multiple hSENPs displaying micromolar IC50 values 
(Albrow et al., 2011).  
Arsenic trioxide, which induces differentiation of leukemic blasts and clinical 
remission, was shown to promote SUMO-dependent poly-ubiquitylation of 
PML-RARα by the ubiquitin E3-ligase RNF4, with consequent degradation of 
the fusion protein responsible for acute promyelocytic leukemia (Lallemand-
Breitenbach et al., 2008;Tatham et al., 2008). Thus, in addition to classic 
approaches based on the chemical inhibition of enzymatic activity, the case of 
arsenic trioxide illustrated that among the variety of possible avenues to inhibit 
function, the exploitation of existing pathways in the cell that may be triggered 
at will, is an important option. 
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FIGURE LEGENDS 
 
Figure 1 – Simplified scheme of ubiquitylation  
The ubiquitylation cascade initiates with an ATP-dependent reaction 
consisting in the formation of a thiolester bond between a cysteine in the 
active site of the E1-activating enzyme and G76 in ubiquitin (Ub). In the 
second step, ubiquitin is transferred to the active cysteine of an E2-
conjugating enzyme. Finally, an E3-ligase enzyme binds the E2-Ub complex 
and transfers ubiquitin to lysine residues of the acceptor substrate (target), 
which is shuttled to the 26S proteasome. Ubiquitin is recycled for another 
round of reactions. 
 
 
Figure 2 – Proximal and widespread DNA damage signals 
(A) In response to the generation of DSBs, ATM is recruited to DNA in an 
MRN-dependent manner and is activated by autophosphorylation. 
ATM-dependent phosphorylation of H2AX triggers the recruitment of 
factors that mark the site of damage and cooperate to amplify the 
signal. In addition, ATM phosphorylates proteins that contribute to 
remodel chromatin and promote homologous recombination (see text 
for details). 
(B) Activation of ATM triggers the phosphorylation of the protein kinase 
CHK2 among others, which freely diffuses from the site of damage to 
transduce DNA damage signals to cell cycle regulators, resulting in the 
inhibition of cell cycle transitions (see text for details). 
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Bologna et al., Figure 1  
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Bologna et al., Figure 2  
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3. AIM OF STUDY 
 
The genetic information contained in DNA is duplicated and faithfully 
segregated into daughter cells during a cycle of cell division. Tight control of 
factors involved in recognition and repair of DNA damage is of key importance 
to maintain a stable genome. Exonuclease-1 (EXO1) is one such factor.  
Exonuclease 1 (EXO1) is an exonucleolytic enzyme and a common 
component of machineries processing stalled replication forks, DSBs and 
DNA base mismatches. Indeed, it resects DNA at site of breaks from 5' to 3' 
producing 3' overhanging ssDNA filaments that are substrates for the 
components of the DNA repair machinery by homologous recombination. 
Previous work from our laboratory demonstrated that the function of human 
and yeast EXO1 at DSBs and stalled forks, respectively, is rigorously 
controlled by specific protein-protein interactions (Eid et al., 2010; Engels et 
al., 2011). Additional studies from our laboratory showed that, in response to 
stalled DNA replication, the cellular level of human EXO1 is regulated by 
phosphorylation-dependent ubiquitylation that channels EXO1 to proteasome-
mediated degradation (El-Shemerly et al., 2008; El-Shemerly et al., 2005).  
 
The aim of my project is to extends these findings and, taking advantage 
of a combination of molecular biology and biochemical techniques as 
well as cell biology assays, to provide new mechanistic insights on the 
regulation of EXO1 by identification of the main players involved in 
EXO1 post-translational modification upon DNA damage.  Furthermore 
my final goal is to elucidate the effects of EXO1 stabilization and 
genome stability. 
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4. RESULTS  
 
Elucidating the mechanism regulating EXO1 upon 
double-strand breaks or stalling of the replication 
forks. 
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ABSTRACT 
 
Processing DNA double-strand breaks (DSBs) by the error-free pathway of 
homologous recombination (HR) requires the concerted action of a number of 
factors. Among these, EXO1 and DNA2/BLM are responsible for the 
extensive resection of DNA ends to produce 3’-overhangs, which are 
essential intermediates for later HR steps. Here we address the role of post-
translational modifications (PTMs) in the control of EXO1 at sites of DNA 
damage. We show that EXO1 is a SUMO target and that sumoylation affects 
EXO1 protein stability under basal as well as DNA damage conditions. We 
identify an UBC9-PIAS1/PIAS4-dependent mechanism controlling human 
EXO1 sumoylation in vivo and, using an in vitro reconstituted system, 
demonstrate conservation of this mechanism in yeast by the Ubc9-Siz1/Siz2. 
Furthermore, we show physical interaction between the desumoylating 
enzyme SENP6 and EXO1, promoting EXO1 stability. We provide evidence 
that sumoylation and ubiquitylation occur sequentially on EXO1 in response to 
DNA damage and that the former affects recruitment of EXO1 to sites of 
damage. Finally, we identify the major sites of sumoylation in EXO1 and show 
that ectopic expression of a sumoylation-deficient form of EXO1 rescues the 
DNA damage-induced chromosomal aberrations observed upon wt-EXO1 
expression. Thus, our study identifies a novel layer of regulation of this DNA 
damage response protein by elucidating the cross-talk between sumoylation 
and ubiquitylation, making EXO1 and the pathways regulating its function an 
ideal target for therapeutic intervention.  
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INTRODUCTION 
 
Faithful repair of DNA lesions is essential to the maintenance of genome 
stability 1. Double-strand breaks (DSBs) are the most toxic DNA lesions 
generated by ionizing radiation (IR), certain chemotherapeutic drugs, collapse 
of stalled DNA replication forks, endogenous metabolic processes or during 
meiotic recombination 2-4. Inappropriate repair of DSBs may cause gross 
chromosomal aberrations 5 resulting in carcinogenesis through activation of 
oncogenes or inactivation of tumor suppressor genes 6. Cells utilize two main 
mechanisms to repair DSBs: non-homologous end-joining (NHEJ) and 
homologous recombination (HR) 7. Rejoining of DSBs by NHEJ takes place 
throughout the cell cycle, whereas HR is restricted to the S and G2 phases, 
where sister chromatids are available as templates. HR is initiated by 5’-3’ 
resection of DSBs to produce single-stranded DNA (ssDNA) tails that function 
not only as a signal for the ATR-mediated DNA damage checkpoint but also 
to allow formation of RAD51 filaments and recruitment of recombination 
proteins 8. Studies conducted in yeast and mammalian cells led to the 
proposal of  a mechanism according to which MRN and CtIP (MRX and Sae2 
in yeast) orchestrate the initial trimming of DNA-ends, which is followed by a 
processive step of resection carried out by two alternative pathways that 
involve either EXO1 or BLM/DNA2 9. 
EXO1 was originally identified in S. pombe 10 and subsequently in humans 11. 
It belongs to the Rad2 family of DNA repair nucleases and is able to remove 
mononucleotides from the 5’ end of the DNA duplex 12. EXO1 is implicated in 
several DNA repair pathways including mismatch repair, post-replication 
repair, meiotic and mitotic recombination and double-strand break repair 13-17. 
S. cerevisiae Exo1 acts redundantly with Rad27 in processing Okazaki 
fragments during DNA replication 18. More recently, Exo1 was shown to be 
recruited to stalled replication forks where it counteracts fork reversal 19.  
The recruitment of proteins that mark sites of DNA damage as well as the 
choice of pathways addressing their repair heavily relies on control by PTMs 
that occur in a defined hierarchy 20. An archetypal example is the 
phosphorylation-dependent binding of MDC1 to γH2AX, followed by 
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recruitment of the E3-ubiquitin ligases RNF8 and RNF168 whose activity is 
enhanced by PIAS1- and PIAS4-mediated sumoylation,  resulting in efficient 
H2A and H2B mono-ubiquitylation 20. An interesting feature of PTMs is not 
only the hierarchical level at which they occur but also their reciprocal 
influence, as demonstrated for FEN1 21. 
We have previously shown that the function of human and yeast EXO1 at 
DSBs and stalled forks is rigorously controlled by interaction with CtIP and 14-
3-3 proteins, respectively 5,22. Additionally, human EXO1 activity is controlled 
by post-translational modifications, with ATR-dependent phosphorylation 
targeting it to ubiquitin-mediated degradation upon replication fork stalling 
23,24, and ATM-dependent phosphorylation apparently restraining its activity 
during homologous recombination 25. Analogously, Mec1-dependent 
phosphorylation inhibits yeast Exo1 activity at uncapped telomeres 26.  
In this study we have focused on elucidating the molecular mechanism of 
EXO1 regulation upon stalled DNA replication. We have performed an RNAi-
based screen of human E2-conjugating enzymes and identified UBE2I, the 
human homolog of yeast Ubc9, as major effector of EXO1 stability. We show 
that EXO1 is sumoylated in vivo in a PIAS1- and PIAS4-dependent manner 
and in vitro using a reconstituted system. We also provide evidence that 
SENP6 physically interacts with EXO1 and that depletion of SENP6 promotes 
EXO1 degradation. Furthermore, identification of the major SUMO-
conjugation sites in EXO1 allowed us to demonstrate that sumoylation affects 
the time of EXO1 residence at sites of DNA damage. Finally, we observed 
that the high rate of chromosome breaks caused by camptothecin in cells 
ectopically expressing wild-type EXO1 did not occur upon expression of a 
SUMO-deficient EXO1 mutant. 
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RESULTS  
 
EXO1 is degraded in response to camptothecin – In response to agents that 
cause stalling of DNA replication forks, such as hydroxyurea (HU) or 
aphidicolin (APH), human EXO1 undergoes ubiquitylation-dependent 
proteasomal degradation 23,24. To substantiate and extend the observation 
that EXO1 degradation occurs upon DNA damage and is S-phase-specific, 
we additonally verified the effect of the topoisomerase-1 inhibitor 
camptothecin (CPT). As shown in Fig. 1a,  a 4h CPT treatment led to a net 
decrease of EXO1 protein level and this effect was rescued by the presence 
of the proteasome inhibitor MG-132. Given the low level of EXO1 expression 
in mammalian cells, which requires combined immunoprecipitation and 
Western blot to visualize the protein (Fig. 1a and 23), we asked whether 
ectopically expressed EXO1 would behave as the endogenous protein. To 
this end, we first performed a dose-response study on HEK-293T cells 
transiently expressing GFP-EXO1. Similarly to the endogenous protein, 
exogenous GFP-EXO1 was sensitive to CPT-treatment already at the lowest 
concentration tested (Fig. 1b and 1c). The ability of CPT to cause a decrease 
in EXO1 protein level was confirmed in U2OS cells stably expressing EXO1 
(U2OS-GFP-EXO1)5 by either Western blot analysis (Fig. 1c) or 
immunofluorescence (Fig. 1d). Addition of the proteasome inhibitor MG-132 or 
the E1-Ubiquitin-activating enzyme inhibitor PYR-41 rescued CPT-induced 
EXO1 degradation (Fig. 1c and 1e).  
Taken together, these data indicate that both endogenous and exogenous 
EXO1 are targets for ubiquitin-dependent proteasomal degradation in 
response to topoisomerase-I inhibition. 
 
EXO1 degradation depends on SUMO pathways – In order to shed light on 
the mechanism controlling EXO1 protein stability, we set out to identify the 
pathway responsible for EXO1 degradation. To this end, we performed an 
immunofluorescence-based high-throughput screen of an siRNA library of all 
37 human E2 ubiquitin-conjugating enzymes in U2OS-GFP-EXO1 cells, 
followed by image and computational analysis of the acquired data. The most 
significant increase in green fluorescence, taken as read-out for GFP-EXO1 
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protein stabilization, was obtained upon depletion of UBE2I (the human 
homologue of the yeast Ubc9 enzyme, referred to as UBC9), both in basal 
and damaging conditions (Fig. 2a). We could exclude any indirect effect of 
UBC9 depletion on cell size and cell cycle phases (Fig. S1). To corroborate 
the role of UBC9, we examined EXO1 stability in U2OS cells depleted for 
UBC9 with a single siRNA. Under these conditions, Western blotting (Fig. 2b) 
and indirect immunofluorescence (Fig. 2d) confirmed an increase in GFP-
EXO1 protein level in both untreated and CPT-treated cells. It should be 
pointed out that stabilization of GFP-EXO1 in non-damaged cells that were 
depleted for UBC9 is consistent with the fact that EXO1 undergoes 
constitutive degradation, as we previously demonstrated by chemical 
inhibition of the proteasome with MG-132 or in ATR-deficient Seckle cells 23,24 
Quantification of GFP-positive cells in untreated conditions showed a 3.1-fold 
increase upon depletion of UBC9 (Fig. 2d and S2a). UBC9-depleted cells 
showed a 1.4-fold increase in fluorescence signal compared to control-
depleted cells (Fig. S2b). Similar values were observed upon CPT treatment 
(data not shown). An analogous pattern of protein stabilization was confirmed 
in UBC9-depleted HEK-293T cells ectopically expressing GFP-EXO1 (Fig. 
2c). To corroborate these observations, we co-expressed HA-UBC9 and GFP-
EXO1 in HEK-293T cells, which resulted in clear reduction of GFP-EXO1 
protein level (Fig. 2e). The minimal EXO1 degradation in response to DNA 
damage observed in this case (Fig. 2e lane 1 vs. 2) is likely due to saturation 
of proteasome-dependent degradation machinery in over-expression studies. 
Taken together, these data indicate that EXO1 protein level is controlled by 
SUMO pathways both in unperturbed conditions and upon stalled DNA 
replication.  
 
EXO1 is a direct target of SUMO pathways – Next, we examined whether 
EXO1 is a direct target for sumoylation. To this end, we performed in vitro 
studies with a reconstituted sumoylation machinery. Using purified 
recombinant components of the yeast machinery, which is a very robust 
system for such enzymatic assays, we observed that both yeast and human 
EXO1 are modified by SUMO (Fig. 3a and 3b). Considering the role of EXO1 
in DNA repair pathways, we asked whether E3-SUMO ligases with an 
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established role in the DNA damage response would affect EXO1 
sumoylation. We observed that the presence of the E3-SUMO ligases Siz1 or 
Siz2 was essential for the sumoylation of yeast Exo1 and significantly 
increased the pattern of human EXO1 sumoylation obtained in the absence of 
a specific E3 enzyme (Fig. 3a and 3b). In vitro assays performed with purified 
recombinant components of the human SUMO machinery (Fig. 3c) confirmed 
that human EXO1 is also target of sumoylation (Fig. 3d). 
To extend these observations to a cellular system, we ectopically expressed 
Myc-SUMO1 and Myc-SUMO2 along with GFP-EXO1 in HEK293T cells. 
Immunoprecipitation of EXO1 followed by probing with a monoclonal antibody 
to the MYC tag showed that EXO1 is constitutively sumoylated and that 
sumoylation slightly increases in response to stalled DNA replication (Fig. 4a). 
To distinguish between effects of SUMO1 and SUMO2 on EXO1, we 
examined HEK293T cells ectopically expressing either one of the two proteins 
along with GFP-EXO1. Data indicated that SUMO1, despite being expressed 
at a significantly lower level than SUMO2 in all experiments that we 
performed, caused a more pronounced decrease of GFP-EXO1 protein level 
than did SUMO2 (Fig. 4b). To follow up the observation that Siz1 and Siz2 
facilitate EXO1 sumoylation in vitro (Fig. 3a and 3b), we depleted PIAS1 or 
PIAS4, the human E3-SUMO ligases homologue of Siz enzymes, in HEK293T 
cells. Data showed that downregulation of PIAS1 or PIAS4 rescued GFP-
EXO1 protein level in response to CPT, with a clear increase of the protein 
also in unperturbed conditions (Fig. 4c).  
Since SENP proteases possess both endopeptidase activity, required for the 
maturation of SUMO1-3 precursors, and isopeptidase activity, necessary for 
reverting protein sumoylation 20, we wished to test their effect on EXO1 
stability. RNAi-mediated depletion of SENP proteases in stable U2OS cells 
(data not shown) revealed that SENP6 downregulation caused a decrease of 
GFP-EXO1 protein stability (Fig. 4d and S3). Protein interaction studies in 
HEK-293T cells ectopically expressing Flag-SENP6 and GFP-EXO1 showed 
that the two proteins could be co-immunoprecipitated, in both untreated and 
CPT-treated conditions, indicative of a physical interaction (Fig. 4e). Pull-
down studies with recombinant proteins showed that intein-tagged EXO1, 
	   112	  
which was affinity-purified with chitin beads, was able to capture soluble 
SENP6 protein (Fig. 4f).  
Taken together, these data indicate a functional role for the E3-SUMO ligases 
PIAS1/PIAS4 and the desumoylating enzyme SENP6 on EXO1 protein 
stability.  
 
Sumoylation and ubiquitylation of EXO1 occur sequentially - To further 
investigate hierarchy as well as functional links between sumoylation and 
ubiquitylation 20, we examined GFP-EXO1 in stable U2OS cells that were 
transfected with HA-Ubiquitin and treated with hydroxyurea (HU), an inhibitor 
of DNA replication that we have previously shown to induce EXO1 
ubiquitylation 23,24. Immunoprecipitation of EXO1 revealed that the HU-
induced increase in ubiquitylation pattern was significantly diminished upon 
treatment of the cells with anacardic acid, the E1-SUMO-activating enzyme 
inhibitor (Fig. 5a). In agreement, the reduction of ubiquitylation observed 
under these conditions was similar to that obtained upon treatment of the cells 
with PYR-41, the E1-UBI-activating enzyme inhibitor (Fig. 5a), indicating that 
sumoylation may precede modification by ubiquitylation. To corroborate these 
findings, we examined the extent of EXO1 ubiquitylation upon down-
regulation of UBC9 expression. As shown in Fig. 5b, the pattern of HU-
induced EXO1 ubiquitylation observed in control siRNA-treated cells was 
clearly reduced upon UBC9 depletion. This effect is particularly remarkable, 
considering the overall increase in the level of EXO1 protein in UBC9- 
depleted cells (Fig. 5b). 
Taken together, these data establish that sumoylation is a prerequisite for 
ubiquitin-mediated degradation of EXO1. 
 
Sumoylation affects EXO1 recruitment to chromatin – PTMs affect protein 
properties such as stability, localization and binding to DNA 20,27. We and 
others have previously described the rapid and transient localization of EXO1 
to DSBs generated by laser micro-irradiation of nuclei 5,25. To assess whether 
sumoylation would influence EXO1 recruitment to DNA, we examined the 
DNA binding properties of recombinant nuclease-deficient EXO1 mutant, in 
order to exclude degradation of the substrate, upon in vitro sumoylation. Data 
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showed that the ability to bind a synthetic DNA substrate was not significantly 
affected by sumoylation (Fig. 6a). Next, we examined the pattern of EXO1 
immunostaining in stable U2OS cells damaged by laser micro-irradiation to 
determine the effect of sumoylation in vivo. GFP-EXO1 was able to localize to 
sites of DNA damage within 5 min of irradiation in both control and UBC9-
depleted cells with a signal still detectable 30 min post-irradiation (Fig. 6b and 
6c), confirming previously published data 5. Notably, the entire population of 
GFP-EXO1 co-localized with γ-H2AX in siCTRL-depleted cells, whereas a 
significant proportion of GFP-EXO1 molecules remained diffused through the 
nucleus in siUBC9-depleted cells (Fig. 6b, inset). 
To substantiate these observations, we examined the chromatin-bound 
fraction of GFP-EXO1 in HEK293T cells that were treated with CPT. Data 
showed that, whereas the total population of GFP-EXO1 underwent almost 
complete degradation in response to CPT, the chromatin-bound population 
was comparable between untreated and treated cells (Fig. 6d), indicating that 
the low number of GFP-EXO1 molecules present upon damage is fully 
localized to chromatin. This population is regulated by ubiquitylation, as 
demonstrated by the increase in chromatin-bound EXO1 upon treatment with 
MG-132 (Fig. 6d). Furthermore, UBC9 depletion caused a great increase of 
the overall GFP-EXO1 population (Fig. 6e, see also Fig. 2a-d). Whereas in 
untreated cells a majority of GFP-EXO1 molecules were chromatin-bound, 
likely due to EXO1 role in other DNA repair pathways than in homologous 
recombination, no signal for GFP-EXO1 was detected on chromatin upon 
CPT treatment (Fig. 6e), indicating a specific role for sumoylation in EXO1 
recruitment to DSBs.  
Hence, while in vitro sumoylation does not have a direct effect on DNA 
binding, in vivo experiments have shown that sumoylation facilitates the 
recruitment of EXO1 to sites of DNA damage, indicating that the complexity of 
events occurring in the cell cannot be recapitulated in a minimal reconstituted 
system.  
 
Identification of sumoylation sites in EXO1 - In order  to assess the 
physiological role of sumoylation, we set out to identify the SUMO conjugation 
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sites in EXO1. Analysis of EXO1 primary sequence revealed the presence of 
four potential sumoylation sites corresponding to the canonical consensus 
motif F-K-x-E/D, with two consecutive lysine residues located at the C-
terminus of the protein (Fig. 7a). Mass spectrometric analysis of in vitro 
sumoylated EXO1 revealed that lysine K655 and K801 were modified by SUMO 
(Fig. S4a and S4b). Hence, we generated the K655/K801/K802>R mutant (EXO1-
3KR) as well as the K48/185/655/801/K802>R mutant (EXO1-5KR) where all 
predicted sites were mutated. In vitro assays conducted on purified 
recombinant EXO1-3KR as well as EXO1-5KR showed that the sumoylation 
pattern observed in wt-EXO1 was essentially abolished in the mutants (Fig. 
7b and data not shown). While binding of EXO1-3KR to a synthetic DNA 
substrate was similar to that observed for the wild-type protein (Fig. 7c), the 
DNA resection activity of EXO1-5KR (Fig. S5) appeared to be lower than that 
of wt-EXO1 and EXO1-3KR (Fig. 7d). This may reflect mutation of lysine 185 
in  the catalytic domain of EXO1 (Fig. 7a). For this reason, the EXO1-5KR 
mutant was not further considered.  
In summary, we have identified the SUMO-conjugation sites in EXO1 protein 
and characterized the corresponding SUMO-deficient mutant. 
 
Effect of sumoylation on DNA resection and genome stability  –To evaluate 
the effect of sumoylation on the above-mentioned EXO1 activities, we first 
examined DNA resection using a synthetic DNA substrate. Despite the high 
stoichiometry of EXO1 modification by SUMO, DNA resection activity was 
apparently not affected (Fig. 8a and 8b). 
However, given that the complexity of protein interactions occurring in the cell 
cannot be reconstituted in a simplified in vitro system, we decided to assess 
the effect of EXO1 sumoylation on DNA processing in vivo coupling 
quantification of DNA resection (phospho-RPA) with analysis of DNA content 
(DAPI) by flow cytometry. In comparison to mock-transfected cells, U2OS 
ectopically expressing GFP-EXO1-wt displayed a two-fold increase of DNA-
bound RPA under basal conditions (Fig. 8c and 8d). A similar pattern was 
observed in untreated and HU-treated HeLa cells transiently expressing GFP-
EXO1-wt (Fig. S6).  
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To appreciate the biological significance of increased DNA resection by 
EXO1, we examined chromosomal abnormalities in cells ectopically 
expressing GFP-EXO1-wt or the GFP-EXO1-3KR mutant. Transfected cells 
were treated with CPT to cause DNA damage, caffeine was added to override 
the G2/M checkpoint and chromosome spreads were obtained upon arresting 
cells in metaphase with colcemid. CPT-treatment of GFP-EXO1-wt expressing 
cells resulted in a significant amount of aberrations, mostly consisting of 
breaks and fragments (Fig. 8e and S7). This pattern was clearly reduced in 
cells expressing the GFP-EXO1-3KR mutant (Fig. 8e and S7). Hence, from 
these data we conclude that sumoylation-mediated targeting to DNA is 
essential for EXO1 to exert its function. 
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DISCUSSION 
Genetic conditions characterized by dysfunction of the machinery that signals 
DNA damage and/or addresses its repair are associated with a predisposition 
to the development of cancer and resistance to therapy 6, providing a direct 
demonstration of the importance of surveillance pathways in genome stability 
28. DSBs, which are among the most dangerous DNA lesions, are estimated 
to occur at a rate of ten per cell per day in primary human or mouse 
fibroblasts 29. These naturally-occurring lesions are generated upon collapse 
of stalled DNA replication forks, replication across nicks, reactive oxygen 
species of endogenous origin or the untimely action of DNA endonucleases 
(topoisomerases or RAG and AID) 29. Additionally, DSBs can occur as a result 
of lesions caused by external agents, such as ionizing radiation and 
mutagenic chemicals 8,30. 
Despite the intense effort currently being exerted to identify proteins and 
pathways involved in recognition of the various forms of DNA damage, we are 
only beginning to appreciate the function of DNA repair mechanisms, their 
cooperation and regulation. In particular, the hierarchy and coordination of 
post-translational modifications (PTMs) on recruitment, function and stability 
of DNA repair proteins at sites of damage represent new challenges in the 
field 20,31. To advance our understanding, and based on previous evidence 
obtained in our laboratory 5,22-24, we undertook a study aimed at investigating 
the molecular mechanism that controls the function of Exonuclease-1 (EXO1), 
a common component of machineries processing stalled replication forks, 
DNA base mismatches and DSBs 19,32-35. EXO1 plays a key role in processing 
damaged DNA structures to generate intermediates that are conveyed to 
error-free pathways of repair 36-38. Specifically, in this work we addressed the 
mechanism controlling proteasome-mediated degradation of EXO1 in 
response to agents that stall DNA replication and lead to the formation of 
DSBs. In search of the pathway that controls EXO1 protein stability, we found 
that EXO1 is a target of sumoylation under unperturbed conditions and in 
response to DNA damage, extending the observations made in a proteome-
wide screen that addressed the role of SUMO in protein quality control and 
reported EXO1 among the SUMO targets 39. We found that interfering with 
sumoylation blocks EXO1 ubiquitin-mediated degradation. We could 
	   117	  
reconstitute EXO1 sumoylation in vitro and establish that EXO1 is sumoylated 
in an UBC9-PIAS1/PIAS4-dependent manner in vivo. Furthermore, we found 
that EXO1 constitutively interacts with the SUMO protease SENP6 that 
regulates its protein level in the cell. We provide evidence that sumoylation 
and ubiquitylation of EXO1 occur sequentially in response to DNA damage. 
The former facilitates EXO1 recruitment to sites of damage, whereas the latter 
occurs on EXO1 bound to chromatin and allows control of DNA processing 
during resection by targeting EXO1 to degradation (Fig. 9). In this respect, we 
observed that over-expression of EXO1, likely mimicking the condition of 
cancer cells with up-regulated EXO1 gene expression 40, led to increased 
DNA resection, mostly resulting in DNA breaks. Identification of sumoylation 
sites allowed us to reveal reduced rates of chromosomal aberrations in cells 
expressing the EXO1 SUMO-mutant compared to the wild-type protein. 
In summary, these data indicate that high EXO1 protein level represents a 
threat to genome stability. Although the cellular ubiquitylation machinery might 
still be able to cope with such a high level of EXO1, sumoylation-induced 
localization of this population to DNA eventually turns resection from 
physiological to pathological. Hence, we speculate that cancer cells with up-
regulated EXO1 gene expression (40 and http://www.nextbio.com) possibly 
exploit inefficient regulation by SUMO pathways 20,41 to limit pathological 
resection of DNA, thus suppressing apoptotic signals that result from the 
accumulation of chromosomal aberrations of the type that we report. Future 
studies are needed to address this issue. 
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MATERIALS AND METHODS 
 
Plasmids and constructs - pGFP-EXO1 was previously described 23. Single- 
and multiple-point mutations were introduced in pEGFP-EXO1 and pTXB1-
EXO1 by site-directed mutagenesis using Phusion DNA polymerase 
(Finnzymes/Thermo Scientific) and primers described in Table S1. pcDNA3.1-
HA-ubiquitin, pCMV4-HA-UBC9, pCMV-Flag-SENP6 and pET28a-His-SENP6 
(628-1112) were purchased at Addgene (Cambridge, MA, USA). pCMV-Myc-
SUMO1 and pCMV-Myc-SUMO2 were kindly provided by P. Macchi (CIBIO, 
University of Trento, Italy). pET23a-His-RanGAP-tail was kind gift of F. 
Melchior (University of Heidelberg, Germany). The human E2 Ubiquitin 
Conjugating Enzyme siRNA library was purchased from Qiagen. 
  
Antibodies and chemicals - The antibodies used in this study were either 
previously described 23 or purchased from NeoMarkers (mouse monoclonal 
anti-EXO1); Abcam (rabbit polyclonal anti-GFP, ab290); Calbiochem (mouse 
monoclonal anti-RPA2); Cell Signaling Tech. (rabbit monoclonal anti-γH2AX, 
anti-CHK1-pS345 and anti-PIAS4); Sigma (mouse monoclonal anti-β-tubulin 
and anti-FLAG); Upstate Biotech. Inc. (mouse monoclonal anti-γH2AX); S. 
Cruz Biotech. (rabbit polyclonal anti-TFIIH and mouse monoclonal anti-UBC9, 
anti-HA and anti-Myc tags). Monoclonal antibodies to SUMO1 (21C7) and 
SUMO2 (8A2) were purchased at DSHB, Iowa. 
Secondary HRP-conjugated anti-mouse and anti-rabbit antibodies were form 
GE-Healthcare. Alexa Fluor-488, -594 and -647 conjugated secondary 
antibodies were from Invitrogen. 
Camptothecin (Sigma), aphidicolin (Sigma), anacardic acid (Millipore) and 
PYR41 (Millipore) were dissolved in DMSO at 10 mM stock concentration. 
Hydroxyurea (Sigma) was dissolved in water at 1 M stock concentration. N-
ehtylmaleimide (Sigma) was disolved in ethanol at 1 M stock concentration. 
MG-132 (Calbiochem) was prepared as 10 mM stock solution in DMSO and 
added to cells at 10 µM final concentration 30 min before additional 
treatments. 
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Preparation of 96-well library plates with pooled siRNAs and 
transfection mix and siRNA transfection - 96 wells contained a pool of 4 
single siRNAs targeting one gene (final concentration = 20 nM for each single 
siRNA). siRNAs were diluted in Optimem and mixed with transfection reagent 
(Invitrogen, Lipofectamine 2000, 0.1 µl in 9.9 µl of Optimem per well). The 
cells were plated on top of the siRNA mix for a reverse transfection at a 
concentration of 2,000 cells/well in 80 µl of complete medium per well (DMEM 
+10%FCS). After 48 hrs of growth in complete medium to allow efficient 
knockdown of the targeted genes, cells were either left untreated or treated 
with HU for 16 hrs and then used for the image-based assay. Using an 
automated-systems for liquid handling, the medium was removed from each 
well and cells were washed twice in PBS, permeabilized for 5 min with 0.1% 
Triton-X100 at RT and stained with a mouse monoclonal antibody against the 
GFP-tag to amplify EXO1 signal. DAPI was used to stain nuclei.  
 
High-content single-cell imaging of populations of cells - 96-well plates 
were imaged with a wide-field 20x objective microscope (ImageExpress 
Micro, Molecular Devices). Five focal planes per image and 49 sites per well 
were acquired. The maximum intensity projection of the 5 focal planes was 
saved for each site and used for further analysis. Images collected in the 
screen were stored as 16-bit uncompressed TIFFs.  
 
Image analysis pipeline, single-cell feature - For each single cell, nuclei 
were detected based on the signal of the DAPI staining using the open-source 
software, Cell Profiler 42. For every nucleus, the intensity for DAPI (blue) and 
EXO1 (green) (11 features per object and channel), shape (30 features per 
object) and texture features (15 features per object and channel) were 
extracted. For measurements of the population context of each single cell a 
point-spread function was used to measure the local cell density, the position 
of the cell in an islet (being on the edge or inside) and distance to cell islet 
edge (minimal distance between a cell and the edge of an islet) 43. In total  
~50 features per single cell were extracted.  
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Finally, for the single-cell EXO1 readout we z-scored (subtracting the average 
value over all single cells in the plate from each single-cell value and dividing 
this with the standard deviation of all single cells of the plate) the mean 
intensity per cell.  
 
Protein expression and purification - Recombinant wild-type or mutant 
forms of EXO1 and the catalytic domain of SENP6 (628-1112) were 
expressed and purified as described in 5 and 44, respectively. The yeast 
SUMO machinery proteins (GST-Aos1/Uba2, His-Ubc9, His-Flag-Smt3, His-
Flag-Smt3-KR, His-Siz1 (1-465), and Siz2) were purified as described 45,46. 
Expression of human SUMO machinery from plasmids pET23a-UBC9, 
pET11a-SUMO1(1-97), and pET11a-SUMO2 (a kind gift from Frauke 
Melchior) was performed as described 47. RanGAP-tail was purified as 
described 48. 
The S. cerevisiae Exo1 protein with a C-terminal intein tag was expressed in 
E. coli BL21(DE3)-RIPL cells. After the cells reached OD600~ 0.6, protein 
expression was induced by IPTG (1mM) for 24 h at 12°C. The cell pellet (18 
g) was resuspended in 150 ml of cell breakage buffer (50 mM Tris-HCl pH 
7.5, 10% sucrose, 10 mM EDTA, 1 mM β-mercaptoethanol, 0.01% Nonidet P-
40) containing 100 mM KCl and protease inhibitors. Suspensions were 
sonicated and cleared by ultracentrifugation. The supernatant was loaded 
onto a 20 ml SP-Sepharose column. The column was developed with 200 ml 
gradient of 125–1000 mM KCl in buffer K (20mM KH2PO4, 10% glycerol, 1 
mM EDTA, 1 mM β-mercaptoethanol, 0.01% Nonidet P-40). Peak fractions 
were pooled, diluted to 100 mM KCl and loaded onto a Heparin column (1 ml). 
The column was developed with 15 ml gradient of 150–1000 mM KCl in buffer 
K (20 mM KH2PO4, 10% glycerol, 1 mM EDTA, 1 mM β-mercaptoethanol, 
0.01% Nonidet P-40). Peak fractions were pooled, concentrated, frozen in 
liquid N2 and stored at -80°C. 
The plasmid pGEX-4T-SAE2/SAE1 (a kind gift from Ronald T. Hay) 
expressing human E1 enzyme was introduced into Escherichia coli strain 
BL21(DE3). Protein expression was induced by 1 mM IPTG at 37°C for 4 h. 
The cell pellet (20 g) was resuspended in 70 ml of CBB buffer (50 mM Tris-
HCl, pH 7.5, 10% sucrose, 2 mM EDTA, 150 mM KCl, 0.01% NP40, 1 mM 
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DTT, protease inhibitor cocktail), sonicated and cleared by ultracentrifugation. 
The resulting supernatant was applied onto a 7-ml Q-Sepharose column (GE 
Healthcare). The column was developed with 70 ml gradient of 100-900 mM 
KCl in buffer K (20mM KH2PO4, 10% glycerol, 1 mM EDTA, 1 mM 
dithiothreitol, 0.01% Nonidet P-40). Peak fractions were pooled and incubated 
with 1.5 ml Glutathione Sepharose 4B beads (GE Healthcare) for 1 hour at 
4°C. The beads were washed with 20 ml of buffer K containing 100 mM KCl 
and proteins were eluted in steps with 10-100 mM glutathione in buffer K. The 
fractions containing GST-SAE2/SAE1 were applied onto a 1-ml MonoQ 
column (GE Healthcare), and eluted using 100-800 mM KCl in buffer K. The 
peak fractions were concentrated to 15 µg/µl in a Vivaspin-2 concentrator. 
 
Cell culture and transfections - HEK293, HEK-293T and U2OS cells were 
maintained as described 23. U2OS (kindly provided by S. P. Jackson, 
University of Cambridge, UK) and HEK293 cells stably expressing GFP-HA-
EXO1 were cultured in DMEM supplemented with 10% fetal calf serum, 
standard antibiotics and G-418 (0.5 mg/ml) 5. Transient transfections were 
performed using Truefect-Lipo (United Biosystems Inc.). siRNA 
oligonucleotides (Microsynth) used in this study are listed in Table S1. siRNA 
duplexes were transfected at 40 nM concentration using Truefect-Lipo (United 
BioSystems Inc. USA) in two consecutive rounds. Experiments were typically 
performed 48-72h. 
 
Pull-down, immunoprecipitation and Western blotting - Purified SENP6 
protein was incubated with 25 µl of intein-tagged EXO1 pre-bound to chitin 
beads (New England Biolabs) for 30 min at 4°C with gentle shaking in 25 µl of 
buffer T (25 mM Tris-HCl pH 7.5, 0.5 mM EDTA, 10% glycerol) containing 100 
mM KCl. After incubation, the supernatants (S) were collected and 20 µl SDS 
Laemmli buffer was added. Beads were washed with 100 µl of buffer T and 
bound proteins were eluted with 30 µl of SDS Laemmli buffer (eluate, E). S 
and E fractions were analyzed by SDS-PAGE. 
To assess ubiquitylation or sumoylation in vivo, cells expressing HA-ubiquitin 
or Myc-SUMO1/Myc-SUMO2 were lysed in buffer B (50 mM Tris-HCl pH 7.5, 
5 mM dithiothreitol, 0.5 mM N-ethylmaleimide (NEM), 1% SDS) and incubated 
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for 10 min at 95oC. Samples were sonicated and clarified by centrifugation for 
10 min at maximum speed in an Eppendorf centrifuge. Finally, samples were 
diluted with four volumes of buffer A (50 mM Tris-HCl pH 7.5, 120 mM NaCl, 
20 mM NaF, 1 mM EDTA, 6 mM EGTA, 15 mM Na-pyrophosphate, 0.5 mM 
Na-orthovanadate, 1 mM benzamidine, 0.1 mM phenylmethylsulfonyl fluoride, 
1% Nonidet P-40) prior to immunoprecipitation. 
Immunoprecipitation and immunoblot analysis were performed as described 
previously 24 and using the FUSION SOLO® chemiluminescence imaging 
system (Vilber). Ethidium bromide was present in co-immunoprecipitation 
experiments to rule out DNA-mediated interactions. 
 
Immunofluorescence staining and analyses - Cells grown on cover slips 
were either fixed directly in ice-cold methanol for 15 min or pre-extracted for 5 
min on ice using 25 mM HEPES pH 7.4, 50 mM NaCl, 1 mM EDTA, 3 mM 
MgCl2, 300 mM sucrose and 0.5% Triton X-100 before fixation in 4% 
formaldehyde (w/v) in PBS for 15 min at room temperature (RT). Cover slips 
were incubated overnight at 4 °C with primary antibodies and Alexa–
conjugated secondary antibodies for 1h at RT. The cover slips were mounted 
with Vectrashield® (Vector Laboratories) containing DAPI. Images were 
acquired using a Leica fluorescence microscope. 
 
In vitro sumoylation assay - The in vitro sumoylation assay using yeast 
proteins was performed in a 10 µl volume containing 150 nM Aos1/Uba2, 250 
nM Ubc9, 4.3 µM Smt3-KR, 10 nM Siz1 or Siz2, 1 mM ATP, buffer S1 (100 
mM Tris-HCl pH 7.5, 10 mM MgCl2), and 1 µM human or yeast Exo1. 
Reactions were incubated at 30°C for 45 min, stopped by addition of SDS 
Laemmli buffer and analyzed by SDS-PAGE. 
The in vitro sumoylation assay using human proteins was performed in a 10 µl 
volume containing 100 nM GST-SAE2/SAE1, 2.8 µM UBC9, 4.3 µM SUMO1, 
4.3 µM SUMO2, 1 mM ATP, buffer S (50 mM HEPES, 10 mM MgCl2, 0.1 mM 
DTT), and 1 µM EXO1. Reactions were incubated at 30°C for 1h, stopped by 
addition of SDS Laemmli buffer, and analyzed by SDS-PAGE. 
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Identification of sumoylation sites by LC-MS/MS - SDS-PAGE protein 
bands were reduced with dithiothreitol (DTT), alkylated by incubation with 
iodoacetamide and subsequently digested by addition of proteomics grade 
trypsin (Roche) over night at 37°C. Digests were separated on an UltiMate 
3000 RSLCnano (Dionex/Thermo Fisher Scientific) with a trapping column 
(PepMap C18, 5µm particle size, 300 µm i.d. x 5mm, Dionex/Thermo Fisher 
Scientific) equilibrated with 0.1% TFA and an analytical column Acclaim 
PepMap RSLC C18, 50 cm × 75 µm × 2 µm, 100 Å, Dionex/Thermo Fisher 
Scientific) applying a 1.6% to 30% acetonitrile (ACN) linear gradient in 30 min. 
The HPLC was directly connected to an LTQ-Orbitrap Velos mass 
spectrometer (Thermo Fisher Scientific) via a nanoelectrospray ionization 
source (Proxeon/Thermo Fisher Scientific) set to 2 kV. The mass 
spectrometer was operated in data-dependent mode: 1 full scan in the 
orbitrap (m/z: 350-2000, resolution 60000) with lock mass (m/z 445.120025) 
enabled was followed by maximal 6 HCD and 6 CID scans. Monoisotopic 
precursors were selected, singly charged signals were excluded from 
fragmentation. For CID, normalized collision energy was set at 35% or 30%, 
Q-value at 0.25 and the activation time at 10 ms. HCD parameters were 0.1 
ms activation time and 35% normalized collision energy. Fragmented 
precursors were excluded from further selection for 30 s. 
Peptide identification was performed either by Sequest or Mascot 2.1 (Matrix 
Science) through the Proteome Discoverer 1.4 or by MassMatrix 2.4.2 49. 
Spectra were searched against a small database containing protein 
sequences plus proteases and contaminants. Search parameters were: tryptic 
specificity with max. 4 missed cleavages, peptide tolerance of 5 ppm, 
fragment ions tolerance of 0.8 Da for CID, 0.05 Da for HCD spectra. 
Carbamidomethylation of Cys was set as static modification, oxidation of Met 
as a variable modification. For the Sequest and Mascot search, the peptide 
mass of the linked fragment EQIGG (+484.2218) from the SUMO protein was 
set as a variable modification of lysines. Alternatively proteins of interest were 
digested in silico with trypsin and the resulting peptides were extended N-
terminally with the sequence of EQIGG and added to the database as 
described in 50. For the search with MassMatrix, SUMO protein sequence was 
truncated at the last C-terminal glycine (..EQIGG) and this residue marked as 
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the cross-linkage site to lysine residues. All spectra assigned to branched 
peptides were validated manually. 
 
DNA-binding and nuclease assays - The hairpin and 3‘-overhang 
substrates were prepared by annealing of 3‘ fluorescently labelled HL-1 
oligonucleotide or oligo-1 and -3 (Table S1) (VBC Biotech) in hybridization 
buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 10 mM MgCl2) for 5 min at 
70°C. The 3’flap substrate was prepared using Oligos-1, -2, and -3 (VBC 
Biotech) according to the procedure described 51. 
For EMSA, indicated amounts of EXO1 protein were incubated with 
fluorescently labeled DNA substrate (4 nM) in 10 µl of buffer E (50 mM Tris-
HCl pH 7.5, 50 mM NaCl, 1 mM EDTA, 1 mM DTT, and 50 ng/µl bovine 
serum albumin) at 37°C for 10 min. Following the addition of loading buffer 
(60% glycerol, 10 mM Tris-HCl pH 7.4 and 60 mM EDTA), the samples were 
separated on native polyacrylamide gel (10%) in 0.5x TBE buffer (40 mM Tris-
HCl pH 7.5, 20 mM boric acid, 2 mM EDTA). DNA was visualized by FLA9000 
Starion (Fujifilm) and quantified using MultiGauge software (Fujifilm). 
For nuclease assays, indicated amounts of EXO1 protein were incubated with 
fluorescently labeled DNA substrate (4 nM) in 10 µl of buffer EN (50 mM Tris-
HCl, pH 7.5, 50 mM NaCl, 2 mM MgCl2, 1 mM DTT, and 0.1 mg/ml bovine 
serum albumin) at 37°C for 20 min. The reactions were stopped by adding 
SDS (0.05 %) and proteinase K (0.5 mg/mL) at 30°C for 3 min. After adding 
loading buffer (10 mM Tris-HCl pH 7.4, 60 mM EDTA, 60% glycerol), the 
samples were separated on native polyacrylamide gel (10%) in TBE buffer. 
DNA was visualized and quantified as described above. 
 
Enrichment of chromatin-bound proteins - A Triton-based extraction 
protocol 52 was used to isolate insoluble proteins. Cells were washed twice in 
cold PBS and once in pre-extraction buffer (25 mM HEPES pH 7.4, 50 mM 
NaCl, 1mM EDTA, 3 mM MgCl2, 300 mM sucrose, 0,5% Triton X-100 and 
protease inhibitors), followed by incubation on ice for 5 min in pre-extraction 
buffer. Cells were then washed once with cold PBS and harvested by 
scraping into Laemmli buffer, heat denatured, sonicated and analyzed by 
Western blot.  
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Laser micro-irradiation of nuclei - DSBs in defined nuclear volumes were 
generated as described 5, using micro-irradiation (MMI CellCut) with a 355 nm 
UV-A laser adjusted at 50% of the power. Prior to irradiation, cells were grown 
for 24 h in the presence of 10 µM BrdU. 
 
Flow cytometric analysis - To quantify DNA-end resection in response to 
CPT or HU, the extent of chromatin-bound RPA was assessed by flow 
cytometry. Briefly, cells either stably or ectopically expressing GFP-EXO1 
were harvested, pre-extracted in 0.2% Triton X-100/PBS and fixed with 4% 
formaldehyde/PBS. Cells were washed with 1% BSA/PBS, permeabilized with 
0.5% saponin/1% BSA/PBS, and stained with anti–γ-H2AX antibody (#9718; 
Cell Signaling Technology) and anti-RPA (#NA19L, Calbiochem) for 2 h, 
followed by incubation with a suitable Alexa-labeled secondary antibody for 30 
min. DNA was stained with 1 µg/ml DAPI. Samples were measured on a Cyan 
ADP flow cytometer (Beckman Coulter) and analyzed with Summit software 
v4.3 (Beckman Coulter). 
 
Chromosome analysis - Metaphase spreads were prepared as described in 
5. Briefly, after treatment with 2.5 µM camptothecin for 1h, cells were allowed 
to recover for 8h in complete medium before chromosome preparation. 
Caffeine (2 mM) was added for the last 5h to override the G2/M checkpoint, 
and colcemid (0.1 mg/ml) was added for the last 3h to arrest cells in 
metaphase. Metaphase chromosomes were stained with DAPI. 
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FIGURE LEGENDS 
 
Figure 1 - Camptothecin targets EXO1 for proteasome-mediated 
degradation 
a. HEK-293T cells were treated with camptothecin (CPT, 1 µM), 
aphidicolin (APH, 15 µM) and MG-132 (10 µM) for 4h, as indicated. 
Endogenous EXO1 was immunoprecipitated with rabbit polyclonal 
antibody F15 and visualized with a specific monoclonal antibody. 
IgG(H) were used as control for the quality of the immunoprecipitation 
(IP). Whole cell extracts (WCEs, inputs) were analyzed before IP using 
the indicated antibodies.  
b. HEK-293T cells ectopically expressing GFP-EXO1 were treated with 
increasing doses of CPT for 4h. WCEs were examined using the 
indicated antibodies. 
c. HEK-293T cells ectopically expressing GFP-EXO1 (left) or stable 
U2OS-GFP-EXO1 cells (right) were treated with CPT (1 µM) and MG-
132 (10 µM) for 4h, as indicated. WCEs were analyzed using the 
indicated antibodies. Mock transfected HEK-293T and wild-type U2OS 
were used as controls. 
d. Indirect immunofluorescence analysis of wild-type and stable U2OS-
GFP-EXO1 cells shown in c. 
e. HEK-293T cells ectopically expressing GFP-EXO1 were treated with 
CPT (1 µM), MG-132 (10 µM) and the E1-UBI inhibitor PYR-41 (50 µM) 
for 4h, as indicated. 
 
Figure 2 - UBC9 controls EXO1 protein level 
a. UBC9 depletion causes stabilization of EXO1. An E2-ubiquitin 
conjugating enzymes siRNA library was screened on stable U2OS-
GFP-EXO1 cells left untreated or treated with HU. Mean intensity of the 
green signal averaged over all cells per gene were plotted (left of the 
panel). Single cell distribution of the green signal for Ctrl and UBC9 
(UBE2I in the figure) depleted cells were plotted (right of the panel). 
Entire well images and magnified indicative fields (greyscale) of Ctrl 
	   128	  
and UBC9 siRNA-depleted cells are shown. Scale bar entire field = 350 
µm. Scale bar enlargement = 50 µm. 
b. Western blot analysis of wild-type or stable U2OS-GFP-EXO1 cells 
transfected with CTRL or UBC9 siRNA oligonucleotides and treated 
with CPT. WCEs were analyzed using the indicated antibodies. 
c. Western blot analysis of HEK-293T cells ectopically expressing GFP-
EXO1 that were treated and analyzed as in b. 
d. Indirect immunofluorescence of stable U2OS-GFP-EXO1 cells treated 
as indicated in b. Image processing and analysis software (ImageJ) 
was used to calculate the percentage of green positive events from the 
DAPI stained cells examined (N).  
e. UBC9 over-expression decreases EXO1 protein level. Western blot 
analysis of HEK-293T cells ectopically expressing GFP-EXO1 and HA-
UBC9 that were treated with CPT (1 µM) for 4h. WCEs were analyzed 
using the indicated antibodies. 
 
Figure 3 - In vitro reconstitution of EXO1 sumoylation 
a. Yeast Exo1 is sumoylated in vitro. Sumoylation of yeast Exo1 was 
reconstituted in vitro with yeast E1, E2 and Smt3-KR in the presence or 
the absence of the E3-ligases Siz1 or Siz2. Samples were resolved by 
SDS-PAGE and visualized by silver staining. Asterisks indicate the 
sumoylated forms of Exo1. 
b. Human EXO1 is sumoylated in vitro. In vitro sumoylation of human 
EXO1 was performed as described in a. Samples were resolved by 
SDS-PAGE and visualized by silver staining. Asterisks indicate the 
sumoylated forms of EXO1. 
c. Recombinant Ran-GAP-tail was used as model substrate to assess the 
functionality of the in vitro reconstituted human sumoylation machinery. 
Samples were resolved by SDS-PAGE and visualized by Western 
blotting. 
d. EXO1 sumoylation with a reconstituted human SUMO-machinery. In 
vitro sumoylation of human EXO1 was performed with human E1, E2, 
SUMO1 and SUMO2. Samples were resolved by SDS-PAGE and 
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visualized by silver staining or Western blotting using a monoclonal 
antibody to SUMO1. Asterisks indicate the sumoylated forms of EXO1. 
 
Figure 4 - EXO1 is target of sumoylation in vivo  
a. HEK-293T cells ectopically expressing MYC-SUMO1, MYC-SUMO2 
and GFP-EXO1 were treated with HU (2 mM) and MG-132 (10 µM) for 
15h, as indicated. GFP-EXO1 was immunoprecipitated with a rabbit 
polyclonal antibody to GFP and visualized using a monoclonal antibody 
to the MYC-tag. The membrane was stripped and re-probed with a 
mouse monoclonal to GFP. IgG(H) were used as control for the quality 
of the IP. WCEs (inputs) were analyzed before IP using the indicated 
antibodies.  
b. EXO1 is sumoylated in a SUMO1-dependent manner. Western blot 
analysis of HEK-293T cells ectopically expressing MYC-SUMO1 or 
MYC-SUMO2 and treated with CPT. WCEs were analyzed using the 
indicated antibodies. 
c. PIAS1/PIAS4 depletion increases EXO1 protein stability. HEK-293T 
cells ectopically expressing GFP-EXO1 were depleted for PIAS1 or 
PIAS4 and treated with CPT. WCEs were analyzed using the indicated 
antibodies. 
d. Depletion of SENP6 affects EXO1 protein level. Western blot analysis 
of stable U2OS-GFP-EXO1 cells depleted for SENP5 or SENP6. 
WCEs were analyzed using the indicated antibodies. 
e. EXO1 interacts with SENP6 in vivo. HEK-293T cells were transfected 
with Flag-SENP6 and GFP-EXO1 as indicated and treated with CPT. 
WCEs were immunoprecipitated with a mouse monoclonal antibody to 
the Flag and membranes were probed with a rabbit polyclonal antibody 
to GFP. The membrane was stripped and re-probed with a mouse anti-
Flag monoclonal antibody. IgG(H) were used as control for the quality 
of the immunoprecipitation (IP). WCEs were analyzed before IP using 
the indicated antibodies. 
f. EXO1 and SENP6 interact in vitro. Intein-tagged EXO1 was bound to 
chitin beads and used as prey to capture purified recombinant SENP6 
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protein (628-1112 aa). The silver-stained gel shows proteins remaining 
in the supernatant after capture (S) or elution from chitin beads (E) 
trapping intein-EXO1 (lanes 1 and 2) or beads alone (lanes 3 and 4). 
The position of EXO1 and SENP6 is indicated. 
 
Figure 5 - Sumoylation and ubiquitylation occur sequentially on EXO1 
a. Chemical inhibition of SUMO-pathways impairs EXO1 ubiquitylation. 
Wild-type and stable U2OS-GFP-EXO1 cells were transiently 
transfected with HA-ubiquitin and left untreated or treated with the E1-
SUMO inhibitor anacardic acid (5 mM), the E1-UBI inhibitor PYR-41 
(50 mM) or the proteasome inhibitor MG-132 (10 mM). CPT was used 
as DNA damaging agent. WCEs were immunoprecipitated with a rabbit 
polyclonal antibody to GFP and membranes were probed with a 
monoclonal antibody to the HA tag. The membrane was stripped and 
re-probed with a mouse monoclonal to GFP. WCEs were analyzed 
before IP using the indicated antibodies. 
b. UBC9 depletion blocks EXO1 ubiquitylation. Stable U2OS-GFP-EXO1 
cells were transfected with CTRL or UBC9 siRNA oligonucleotides and 
treated with CPT. WCEs were immunoprecipitated and analyzed as in 
a. 
 
Figure 6 - Sumoylation controls EXO1 recruitment to DNA  
a. Sumoylation does not affect DNA binding of EXO1 in vitro. Increasing 
concentrations of non-sumoylated or sumoylated EXO1-D173A were 
tested for DNA binding activity using a 3’-flap substrate (4 nM). 
Quantification of the gel using MultiGauge software is shown. 
b. UBC9 depletion affects EXO1 recruitment at sites of damage. Stable 
U2OS-GFP-EXO1 cells transfected with CTRL or UBC9 siRNA 
oligonucleotides were laser microirradiated and fixed at the indicated 
time points. Cells were immunostained with antibodies to γH2AX and 
GFP and analyzed by fluorescence microscopy. Nuclei were visualized 
with DAPI. 
c. Western blot analysis of the cells shown in b. 
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d. Chromatin-bound EXO1 is ubiquitylated. HEK-293T cells ectopically 
expressing GFP-EXO1 were treated with CPT and MG-132. GFP-
EXO1 present in the soluble and the chromatin fractions were  
detected by Western blot. 
e. UBC9 depletion decreases the ratio of chromatin-bound to free EXO1. 
HEK-293T cells ectopically expressing GFP-EXO1 were transfected 
with CTRL or UBC9 siRNA oligonucleotides. The total and chromatin-
bound fractions of GFP-EXO1 were detected by Western blot. 
Established markers for the total or the chromatin fraction were used. 
 
Figure 7 - EXO1 is sumoylated on lysine residues K655/801/802 
a. Schematic representation of EXO1. The N- and I-catalytic domains are 
shown in orange and the five potential sumoylation sites are shown in 
blue. Amino acid sequences flanking sumoylation sites are shown. 
b. EXO1-3KR is not sumoylated in vitro. In vitro sumoylation assay of 
human EXO1-wt or EXO1-3KR (K655,801,802>R) was performed with 
yeast E1, E2, Smt3-KR and Siz1 in the presence or the absence of 
ATP. The asterisk indicates the sumoylated form of EXO1. 
c. EXO1-3KR possesses  DNA binding activity similar to that of  EXO1-
wt. The DNA binding activity of purified EXO1-wt or EXO1-3KR was 
assessed using a 3’-flap substrate. Quantification of the gel using 
MultiGauge software is shown at the bottom. 
d. In vitro exonuclease assay. The exonuclease activity of purified EXO1-
wt or EXO1-3KR was assessed using a hairpin substrate. 
Quantification of the gel using MultiGauge software is shown at the 
bottom. 
 
Figure 8 - Defective EXO1 sumoylation reduces chromosomal 
aberrations caused by camptothecin 
a. Sumoylation does not affect EXO1 nuclease activity in vitro. Increasing 
amounts of non-sumoylated and sumoylated EXO1 were assessed for 
nuclease activity on a hairpin substrate (4 nM). Quantification of the gel 
using MultiGauge software is shown at the bottom. 
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b. Extent of in vitro sumoylation of EXO1 used in the nuclease assay 
described in a. 
c. EXO1 protein level in the cell affects the extent of DNA resection. The 
extent of chromatin-bound RPA as indicator of DNA resection was 
assessed by flow cytometric analysis in U2OS cells ectopically 
expressing GFP-EXO1. 
d. Western blot analysis of the cells described in c. 
e. Sumoylation sites mutation rescues the chromosomal aberrations 
caused by EXO1. Chromosome breaks observed in metaphase 
spreads of HEK-293T cells ectopically expressing GFP-EXO1-wt or 
GFP-EXO1-3KR and treated in the presence or the absence of CPT. 
Inset: example of chromosome breaks used in the quantification. 
f. Western blot analysis of the cells described in e. 
 
Figure 9 - Model of the sequential modifications of EXO1  
Reversible EXO1 sumoylation is controlled by UBC9-PIAS1/PIAS4 and 
SENP6. In response to stalled replication, sumoylated EXO1 is recruited 
to DNA and subsequently ubiquitylated. Proteasome-dependent 
degradation ensues, thus controlling the extent of DNA resection and 
avoiding chromosomal aberrations. 
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SUPPLEMENTARY FIGURE LEGENDS 
 
Supplementary Figure 1 (related to Fig. 2) - RNAi-based screening of 
human E2 ubiquitin conjugating enzyme library 
Distribution of local cell density (cell crowding), nuclear size and total 
intensity of the DAPI staining (indicative for cell cycle phases) were 
plotted for Ctrl and UBC9 (UBE2I) siRNA-depleted cells left untreated or 
treated with HU. 
 
Supplementary Figure 2 (related to Fig. 2) - Quantification of green 
fluorescence intensity in stable U2OS-GFP-EXO1 cells depleted for 
UBC9  
a. IF images from siCTRL and siUBC9 cells. Left: merge of DAPI (DNA) 
and GFP (EXO1) signals. Middle: DAPI images converted to binary 
colors. Right: EXO1-positive cells identified over the threshold applied.  
b. Quantification of the EXO1 signal intensity.  The green fluorescent 
signal in siCTRL and siUBC9-positive cells from panel A was quantified 
and values were normalized to siCTRL cells.  
 
Supplementary Figure 3 (related to Fig. 4) - Efficiency of SENP6 
depletion 
Western blot analysis of HEK-293T WCEs upon depletion with CTRL 
or SENP6 siRNA oligonucleotides. 
 
Supplementary Figure 4 (related to Fig. 7) - Identification of sumoylation 
sites in EXO1 
a. LC-MS/MS identification of SUMO-K655. Annotated CID spectrum of the 
+5-charged branched peptide 
KSDSPTSLPENNM(ox)SDVSQLK(sumo)SEESSDDESHPLR proving 
SUMOylation at K655. b-ions are indicated in red and y-ions in blue. 
The peptide was identified with Sequest with an XCorr value of 4.47 
and shows a mass deviation of 0.23 ppm. 
b. LC-MS/MS identification of SUMO-K801. Annotated CID spectrum of the 
doubly charged branched peptide NFGFK(sumo)K showing 
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SUMOylation at K801. The assigned b-ions are indicated in red and y-
ions in blue. The fragment ions `y and `b result from the dissociation 
along the sumo-side chain (EQIGG) and are indicated in green. The 
peptide was identified with MassMatrix with a Score of 44 and 0.0018 
Da mass deviation. 
 
Supplementary Figure 5 (related to Fig. 7) - Nuclease activity of EXO1-
5KR  
In vitro exonuclease assay. The exonuclease activity of purified EXO1-
wt or EXO1-5KR was assessed using a 3’-overhang substrate. 
 
Supplementary Figure 6 (related to Fig. 8) - Analysis of DNA resection by 
flow cytometric analysis 
Quantification of DNA resection in HeLa cells. Quantitative flow 
cytometric analysis of DNA end resection  (RPA) and DNA content 
(DAPI) in HeLa cells ectopically expressing GFP-EXO1-wt and treated 
with HU. 
 
Supplementary Figure 7 (related to Fig. 8) - Metaphase spreads 
Representative images of metaphase spreads. Mock transfected HEK-
293T and cells ectopically expressing GFP-EXO1-wt or GFP-EXO1-3KR 
were treated in the presence or the absence of CPT and metaphase 
spreads prepapred as described in Materials and Methods. Examples of 
chromosome breaks used in the quantification are indicated by arrows. 
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Supplementary Table 1 - List of oligonucleotides used in RNA interference 
studies, nuclease assays and generation of point mutations in EXO1, 
respectively.   
 
siCTRL CGUACGCGGAAUACUUCGATT 
siUBC9 CCACCAUUAUUUCACCCGATT 
siEXO1 CAAGCCUAUUCUCGUAUUUTT 
siPIAS1 CGAAUGAACUUGGCAGAAATT 
siPIAS4 AGGCACUGGUCAAGGAGAATT 
siSENP6 AAGGCGUAUGUAUUAAGUAAATT 
HL-1 ATCATTGCCTATCCTGACAGTCCGACACATCGGACTGTCA
GG 
ATAGGCAATGATCTTTTTTTTT 
Oligo-1 AGCTACCATGCCTGCACGAATTAAGCAATTCGTAATCATG
GTCATAGCT 
Oligo-2 AGCTATGACCATGATTACGAATTGCTTGGAATCCTGACGAA
CTGTAG 
Oligo-3 AATTCGTGCAGGCATGGTAGCT 
EXO1(K655R)-for GTGTCGCAGTTAAGGAGCGAGGAGTCC 
EXO1(K655R)-rev GGACTCCTCGCTCCTTAACTGCGACAC 
EXO1(K801/802R)-for GGAAAAACTTTGGATTTAGAAGAGATTCTGAAAAGC 
EXO1(K801/802R)-rev GCTTTTCAGAATCTCTTCTAAATCCAAAGTTTTTCC 
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5. INTRODUCTION 
5.1 TRIM family proteins 
 
The RING finger motif consists of a unique linear series of conserved cysteine 
and histidine residues (Cys-X2-Cys-X11-16-Cys-X-His-X2-Cys-X2-Cys-X7-74-Cys-
X2-Cys (C3HC4 type), where X can be any amino acid. Three-dimensional 
analysis of RING domains have confirmed that the RING finger motif is 
composed of a unique "cross-brace" arrangement with 2 zinc ions and its 
folding shows a small central β sheet and an α helix [1,2]. Often, the RING 
domain associates with cysteine-rich B-box domains followed by a predicted 
coiled-coil domain; a RING domain, 1 or 2 B-box domains and a coiled-coil 
domain at the N-terminal region of a protein is called RBCC or TRIM [3]. 
Studies have demonstrated that RING finger proteins have a fundamental role 
in growth, differentiation, transcription, signal transduction and oncogenesis 
[4]; more recently, proteins member of the RING family have been shown to 
be involved in ubiquitin-mediated degradation process.  
In particular, the C3HC4 - type RING finger domain is found in many E3-
ubiquitin ligases, such as Cbl [5], BRCA1 [6], estrogen-responsive finger 
protein (Efp) [7] and murine double minute 2 (Mdm2) [8]. The RING-H2 
subtype in which the Cys5 is substituted by a histidine, is found in RING box 
protein 1 (Rbx1) and anaphase promoting complex (APC) subunit 11 (Apc11), 
which are components of the SCF (Skp1‑Cullin‑F‑box) and APC E3 
complexes [9]. Chu Y. and Yang X. recently published a study in which they 
showed that TRIM proteins represent a new class of E3-SUMO ligases and 
that this enzymatic activity relies on the presence of the RING domain and of 
an intact B-box domains [10].  
 
5.1.1 TRIM27 as the putative EXO1 E3-SUMO ligase 
 
TRIM27 is a member of the TRIM proteins family and it represents a clear 
example of the dual E3 activity features characteristic of many RING finger 
proteins. TRIM27 (also known as Ret finger protein or RFP) acquires 
oncogenic activity when it is fused to the Ret receptor tyrosine kinase [11]. 
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TRIM27 was found to directly interact with Ubc9 and to notably stimulate 
Mdm2 sumoylation in-vivo and in-vitro enhancing its stability [11]. This is an 
example of the fact that SUMO (ubiquitin-like modifiers) molecules can 
compete with another post-translational modification system, namely 
ubiquitylation, for the attachment to Lys residues; indeed, Mdm2 stabilization 
upon TRIM27-dependent sumoylation is due to the consequent inhibition of 
ubiquitylation [12].  
 
5.2 RESULTS 
 
5.2.1 TRIM27 as the putative EXO1 E3-ubi ligase 
A preliminary siRNA-based screening of an E2-ubiquitin conjugating enzyme 
library was initially performed by Western blotting analysis. The protocol for 
the screening was first optimized in order to be able to obtain the most 
pronounced exogenous EXO1 degradation upon different DNA damaging 
treatments (Figure 1A). In a second experiment we also tested whether the 
cellular stress induced by the siRNA transfection per se could have an effect 
on exogenous EXO1 protein stability (Figure 1B).  
  
A.                                                                     B. 
 
 
Figure 1. Protocol optimization for E2-ubiquitin conjugating enzymes screening. A) 
HeLa cells were transiently transfected with a GFP-EXO1 expression construct; after 8 hours 
cells were left untreated or treated with HU (either for 16 or 24 hours) or with CPT for 4 hours 
(either with 1 µM or 2.5 µM). Cells were then harvested and total cell extracts were analyzed 
by Western blot by using specific antibodies. B) HeLa cells were transfected with siCTRL for 
72 hours. Transient GFP-EXO1 transfection was then performed after 48 hours post-siRNA 
and they were left untreated or treated with HU for 16 hours. Cells were then harvested and 
total cell extracts were analyzed by Western blot by using specific antibodies. 
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Once optimized, the protocol was applied to the screening of the library of E2 
enzymes by RNAi. Few candidates, namely UBE2H, UBE2J1, UBE2L3, 
UBE2L6, UBE2G2, UBE2K, showing rescue of EXO1 degradation upon DNA 
damaging treatment, were identified (Figure 2). 
  
 
 
Figure 2. E2-ubiqutin conjugating enzymes' siRNA library screening.  
HeLa Cells were downregulated for the specific genes coding for the E2s. For 
each gene, the preliminary screened library was composed of two RNA 
oligomers.   After 48 hours post-siRNA reaction, cells were transfected with an 
expression plasmid encoding GFP-EXO1 and treated with HU.  Whole cell 
lysates were analyzed by Western blotting using specific antibodies. 
Candidates showing abolishment of EXO1 degradation upon HU treatment 
are shown.  
 
Among the six candidates identified by the screening as putative EXO1 
ubiquitin-conjugating enzymes, we found that four of them have been 
previously reported in literature to be interacting with the RING finger protein 
TRIM27. Recent studies on TRIM27 revealed its dual-activity feature as an 
E3-SUMO and Ubi ligase, thus we decided to investigate in more detail the 
connection linking TRIM27 with EXO1 post-translational modifications.  
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In order to clarify whether TRIM27 could be involved in the DNA damage 
repair pathway by homologous recombination and thus, to connect it to EXO1 
protein modification upon DNA damage repair, we first decided to check its 
regulation along the cell cycle upon Aphidicolin treatment of cells. Aphidicolin 
is an inhibitor of DNA polymerase α and δ causing a block of DNA replication 
forks that first stall and secondly collapse creating DNA double-strand breaks. 
293T cells were synchronized in mitosis with the microtubule-depolymerizing 
agent Nocodazole and subsequently released into the cell cycle (Figure 3A). 
Aphidicolin was added at the time of transition into G1 (5h from the release) or 
during S phase (14h from the release) and TRIM27 protein level was 
assessed by Western blotting. Results showed that TRIM27 protein 
undergoes S-phase specific stabilization upon DNA damaging treatment 
(Figure 3B).  
 
A.                                                                                 B. 
 
 
 
Figure 3.  TRIM27 involvement in DNA damage response. 
A) FACS analysis of different time points acquired from HEK 293T cells synchronized by 
Nocodazole (300 ng/mL) for 16 hours and released into cell cycle. B) HEK 293T cells were 
synchronized by treatment with nocodazole as described in A and released for 5 hours (M-G1 
cells, lanes 1-2) or 14 hours (S-phase cells, lanes 3-5); at these time points, cells were left 
untreated (lanes 1 and 3) or treated in the presence of 5 µg/mL aphidicolin as indicated. Cell 
extracts were analyzed by Western blotting. 
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We then proceeded investigating the effects of TRIM27 downregulation on 
EXO1 protein stability. First, we could prove (demonstrate) TRIM27 
stabilization upon another DNA damaging treatment, namely HU (Figure 4C). 
Secondly, we could show that depletion of TRIM27 by siRNA rescued EXO1 
protein degradation upon DNA damage in GFP-EXO1 transiently-  or stably-
expressing U2OS cell lines (Figure 4A and 4B respectively).    
 
A.                                                                      B. 
 
                                                                         C. 
 
Figure 4. TRIM27 depletion stabilized GFP-EXO1 upon DNA damage. 
A) U2OS cells transfected with siCTRL or siTRIM27 and transiently expressing GFP-EXO1 
construct were left untreated or treated with HU for 16 hours. Cell extracts were analyzed by 
Western blotting. B) U2OS cells transfected with siCTRL or siTRIM27 and stably expressing 
GFP-EXO1 construct were left untreated or treated with HU for 16 hours. Cell extracts were 
analyzed by Western blotting. C) U2OS cells were left untreated or treated with HU. Cells 
extracts at three different time points after addition of HU to the cells were analyzed by 
Western blot analysis.  
 
To confirm this last result, we performed an immunofluorescence experiment 
on GFP-EXO1 stable U2OS cells depleted for TRIM27. The acquired images 
show a pronounced increase in the GFP signal for the TRIM27 knock-down 
cells (Figure 5).  
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Figure 5. TRIM27 depletion stabilized GFP-EXO1 upon DNA damage. 
U2OS cells stably expressing GFP-EXO1 protein were either left untreated or transfected with 
siCTRL or siTRIM27. IF analysis upon staining with the indicated antibody was performed.  
 
 
Next, we decided to clarify the mechanism by which TRIM27 regulates GFP-
EXO1 protein stability upon DNA damage. Thus, we performed a laser-
microirradiation experiment on U2OS stable GFP-EXO1 cell line 
downregulated for TRIM27. The result showed that GFP-EXO1 could be still 
detected at double-strand breaks, indicating that EXO1 recruitment at 
damaged sites on DNA is not affected upon depletion of TRIM27. 
 
 
Figure 6. TRIM27 siRNA does not affect EXO1 recruitment at sites of DNA damage. 
Stable U2OS GFP-EXO1 cells were depleted for TRIM27 by siRNA for 72 hours and then 
UVA-microirradiated. Cells were fixed at different time points upon irradiation and stained with 
the indicated antibody for immunofluorescence analysis.  
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We then assessed the interaction between TRIM27 and EXO1 by performing 
pull-down experiments.  We were able to show the interaction between the 
two proteins both in-vivo and in-vitro. Moreover, the in-vivo interaction was 
detected in both untreated and CPT-treated cells (Figure 7).   
 
A. 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. EXO1 interacts with TRIM27. 
A) HEK 293T cells were transfected either with Strep-EXO1 or with Strep-mock constructs for 
24 hours and then left untreated or treated with CPT. Cells were harvested and Strep-pull 
down was performed with whole cell extracts. Eluates from Strep-beads were ran on an SDS-
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polyacrylamide gel and analyzed by Western blotting using the indicated antibodies. MRE11 
and CtIP were used as negative and positive control, respectively, for the assay. B) In-vitro 
purified components (GST-TRIM27 pulled-down with glutathione beads and increasing 
amounts of recombinant human EXO1) were mixed. Proteins were examined by 
polyacrylamide gel electrophoresis. Recombinant human EXO1 protein interacting with 
TRIM27 was detected by using a specific antibody. 
 
In collaboration with Prof. Martin Scheffner's laboratory at the University of 
Konstanz, we performed experiments testing the hypothesis that TRIM27 
could be EXO1 E3-ubiquitin ligase. We first conducted preliminary in-vitro and 
in-vivo experiments to confirm the ability of TRIM27 to auto-ubiquitylate and 
thus to be active as an E3-ubiquitin ligase (Figure 8). The results showed that 
TRIM27 is a substrate for auto-ubiquitylation in-vitro and in-vivo. However, in-
vitro assays including EXO1 as a substrate for ubiquitylation did not provide a 
clear-cut answer to our hypothesis.  
 
A.                                                                         B. 
 
                       C.  
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Figure 8.TRIM27 auto-ubiquitylation. 
A) Coomassie staining and Western blot analysis with the indicated antibody of in-vitro 
ubiquitylation reactions on purified GST-TRIM27. Reactions missing either the E2-ubi 
conjugating enzyme Ubc5H or Ubiquitin, were used as negative controls for the assay. B) 
HEK 293T cells were transiently co-transfected with His-Ubi, His-NEDD8 and GFP-TRIM27 
constructs. Cells were then lysed and Nichel NTA pull-down was performed on whole cell 
extracts. Eluates from Nichel beads were ran on an SDS-polyacrylamide gel and analyzed by 
Western blotting with an antibody against TRIM27. The first and the last lanes were used as 
negative controls for the assay. C) In-vitro auto-ubiquitylation assay on both purified TRIM27 
wt and ΔRING-mutant confirmed that the intact RING-finger domain is needed for TRIM27 
efficient E3-Ubi ligase activity.   
 
 
Finally, since TRIM27 was reported to be a DNA binding protein acting as co-
repressor of transcription (Isomura NAR 1992; Shimono JBC 2000), we 
decided to exclude the possibility that our observations on EXO1 protein 
stabilization upon TRIM27 depletion were the result of effects on transcription. 
Thus, we performed RT-qPCR experiments on RNA samples extracted from 
cells depleted for TRIM27 and we examined EXO1 mRNA levels. The assay 
proved that there is no significant effect on EXO1 at the transcriptional level 
as result of TRIM27 depletion (Figure 9). 
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Figure 9. TRIM27 is not a transcriptional regulator of EXO1. 
HeLa cells were transfected with siCTRL or siTRIM27 for 72 hours and then left untreated or 
treated with HU for the last 16 hours. Cells were harvested, total RNA was extracted and RT-
qPCR analysis was performed using oligos specific for endogenous EXO1 mRNA. PBDG was 
used as a positive control of the assay (house-keeping gene) (data not plotted). 
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5.3 DISCUSSION 
 
Ubiquitylation machinery, consisting of the three main players E1-activating, 
E2- conjugating and E3-ligating enzymes, represents a suitable target for 
interfering with post-translational modifications of its substrate proteins and 
thus, for de-regulating the pathways they it controls. Identifying the enzymes 
that attach ubiquitin molecules to EXO1 protein, thus targeting it for 
proteasomal degradation, will allow finding a therapeutic target the inhibition 
of which would result in EXO1 stabilization and DNA over-resection. This, in 
turn, would be the starting point to induce irreversible damage to DNA in 
cancer cells and triggering apoptosis as a result. 
Data showed in the PART II, were aimed to investigate whether TRIM27 
represents the putative E3-ubiquitin ligase for EXO1. The initially described 
screening of the library of E2s resulted in the identification of few candidate 
genes, which, once downregulated by siRNA, led to GFP-EXO1 protein 
stabilization. Although we decided to proceed restricting the field of E3-ligases 
to be screened to those reported in the literature as interacting partners of 
such candidates, the screening had to be repeated using a different approach 
due to drawbacks that conferred inconsistency to the results of the first 
analysis; for example, the siRNAs library had to be enlarged in the second 
screening in order to have at least four oligos per gene (validated and non-
validated). Moreover, as described in paragraph 4, the screening was 
repeated in stable GFP-EXO1 U2OS cell line in order to avoid unequal GFP-
EXO1 starting level between different samples due to the transient 
transfection protocol. Finally, we decided to perform the second screening by 
taking advantage of automated system for the acquisition of images of 
immuno-stained cells, in order to avoid the variability intrinsic to the Western 
blot analysis procedure.  
Preliminary experiments aimed to identify the best DNA damaging treatment 
to be used for the screening, showed that cells treated with HU for 24 hours 
completely degraded GFP-EXO1, although also shorter HU treatment led to a 
very efficient degradation of the protein. CPT resulted, in turn, to be even 
stronger than HU if we consider the rate between the amount of EXO1 protein 
left and the length of the respective treatment. Furthermore, we could show 
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that the RNA interference reaction (siCTRL) itself, somehow affected EXO1 
protein stability, mostly due to the cellular stress induced by the chemical 
reagents used in the protocol (assay, method…).   
We were also able to link TRIM27 to DNA damage response pathways; 
indeed, results showed first that TRIM27 proteins is stabilized upon DNA 
damage treatment and secondly that this effect is specific for the S-phase of 
cell cycle, which puts TRIM27 in strong correlation with homologous 
recombination-based DNA damage repair pathways. 
As expected, on the base of our speculation that TRIM27 is the enzyme 
responsible for EXO1 ubiquitylation and degradation, we could prove that 
depletion of TRIM27 led to exogenous EXO1 protein stabilization, both by 
Western blot analysis and IF.  
The model established by a former post-doctoral fellow in our laboratory and 
based on previously published data, claims that EXO1 poly-ubiquitylation 
occurs once EXO1 has resected the DNA broken ends from 5' to 3' and is 
necessary to avoid pathological resection of DNA. Having said that, we were 
wondering whether EXO1 stabilization upon TRIM27 depletion could be 
related to the interference with the process of EXO1 recruitment at sites of 
damage. If this is the case, one could foresee two possible scenarios: the first 
is that ubiquitylation is required for EXO1 recruitment to chromatin, a condition 
that is no more satisfied in the absence of TRIM27; the second is that 
ubiquitylation is necessary to keep EXO1 on chromatin. In the absence of this 
modification EXO1 is released from DNA with very fast kinetics so that it is no 
longer detectable on chromatin. Both these explanations did not find any 
support from the laser-microirradiation of GFP-EXO1 U2OS cells depleted for 
TRIM27, since the GFP signal could still be detected at the damaged regions, 
indicating that EXO1 ubiquitylation occurs after its localization on DNA and 
that, in the absence of TRIM27, EXO1 is not ubiquitylated and thus not 
recognized by factors shuttling it from chromatin to the proteasome, resulting 
in the observed EXO1 stabilization. 
Biochemical assays confirmed that TRIM27 and EXO1 constitutively interact 
in-vivo and in-vitro. In-vitro ubiquitylation assay performed on TRIM27, 
confirmed it to be active as E3-ubiquitin ligase being able to transfer ubiquitin 
molecules to itself as substrate. Moreover, the RING-domain deleted mutant 
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form of TRIM27 failed to undergo auto-ubiquitylation, confirming the essential 
feature of the RING domain for an E3  enzyme to be catalytically active. 
However, we could not demonstrate any direct E3-ligase activity of TRIM27 
on EXO1. 
Finally, we could exclude that the stabilization of EXO1 upon TRIM27 
depletion was due to transcriptional regulation, since TRIM27 is known to 
possess also this kind of enzymatic activity.      
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6. OUTLOOK 
 
The studies reported in this thesis start shedding light on the mechanisms 
regulating EXO1 upon DNA damage and in particular on the post-translational 
modifications involved in such mechanisms.  
 
Phosphorylation, sumoylation and ubiquitylation have been so far identified as 
the three main PTMs occurring on EXO1 protein and affecting its stability. 
Regarding EXO1 phosphorylation, it has been previously demonstrated that 
among the twelve identified phosphorylation sites, three of them are induced 
upon hydroxyurea treatment; this data led to the hypothesis that 
phosphorylation is needed for the consequent EXO1 proteasome-dependent 
degradation, which occurs upon HU treatment. Previous reports from our 
laboratory also proved that EXO1 phosphorylation seems to be mostly 
dependent on ATR, one of the two main Kinases regulating the DNA damage 
response, since its depletion or inhibition leads to stabilization of EXO1 
protein upon stalling of replication forks. Additionally, it was shown that upon 
the combined treatment of cells with HU and MG-132 proteasome inhibitor, 
EXO1 is phosphorylated confirming that phosphorylation precedes EXO1 
degradation. S714 has been identified as the main DNA damage-induced 
phosphorylation site on EXO1, since its point mutation resulted in the most 
pronounced rescue of EXO1 protein upon HU treatment compared to point 
mutation of the other sites (El-Shamerly, 2008).   
 
In the present study, we report sumoylation, another modification found on 
EXO1 protein, to occur constitutively in undamaged and damaged conditions. 
Results, especially from experiments conducted in-vivo, revealed a 
pronounced hyper-sumoylation of EXO1 since the smeared signal detected by 
Western blot analysis and corresponding to sumoylated EXO1 tends to 
accumulate in the upper part of the gels, where the protein runs when 
acquiring high molecular weight due to modifications. In-vitro experiments 
mainly showed more defined and smaller modification intermediates most 
probably due to the reaction time length or to the components limiting 
amounts. We could prove that Siz1 and Siz2, yeast E3-sumo ligases, strongly 
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promoted EXO1 sumoyaltion in-vitro for both human and yeast EXO1, 
suggesting their involvement in the post-translational modification process. 
PIAS1 and PIAS4, the human homologues of Siz1 and Siz2, were also shown 
to affect EXO1 stability in-vivo, although abolishment of sumoylation upon 
depletion of the two ligases, supporting a direct role for these E3-ligases, is 
not yet available. This, together with other in-vivo experiments aimed to prove 
in a different way and to solidify the results proposed so far, will be performed 
next. Ideally, it would be also essential to show a correlation with the 
previously described EXO1 phosphorylation; we speculate that the three post-
translational modifications mentioned here occur sequentially, as indicated by 
preliminary experiments described in the submitted manuscript showing 
abolishment of ubiquitylation upon interference with the sumoylation 
machinery. Thus, it will be important to investigate whether inhibition of EXO1 
phosphorylation upon DNA damage, for example by using the A714 point 
mutant or in a less specific way by inhibiting ATR signal, results in 
abolishment or reduction of the sumoylation pattern on EXO1.  
By mass spectrometry analysis of the in-vitro sumoylated human recombinant 
EXO1 we were able to identify some of the sumoylation sites predicted by 
computational tools. We created a Lys-->Arg mutant of three sumoylation 
sites, for in-vitro and mammalian expression. We could confirm an impaired 
sumoylation of the 3KR mutant in-vitro, although not a complete, very 
probably due to the fact that other lysine residues are involved. In this respect, 
we plan to mutate additional residues on EXO1 in order to verify whether 
there is a stronger effect on its stabilization and sumoylation.  
Our hypothesis on the functional role of sequential PTMs occurring on EXO1 
is based on the evidence published so far and on our findings that EXO1 is 
responsible for the second step of extended DNA resection at double-strand 
breaks (Lee et al., 1999); once the 5'-3' resection needed is completed, EXO1 
is phosphorylated, sumoylated, ubiquitylated and degraded via proteasome. 
We speculate that understanding and then interfering with any of these post-
translational modifications represents a clever approach aimed to create a 
stable and constantly enzymatically active exonuclease which does not 
undergo any kind of cellular regulation and which is allowed to "over-exert" its 
exonucleolytic activity. Over-resection of broken DNA ends could results in 
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the failure to repair the damage by homologous recombination, so that 
accumulation of un-repaired breaks as well as fusion between the extended 
single-strand filaments created by EXO1, will lead to progressively increased 
DNA damage and finally to apoptosis. Indeed, in the manuscript reported in 
this thesis, we show that cells over-expressing the wild type form of EXO1 to 
a level that likely saturates the ability of the proteasome to degrade it, leads to 
increased chromosome fragmentation already in unperturbed DNA conditions. 
This situation mimics the condition in which EXO1 over-resects DNA as 
consequence of inhibition of the pathways controlling its PTMs. Ideally, this 
hypothesis, once confirmed, could have a beneficial impact on cancer 
therapy; we propose, as a putative approach, the inhibition of the interaction 
between EXO1 and any of the factors involved in its direct modification, for 
example by chemical compounds competing for the interaction pocket on 
EXO1, associated with the most recent chemotherapeutic treatment with 
Olaparib and site-directed radiotherapy to selectively hit cancer cells. 
In our study, this hypothesis could not be completely verified, since we 
observed decreased chromosomal aberrations in cells over-expressing a 
"stabilized" EXO1 sumoylation mutant (3KR). A possible explanation to this 
observation, however, is provided by other data that we present and resides 
in the fact that interference with the sumoylation pathway certainly causes 
stabilization of EXO1 protein, but also seriously affects its recruitment to 
chromatin, thus compromising its ability to resect DNA. Hence, we 
hypothesize that sumoylation of EXO1 occurs when the protein is still diffused 
through the nucleus; upon sumoylation EXO1 is likely targeted for recognition 
by a factor "X" that brings it to the damaged site on DNA, where it is then 
ubiquitylated and targeted for proteasomal-degradation. On the other hand, 
in-vitro DNA binding assays did not show any significant difference in the 
binding to DNA between the unmodified and the sumoylated form of EXO1, 
although a higher affinity would be expected for the latter as a confirmation of 
the previously provided explanation for the in-vivo data. This could be 
explained with the fact that in-vitro, the so called "X" factor, is not present to 
improve binding of sumoylated EXO1 to DNA; moreover, in-vitro reactions 
represent an artificial system where the stoichiometry of the reactions could 
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be very far from the in-vivo situation, justifying the binding to DNA of the 
unmodified form of EXO1.  
 
The hypothesis that EXO1 sumoylation is needed for its recruitment to sites of 
DNA damage can also be exploited in cancer cell lines known to produce 
higher levels of EXO1 transcripts compared to normal cell lines. Indeed, we 
first intend to confirm that such elevated mRNA levels correlates with 
increased protein levels and secondly to investigate whether these cancer 
cells are able to silence the pathological exonucleolytic effects of the hyper 
expressed EXO1 by interfering with its sumoylation machinery. Possibly, 
components such as PIAS1 and PIAS4 are expressed at a physiological level 
which thus, represents a limiting factor for EXO1 sumoylation to occur. If this 
is the case, we would try overexpressing such components to compensate the 
different protein expression and test our hypothesis. In this way an additional 
piece of knowledge would be elucidated providing the base for future 
extended research on tumorigenesis and possible therapeutic approaches.    
 
Concerning another PTMs occurring on EXO1, namely ubiquitylation, it has 
been shown that EXO1 polyubiquitylation can be detected upon inhibition of 
the proteasome with MG-132 under DNA damaging conditions (El-Shamerly, 
2005). In the present study, we showed that interfering with the sumoylation 
pathways by UBC9 down-regulation or by treating cells with Anacardic Acid, 
EXO1 ubiquitylation is also compromised. We plan to further investigate this 
sequential feature of PTMs in order to confirm that sumoylation and 
ubiquitylation occur directly on EXO1 and are functionally linked, excluding 
indirect effects of sumoylation on components of the EXO1 ubiquitylation 
pathway. 
 
Unpublished data on TRIM27 were no longer considered because not all of 
them could be confirmed on endogenous EXO1 and await further testing. In 
this respect, since the identification of the E2 and E3 enzymes involved in 
EXO1 ubiquitylation is still missing, we would like to proceed with two different 
approaches: the first one consists in the repetition of the E2s-ubiquitin 
conjugating enzymes' siRNA library screen using a higher sensitivity protocol; 
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the idea is to be able to catch the finest differences between the different 
depletions in order to identify a small group of candidates and to be able to 
restrict the group of E3-ubiquitin ligases on the base of the established 
interaction network of this family of proteins. The second approach consists in 
performing mass spectrometry analysis of EXO1, examining interactors that 
are involved in post-translational modification pathways upon DNA damage.    
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